Flagellin-based agents and uses including effective vaccination

Information

  • Patent Grant
  • 11542306
  • Patent Number
    11,542,306
  • Date Filed
    Tuesday, March 9, 2021
    3 years ago
  • Date Issued
    Tuesday, January 3, 2023
    a year ago
Abstract
The present invention relates to, in part, compositions comprising improved flagellin derived constructs and methods of using for vaccination, including adjuvants comprising flagellin-based agents.
Description
FIELD OF THE INVENTION

The present invention relates to, inter alia, new compositions and methods for vaccination, including adjuvants comprising flagellin-based agents.


DESCRIPTION OF THE TEXT FILE SUBMITTED ELECTRONICALLY

The contents of the text file submitted electronically herewith are incorporated herein by reference in their entirety: A computer readable format copy of the Sequence Listing (filename: CLE019PC SequenceListing.txt; date recorded: Jul. 24, 2015; file size: 261 KB).


BACKGROUND

Vaccines are one of the most effective preventative health tools available against infectious diseases, cancers, and allergies. Vaccination aims to generate a strong immune response to the administrated antigen and provide long-term protection against a disorder. Often, however, an antigen alone is insufficient to stimulate protective immunity.


Vaccine adjuvants are compounds that enhance the specific immune responses against antigens in vaccines. Currently, several hundred natural and synthetic compounds are known to have adjuvant activity but only alum salts and AS04 are licensed for use in humans in the United States. This limited list of adjuvants is insufficient for meeting the functional needs of effective vaccination. For example, although alum is able to induce a good TH2 response, it has little capacity to stimulate cellular (TH1) immune responses which are so important for protection against many pathogens.


Accordingly, there remains a need for improved vaccines and/or adjuvants that can effectively stimulate a subject's immune response.


SUMMARY OF THE INVENTION

Accordingly, in some aspects, the present invention provides for improved vaccines and/or adjuvants.


In some aspects, the present invention provides a vaccine composition, comprising an adjuvant comprising a flagellin-based agent, such as, for example, CBLB502 (a/k/a entolimod) as well as any of the flagellin-based agents or derivatives described herein (e.g. Table 1), and an aluminum gel or salt and an antigen and, optionally, an additional adjuvant. In some aspects, the present invention provides an adjuvant composition, comprising an adjuvant comprising a flagellin-based agent, including CBLB502 as well as any of the flagellin-based agents or derivatives described herein (e.g. Table 1), and an aluminum gel or salt. In various embodiments, the vaccine described herein causes an improvement in adjuvant properties relative to a vaccine comprising the antigen and the aluminum gel or salt alone. In various embodiments, the vaccine and/or adjuvant described herein causes a broader, more diverse, more robust and longer lasting immunostimulatory effect than the vaccine comprising the antigen and the aluminum gel or salt alone and/or the adjuvant comprising the aluminum gel or salt alone. In various embodiments, the vaccine and/or adjuvant described herein causes immunostimulation of one or more of TH1 and TH2-mediated immune response (e.g. both of TH1 and TH2-mediated immune response) and/or the vaccine and/or adjuvant described herein causes immunostimulation of TH1-mediated immune response at levels greater than a vaccine comprising the antigen and the aluminum gel or salt alone and/or the adjuvant comprising the aluminum gel or salt alone.


In some embodiments, the flagellin-based agent may be a flagellin molecule or flagellin-based agent, or variants thereof that has TLR5 agonist activity. The flagellin-based agent may comprise one or more of the sequences of Table 1 (SEQ ID Nos.: 1-252), or variants thereof that have TLR5 agonist activity and can include a variant of Salmonella dublin wild type flagellin (SEQ ID No: 1), CBLB502 (SEQ ID NO: 2) or variants thereof (including closely-related variants such as S33ML (SEQ ID NO: 35), CBLB502-485CT (CBLB533, SEQ ID NO: 71), and CBLB502-S33MX (SEQ ID NO: 150)) and more distantly related variants such as flagellin derivatives from a thermophilic microorganism or flagellin derivatives from a microorganism well-tolerated by human (e.g. SEQ ID NOs: 243-252). In some embodiments, the aluminum gel or salt is selected from aluminum hydroxide, aluminum phosphate, and potassium aluminum sulfate, and ALHYDROGEL.


In various embodiments, the present vaccine composition is part of the following vaccines (e.g. the antigens of these vaccines may be used as the antigen of the present vaccines): DTP (diphtheria-tetanus-pertussis vaccine), DTaP (diphtheria-tetanus-acellular pertussis vaccine), Hib (Haemophilus influenzae type b) conjugate vaccines, Pneumococcal conjugate vaccine, Hepatitis A vaccines, Poliomyelitis vaccines, Yellow fever vaccines, Hepatitis B vaccines, combination DTaP, Tdap, Hib, Human Papillomavirus (HPV) vaccine, Anthrax vaccine, and Rabies vaccine.


In various embodiments, the vaccine described herein is formed, in part, by mixing the flagellin-based agent and aluminum gel or salt to form a stable complex, the ratio (w/w) of flagellin-based agent to aluminum gel or salt being about 1:500 or less (e.g. about 1:500, or about 1:600, or about 1:700, or about 1:800, or about 1:900, or about 1:1000, or about 1:2000, or about 1:5000). In some embodiments, the flagellin-based agent and aluminum gel or salt are mixed in a ratio that is substantially below a loading capacity of the aluminum gel or salt. In some embodiments, the flagellin-based agent and antigen are adsorbed to the aluminum gel or salt.


In another aspect, the present invention provides a method of vaccinating a subject against a disorder, comprising administering an effective amount of a vaccine comprising an adjuvant comprising a flagellin-based agent and an aluminum gel or salt and an antigen associated with the disorder. In another aspect, the present invention provides a method of immunostimulating a subject in advance of or concurrent with vaccination, comprising administering an effective amount of an adjuvant comprising a flagellin-based agent and an aluminum gel or salt, wherein both TH1 and TH2-mediated immune responses are immunostimulated. In various embodiments the disorder is selected from infectious diseases, cancer, allergy, and autoimmune diseases (by way of example, diphtheria, tetanus, pertussis, influenza, pneumonia, hepatitis A, hepatitis B, polio, yellow fever, Human Papillomavirus (HPV) infection, various cancers, anthrax, rabies, Japanese Encephalitis, meningitis, measles, mumps, rubella, gastroenteritis, smallpox, typhoid fever, varicella (chickenpox), rotavirus, and shingles).


The details of the invention are set forth in the accompanying description below. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, illustrative methods and materials are now described. Other features, objects, and advantages of the invention will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.





BRIEF DESCRIPTION OF THE FIGURES


FIGS. 1A and 1B show the 13 conserved amino acids of flagellin that may be important for TLR5 activity. FIGS. 1A and 1B show a comparison of amino acid sequences of the conserved amino (FIG. 1A) and carboxy (FIG. 1B) terminus from 21 species of bacteria. The 13 conserved amino acids important for TLR5 activity are indicated by the letter “C” at the bottom of each column. The amino acid sequences are identified by their accession numbers from TrEMBL (first letter=Q) or Swiss-Prot (first letter=P). With respect to FIG. 1A, SEQ ID Nos: 253-273 correspond to the sequences listed on the figure from top to bottom, respectively. With respect to FIG. 1B, SEC ID Nos: 274-294 correspond to the sequences listed on the figure from top to bottom, respectively.



FIG. 2 shows ELISA data for the average response of five mouse treatment groups at the time point of 1 week post-boost. Panel A is total IgG, Panel B is IgG1, Panel C is IgG2a, Panel D is IgG2b and Panel E is IgG3. Groups 1-5 are defined in TABLE B (Example 2): Group 1 is also called “Untreated;” Group 2 is also called “OVA,” Groups 3 is also called “OVA+Alum,” Group 4 is also called “SA 1 μg,” and Group 5 is also called “SA 10 μg.”



FIG. 3 shows ELISA data for the average response of five mouse treatment groups at the time point of 2 weeks post-boost. Panel A is total IgG, Panel B is IgG1, Panel C is IgG2a, Panel D is IgG2b and Panel E is IgG3. Groups 1-5 are defined in TABLE B (Example 2): Group 1 is also called “Untreated;” Group 2 is also called “OVA,” Groups 3 is also called “OVA+Alum,” Group 4 is also called “SA 1 μg,” and Group 5 is also called “SA 10 μg.”



FIG. 4 shows ELISA data for the average response of five mouse treatment groups at the time point of 4 weeks post-boost. Panel A is total IgG, Panel B is IgG1, Panel C is IgG2a, Panel D is IgG2b and Panel E is IgG3. Groups 1-5 are defined in TABLE B (Example 2): Group 1 is also called “Untreated;” Group 2 is also called “OVA,” Groups 3 is also called “OVA+Alum,” Group 4 is also called “SA 1 μg,” and Group 5 is also called “SA 10 μg.”



FIG. 5 shows a determination of CBLB502/ALHYDROGEL activity using a cell-based NF-κB activation assay. CBLB502/ALHYDROGEL formulation (5 μg/100 μl) and ALHYDROGEL control were serially diluted in assay media 2000- to 13122000-fold (2.6-0.0004 μg/ml aluminium) and incubated with 293-hTLR5-LacZ cells for 20 hr. Activity of β-galactosidase was measured after addition of cell lysis buffer and ONPG substrate and expressed as optical density at 414 nm (OD414).



FIG. 6 shows NF-κB-inducing activity of CBLB502/ALHYDROGEL formulated with different CBLB502 doses. 293-hTLR5-LacZ cells were incubated with CBLB502/ALHYDROGEL suspensions prepared at CBLB502 doses ranging from 2.5 to 0.00015 μg/100 μl and diluted 200-fold with media. Activity of β-galactosidase reporter enzyme was measured after 20 hr incubation.



FIG. 7 shows dose-response titration curves CBLB502/ALHYDROGEL generated with 293-hTLR5-LacZ reporter cells. CBLB502 was adsorbed to ALHYDROGEL at indicated doses (20 μg/100 μl: top panel, 0.31 μg/100 μl: middle panel and 0.078 μg/100 μl: bottom panel), serially diluted with media and assayed together with soluble CBLB502 standards.



FIG. 8 shows the activity of CBLB502/ALHYDROGEL (1 μg/100 μl dose) stored at 4° C. for 2 and 6 days. NF-κB-inducing activity was measured using 293-hTLR5-LacZ reporter cell assay.



FIG. 9 shows pharmacokinetics of CBLB502 in mouse serum after subcutaneous injection of a 1 μg dose of CBLB502 adsorbed to ALHYDROGEL 2%. The graph shows per-group mean serum CBLB502 concentrations and SEM (standard error of the mean) for each time point.



FIG. 10 shows induction of KC, G-CSF and IL-6 following s.c. administration of a 1 μg dose of CBLB502 adsorbed to ALHYDROGEL 2%. Serum concentrations of the cytokines were determined using R&D Systems DuoSet kits DY453 (KC, top panel), DY414 (G-CSF, middle panel) and DY406 (IL-6, bottom panel). The graphs show per-group mean serum cytokine concentrations and SEM (standard error of the mean) for each time point.



FIG. 11 shows immunopotentiating effects of a 502 adjuvant. Anti-MA IgG (μg/ml) response (panel A) and anti-502 antibody response (panel B) by ELISA to TT-SMA vaccine in the presence and absence of alum or entolimod (a varying range from 0 to 20 μg) in pooled sera collected at week 2, 4 and 6 post initial vaccination is shown. Data represent the levels of antibody in the pooled samples from each group (n=5/group).





DETAILED DESCRIPTION OF THE INVENTION

The present invention is also based, in part, on the surprising discovery that flagellin-based agents, including CBLB502 and any of the flagellin-based agents (e.g. agents comprising the sequences of Table 1, including MX-33) described herein, can be mixed with aluminum gels or salts (and, optionally antigens), in ratios well-below the loading/adsorbing capacity of the aluminum gel or salt (e.g. 1:500), and cause a broader, more diverse, more robust and longer lasting immunostimulatory effect than the vaccine comprising the antigen and the aluminum gel or salt alone and/or the adjuvant comprising the aluminum gel or salt alone. The inventors have also surprisingly discovered that the immunostimulatory effect can influence both the TH1 and TH2-mediated arms of an immune response. The inventors have also surprisingly discovered that low amounts of flagellin-based agents, including CBLB502 and any of the flagellin-based agents (e.g. agents comprising the sequences of Table 1, including MX-33) relative to antigen are effective for immunostimulation.


In one aspect, the invention provides a vaccine composition, comprising an adjuvant comprising a flagellin-based agent and an aluminum gel or salt and an antigen and, optionally, an additional adjuvant. In one aspect, the invention provides an adjuvant comprising a flagellin-based agent and an aluminum gel or salt.


In some embodiments, the described vaccine causes an improvement in adjuvant properties relative to a vaccine comprising the antigen and the aluminum gel or salt alone. In various embodiments, the vaccine and/or adjuvant described herein causes a broader, more diverse, more robust and longer lasting immunostimulatory effect than the vaccine comprising the antigen and the aluminum gel or salt alone (or as compared to the vaccine comprising the antigen and flagellin-based agent alone) and/or the adjuvant comprising the aluminum gel or salt alone (or as compared to the adjuvant comprising the flagellin-based agent alone).


In some embodiments, the described vaccine and/or described adjuvant causes immunostimulation of one or more of TH1 and TH2-mediated immune response. In some embodiments, the described vaccine and/or described adjuvant causes immunostimulation of both of TH1 and TH2-mediated immune response. In some embodiments, the described vaccine and/or described adjuvant causes immunostimulation of TH1-mediated immune response at levels greater than a vaccine comprising the antigen and the aluminum gel or salt alone or an adjuvant comprising the aluminum gel or salt alone.


TH1-mediated immune response (or “Type 1 response”) largely involves interaction with macrophages and CD8+ T cells and may be linked to interferon-γ, TNF-β, interleukin-2, and interleukin-10 production. The TH1-mediated immune response promotes cellular immune system and maximizes the killing efficacy of the macrophages and the proliferation of cytotoxic CD8+ T cells. The TH1-mediated immune response also promotes the production of opsonizing antibodies (e.g. IgG, IgM and IgA). The Type 1 cytokine IFN-γ increases the production of interleukin-12 by dendritic cells and macrophages, and via positive feedback, IL-12 stimulates the production of IFN-γ in helper T cells, thereby promoting the TH1 profile. Interferon-γ also inhibits the production of cytokines such as interleukin-4, a cytokine associated with the Type 2 response, and thus it also acts to preserve its own response.


TH2-mediated immune response (or “Type 2 response”) largely involves interaction with B-cells, eosinophils, and mast cells and may be linked to interleukin-4, interleukin-5, interleukin-6, interleukin-9, interleukin-10, and interleukin-13. TH2-mediated immune response promotes humoral immune system and may stimulate B-cells into proliferation, induce B-cell antibody class switching, and increase neutralizing antibody production (e.g. IgG, IgM and IgA as well as IgE antibodies). Other functions of the Type 2 response include promoting its own profile using two different cytokines. Interleukin-4 acts on helper T cells to promote the production of TH2 cytokines (including itself; it is auto-regulatory), while interleukin-10 (IL-10) inhibits a variety of cytokines including interleukin-2 and IFN-γ in helper T cells and IL-12 in dendritic cells and macrophages. The combined action of these two cytokines suggests that once the T cell has decided to produce these cytokines, that decision is preserved (and also encourages other T cells to do the same).


The division is medically relevant to, inter alia and without wishing to be bound by theory, the fact that alum adjuvants are only effective at inducing a TH2-mediated response and not a TH1-mediated response (see, e.g., Smith Korsholm, et al. Immunology. January 2010; 129(1): 75-86, the contents of which are hereby incorporated by reference in their entirety).


In various embodiments, the stimulation of TH1 and TH2-mediated immune responses may be measured by assays known in the art, including a number of antibody surrogate assays (e.g. ELISA and the like). For instance, without wishing to be bound by theory, IgG1 is associated with a TH2-like response, while a TH1 response is associated with the induction of IgG2a, IgG2b, and IgG3 antibodies.


In some embodiments, the described vaccine and/or described adjuvant causes an increase in titer of one or more of IgG1, IgG2a, IgG2b, and IgG3 antibodies (e.g. relative to the adjuvant comprising the aluminum gel or salt or flagellin-based agent alone, or relative to the vaccine comprising the antigen and the aluminum gel or salt alone (or flagellin-based agent) alone)). In some embodiments, the described vaccine and/or described adjuvant causes a relative increase in the titer of all of IgG1, IgG2a, IgG2b, and IgG3 antibodies. In some embodiments, the described vaccine and/or described adjuvant causes a relative increase in the titer of more IgG3 antibodies than the described vaccine and/or described adjuvant in the absence of a flagellin-based agent (or the described vaccine and/or described adjuvant in the absence of an aluminum gel or salt alone).


Accordingly, in some embodiments, the described vaccine and/or described adjuvant causes a diversified immune response. For example, in some embodiments, the total IgG generated by the described vaccines and/or adjuvants is greater than the described vaccines and/or adjuvants without the flagellin-based agent.


In some embodiments, the flagellin-based agent may be a flagellin molecule or flagellin-related polypeptide, or variants thereof that have TLR5 agonist activity. The flagellin-based agent may be from various sources, including a variety of Gram-positive and Gram-negative bacterial species. In some embodiments, the flagellin-based agents may have an amino acid sequence that is derived from any of the flagellins from bacterial species that are depicted in, for example, FIG. 7 of U.S. Patent Publication No. 2003/0044429, the contents of which are incorporated herein by reference in their entirety. The flagellin-based agent may have nucleotide sequences related to those encoding the flagellin polypeptides listed in, for example, FIG. 7 of U.S. 2003/0044429, which are publicly available at sources including the NCBI Genbank database.


The flagellin-based agent may be the major component of bacterial flagellum. The flagellin-based agents may be composed of one, or two, or three, or four, or five, or six, or seven domains or fragments thereof (see, e.g., FIG. 10 of U.S. Pat. No. 8,324,163, the contents of which are incorporated herein by reference in their entirety). The domains may be selected from ND0, ND1, ND2, D3, CD2, CD1, and CD0. Domains 0 (D0), 1 (D1), and 2 (D2) may be discontinuous and may be formed when residues in the amino terminus and carboxy terminus are juxtaposed by the formation of a hairpin structure. The amino and carboxy terminus comprising the D1 and D2 domains may be most conserved, whereas the middle hypervariable domain (D3) may be highly variable. The non-conserved D3 domain may be on the surface of the flagellar filament and may contain the major antigenic epitopes. The potent proinflammatory activity of flagellin may reside in the highly conserved N and CD1 and D2 regions.


The flagellin-based agents may be from a species of Salmonella, representative examples of which are S. typhimurium and S. dublin (encoded by GenBank Accession Number M84972). The flagellin related-polypeptide may be a fragment, variant, analog, homolog, or derivative of wild type flagellin (SEQ ID NO: 1), or combination thereof. A fragment, variant, analog, homolog, or derivative of flagellin may be obtained by rational-based design based on the domain structure of flagellin and the conserved structure recognized by TLR5.


The flagellin-based agent may be related to a flagellin polypeptide from any Gram-positive or Gram-negative bacterial species including, but not limited to, the flagellin polypeptides disclosed in U.S. Pat. Pub. 2003/0044429, the contents of which are incorporated herein, and the flagellin peptides corresponding to the Accession numbers listed in the BLAST results shown in FIG. 7 (panels A-F) of U.S. Patent Pub. 2003/0044429, or variants thereof.


In some embodiments, the flagellin-based agent comprises or consists of any of the polypeptides or nucleic acids encoding said polypeptides listed in Table 1. In some embodiments, the flagellin-based agent is encoded by the nucleotide sequences listed in Table 1. In a further embodiment, the flagellin-based agent comprises the polypeptides listed in Table 1. In some embodiments, the flagellin-based agent comprises one or more of SEQ ID NOs.: 1-252. In some embodiments, the flagellin-based agent comprises a flexible linker. In a further embodiment, the flexible linker comprises SEQ ID NO: 16. In yet a further embodiment, the flexible linker comprises SEQ ID NO: 242.


In some embodiments, the flagellin-based agent is a variant of SEQ ID NO: 1. In various embodiments, the flagellin-based agent is not SEQ ID NO: 1.


In some embodiments, the flagellin-based agent comprises or consists of CBLB502 (SEQ ID NO: 2) or is a variant of CBLB502 (SEQ ID NO: 2). In various embodiments, CBLB502 provides the advantage of, inter alia, removal of epitopes that generate neutralizing anti-flagellin antibodies and therefore allow for the surprising adjuvant properties seen here in combination with alum.


In some embodiments, the flagellin-based agent comprises mutations in epitopes recognized by neutralizing anti-CBLB502 antibodies. The flagellin-based agent may comprise one or more mutations in the epitopes recognized by neutralizing anti-CBLB502 antibodies which inhibit or abrogate the ability of the antibodies to neutralize the composition. In yet a further embodiment, the flagellin-based agent comprises a truncation and mutations in one or more epitopes. In a further embodiment, the mutations comprise replacement of the epitope residues with alanine. In a further embodiment, the mutated epitopes comprise one or more of the following residues: E153, S444, T154, N440, Q142, F131, D443, N68, T447, S110, Q117, R124, D113, E120, N127, and Q128.


The flagellin-based agent may comprise insertions, deletions, transposon insertions, and changes to any one of the D0, D1, D2, and the variable D3 domains. The D3 domain may be substituted in part, or in whole, with a hinge or linker polypeptide that allows the D1 and D2 domains to properly fold such that the variant stimulates TLR5 activity.


In some embodiments, the flagellin-based agent may be a minimal functional core of a flagellin, for example, deleting residues relative to the already shortened CBLB502 molecule. In some embodiments, the flagellin-based agent has altered amino acid identity relative to wild type, including deletions, additions and substitutions, that provide for improved activity. In some embodiments, the flagellin-based agent is derived from CBLB502 (SEQ ID NO: 2). In some embodiments, the flagellin-based agent comprises a truncation in one or more domains. In a further embodiment, the flagellin-based agent comprises a deletion in an N-terminal domain. In yet a further embodiment, the flagellin-based agent comprises a deletion in the ND0 domain. In yet a further embodiment, the flagellin-based agent comprises a deletion of the entire ND0 domain. In a further embodiment, the flagellin-based agent comprises a deletion in a C-terminal domain. In yet another embodiment, the flagellin-based agent comprises a deletion in the CD0 domain. In yet another embodiment, the flagellin-based agent retains amino acids 470-485 of the CD0 domain. In yet a further embodiment, the flagellin-based agent is CBLB502-S33 (SEQ ID NO: 17).


The flagellin-based agent may comprise at least 10, 11, 12, or 13 of the 13 conserved amino acids shown in FIG. 1A and FIG. 1B (positions 89, 90, 91, 95, 98, 101, 115, 422, 423, 426, 431, 436 and 452). The flagellin may be at least 30-99% identical to amino acids 1-174 and 418-505 of SEQ ID NO: 1.


In some embodiments, the flagellin-based agent comprises a tag. In yet a further embodiment, the tag is attached to the N-terminus of the flagellin-based agent. In yet another embodiment, the tag is attached to the C-terminus of the flagellin-based agent.


In some embodiments, the flagellin-based agent comprises a flexible linker. In a further embodiment, the flexible linker comprises SEQ ID NO: 16. In yet a further embodiment, the flexible linker comprises SEQ ID NO:242.


In various embodiments, the flagellin-based agent is one or more of the flagellin related composition derived from SEQ ID NO: 2. In various embodiments, the flagellin-based agent is one or more of CBLB502-S33ML (SEQ ID NO: 35), CBLB502-485CT (CBLB533, SEQ ID NO: 71), and CBLB502-S33MX (SEQ ID NO: 150).


In various embodiments, the flagellin-based agent is a flagellin derivative from a thermophilic microorganism. In various embodiments, the flagellin-based agent is a flagellin derivative from a microorganism well-tolerated by human. In some embodiments, the flagellin-based agent is one or more of SEQ ID NOs: 243-252.


In some embodiments, a variant includes molecules that have TLR5 agonist activity. In some embodiments, a variant includes molecules comprising an amino acid sequence having at least about 70% (e.g. about 70%, or about 71%, or about 72%, or about 73%, or about 74%, or about 75%, or about 76%, or about 77%, or about 78%, or about 79%, or about 80%, or about 81%, or about 82%, or about 83%, or about 84%, or about 85%, or about 86%, or about 87%, or about 88%, or about 89%, or about 90%, or about 91%, or about 92%, or about 93%, or about 94%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99%) sequence identity with SEQ ID NO: 1 or SEQ ID NO: 2.


In some embodiments, the flagellin-based agent comprises or consists of any of the polypeptides or nucleic acids encoding said polypeptides listed in Table 1. In some embodiments, the flagellin-based agent is encoded by the nucleotide sequences listed in Table 1. In a further embodiment, the flagellin-based agent comprises one or more of the polypeptides listed in Table 1. In some embodiments, the flagellin-based agent comprises or consists of polypeptides encoded by either SEQ ID NOs: 69 or 70. In some embodiments, the flagellin-based agent comprises or consists of the polypeptides of SEQ ID NO: 71, “CBLB543”. In some embodiments, the flagellin-based agent comprises or consists of polypeptides encoded by either SEQ ID NOs: 149 or 151. In some embodiments, the flagellin-based agent comprises or consists of the polypeptides of SEQ ID NO: 150, “CBLB533”.









TABLE 1







Illustrative Flagellin-Based Agents











SEQ

DNA/




ID
Construct Name
PRT
Species
Sequence





0001
Wild type
PRT

Salmonella

MAQVINTNSLSLLTQNNLNKSQSSLSSAIERLSSGLRINSAKDDAAGQAI






dublin

ANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQAT






NGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGA






NDGETITIDLQKIDVKSLGLDGFNVNGPKEATVGDLKSSFKNVTGYDTYA






AGADKYRVDINSGAVVTDAAAPDKVYVNAANGQLTTDDAENNTAVDLFKT






TKSTAGTAEAKAIAGAIKGGKEGDTFDYKGVTFTIDTKTGDDGNGKVSTT






INGEKVTLTVADIATGAADVNAATLQSSKNVYTSVVNGQFTFDDKTKNES






AKLSDLEANNAVKGESKITVNGAEYTANATGDKITLAGKTMFIDKTASGV






STLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNL






GNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNV






LSLLR





0002
CBLB502
PRT
Artificial
MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPMAQVINTNSLSLLTQNN





Sequence
LNKSQSSLSSAIERLSSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRN






ANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQ






QRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKS






LGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSAL






SKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNM






SKAQILQQAGTSVLAQANQVPQNVLSLLR





0003
T7 Promoter (forward)
DNA
Artificial
TAATACGACTCACTATAGGGG





Sequence






0004
FliC AA74-80 (forward)
DNA
Artificial
ATTGCGCAGACCACTGAAGG





Sequence






0005
Thrombin cleavage site
PRT
Artificial
LVPRGS





Sequence






0006
Enterokinase cleavage

Artificial
DDDDK



site

Sequence






0007
NS (N-terminal spoke
PRT
Artificial
SSGLRINSAKDDA



region; Ser32-Ala44)

Sequence






0008
CS (C-terminal spoke
PRT
Artificial
EDADYA



region; Glu464 to

Sequence




Ala469)








0009
linker
PRT
Artificial
AASAGAGQGGGGSG





Sequence






0010
linker
PRT
Artificial
EGKSSGSGSESKST





Sequence






0011
linker
PRT
Artificial
GGGRTSSSAASAGAGQGGGGSG





Sequence






0012
linker
PRT
Artificial
GPSG





Sequence






0013
linker
PRT
Artificial
GSAGSAAGSGEF





Sequence









0014
linker
PRT
Artificial
GSPG





Sequence






0015
linker
PRT
Artificial
KESGSVSSEQLAQFRSLD





Sequence






0016
linker
PRT
Artificial
SPGISGGGGGILDSMG





Sequence






0017
Mutant 33-485
PRT
Artificial
MRGSHHHHHHGMASMTGGQQMGRDLYDLVPRGSAKDPSGLRINSAKDDAA



Mutant S33

Sequence
GQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELS






VQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKI






QVGANDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLIN






EDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVT






NLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLR





0018
Mutant 33-485
DNA
Artificial
GCAGATTCTGCAGCAGGCTGGTTGATAATCTGGCGCAGGCTAACCAGG



Forward Primer

Sequence




CBLB485








0019
Mutant 33-485
DNA
Artificial
TCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGC



502 template sequence

Sequence
TAACCAGGTT





0020
Mutant 33-485
DNA
Artificial
CCTGGTTAGCCTGCGCCAGATTATCAACCAGCCTGCTGCAGAATCTGC



Reverse Primer

Sequence




CBLB485








0021
Mutant 33-485
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



DNA sequence of 485

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGCGGGGTTCTC



Mutant (T7 Promoter to


ATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAATG



Stop)


GGTCGGGATCTGTACGACCTGGTTCCGCGCGGTAGCGCGAAGGATCCGTC






TGGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTG






CTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAAC






GCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGA






AATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTA






ACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAG






CAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGG






TGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTA






ACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGC






CTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGG






TGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCG






CAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTG






TCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGTTT






TGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCG






CGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATG






TCTAAAGCGCAGATTCTGCAGCAGGCTGGTTGATAA





0022
Mutant 33-485
PRT
Artificial
MRGSHHHHHHGMASMTGGQQMGRDLYDLVPRGSAKDPSGLRINSAKDDAA



Expressed Mutant

Sequence
GQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELS



33-485


VQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKI






QVGANDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLIN






EDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVT






NLNSARSRIEDADYATEVSNMSKAQILQQAG





0023
Mutant 45CT
PRT
Artificial
MAQVINTNSLSLLTQNNLNKSQSSLSSAIERLSSGLRINSAKDDAAGQAI



Mutant 506T

Sequence
ANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQAT






NGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGA






NDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAA






AAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNS






ARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGS






HHHHHHGMASMTGGQQMGRDLYDDDDKDP





0024
Mutant 45CT
DNA
Artificial
ATGGCACAAGTCATTAATACAAACAGCCTGTCGCTGTTGACCCAGAATAA



Mutant 506T

Sequence
CCTGAACAAATCTCAGTCCTCACTGAGTTCCGCTATTGAGCGTCTGTCCT






CTGGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATT






GCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAA






CGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATG






AAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACT






AACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCA






GCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACG






GTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCT






AACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAG






CCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTG






GTGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCC






GCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATT






GTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGTT






TTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCC






GCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATAT






GTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGG






CTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCT






CATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAAT






GGGTCGGGATCTGTACGACGATGACGATAAGGATCCGTAAGTCGACAAGC






TTGCG





0025
Mutant 45CT
DNA
Artificial
CGAAAGACCATATGGCAGGCCAGGCGATTGC



Forward F45CT

Sequence






0026
Mutant 45CT
DNA
Artificial
CGCAAGCTTGTCGACTTACGGATCCTTATCGTC



Reverse R45CT

Sequence






0027
Mutant 45CT
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



Sequence of 45CT

Sequence
GAAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGGCAGGCCAG



construct


GCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTC






CCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGC






TGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAG






GCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGA






AATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAAT






TTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTT






GGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGT






GAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCG






GTGGTGGTGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGAC






GCTGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTC






TGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAA






ACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTG






AACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTC






TAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGG






CGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGG






GGTTCTCATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACA






GCAAATGGGTCGGGATCTGTACGACGATGACGATAAGGATCCGTAAGTCG






AC





0028
Mutant 45CT
PRT
Artificial
MAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRE



Expressed Mutant 45CT

Sequence
LSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQM






KIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTL






INEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNT






VTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSL






LVPRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDP





0029
Mutant 33GPS
DNA
Artificial
ATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGC



Expressed Mutant 33ML

Sequence
GATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCC






GTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTG






AATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGC






CACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCGGACCATCAG






GTCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAAT






CAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAA






AATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAA






AAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCG






GGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGT






GGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAG






CCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGC






CGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGC






GCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGG






TTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCAT






CATCATCATGGTTAA





0030
Mutant 33GPS
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



Expressed Mutant 33ML

Sequence
NEINNNLQRVRELSVQATNGTNSDSDLKSIGPSGQDEIQQRLEEIDRVSN






QTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSP






GSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARS






RIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHH






HHHG





0031
Mutant 33GPS
DNA
Artificial
GATATACATATGAGCGGGTTACGGATCAACAG



Forward primer FSY3CT

Sequence






0032
Mutant 33GPS
DNA
Artificial
AGATCTCCCGGGGAATTAACATTGAACCC



Reverse primer RMIMxN

Sequence






0033
Mutant 33GPS
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



DNA sequence of

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC



mutant 33GPS


GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTGGACCATCA






GGTGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGAC






TCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCC






AGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATT






GATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAG






TACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACG






CAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATT






ACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTAT






CGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGA






TTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCG






CAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCA






TCATGGTTAAGTCGAC





0034
Mutant 33GPS
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



Expressed Mutant

Sequence
NEINNNLQRVRELSVQATGPSGEIQQRLEEIDRVSNQTQFNGVKVLSQDN



33GPS


QMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTANPLASIDSAL






SKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNM






SKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHG





0035
Mutant 33ML
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



Mutant 33CT (Fixed A)

Sequence
NEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQF






NGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGISG






GGGGILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQN






RFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLA






QANQVPQNVLSLLVPRGSHHHHHHG





0036
Mutant 33ML
DNA
Artificial
ATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGC



Mutant 33CT (Fixed A)

Sequence
GATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCC






GTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTG






AATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGC






CACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAA






TTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTT






AACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGG






TGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGA






AAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGT






GGTGGTGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGC






TGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTG






CATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAAC






CGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAA






CTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTA






ATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCG






CAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGG






TTCTCATCATCATCATCATCATGGTTAA





0037
Mutant 33ML
DNA
Artificial
TCTAGACCCGGGAAGTACCGCTAACCCACTGGCTTCAATTG



Forward primer F502ML

Sequence






0038
Mutant 33ML
DNA
Artificial
CCAGTCATGTCGACTTAACCATGATGATGATGATGATGAG



Reverse primer R33CT

Sequence






0039
Mutant 33ML
DNA
Artificial
CTCATCATCATCATCATCATGGTTAAGTCGACAAGCTTGCGGCCGCAGAG



502 template sequence

Sequence
CTCGC





0040
Mutant 33ML
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



33ML construct

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC






GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACT






AACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCT






GGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAG






TCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGT






GAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCT






TGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTT






CAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGG






GCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGT






AACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAA






CGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACT






TCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACT






GGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC





0041
Mutant 33ML
DNA
Artificial
ATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGC



Expressed Mutant 33ML

Sequence
GATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCC






GTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTG






AATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGC






CACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAA






TTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTT






AACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGG






TGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGA






AAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCT






AACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCG






TTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACC






TTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGAT






GCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCA






GCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACG






TCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGT






TAA





0042
Mutant 33ML
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



Mutant 33ML

Sequence
NFINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQF






NGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIED






ADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHG





0043
Mutant 37CT
DNA
Artificial
ATGGCACAAGTCATTAATACAAACAGCCTGTCGCTGTTGACCCAGAATAA



delta ND0 mutant based

Sequence
CCTGAACAAATCTCAGTCCTCACTGAGTTCCGCTATTGAGCGTCTGTCCT



on CBLB506T


CTGGTCTGCGTATCAACGGCGCGAAAGACGATGCGGCAGGCCAGGCGATT






GCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAA






CGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATG






AAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACT






AACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCA






GCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACG






GTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCT






AACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAG






CCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTG






GTGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCC






GCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATT






GTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCT






TTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCC






GCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATAT






GTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGG






CTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCT






CATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAAT






GGGTCGGGATCTGTACGACGATGACGATAAGGATCCGTAAGTCGACAAGC






TTGCG





0044
Mutant 37CT
PRT
Artificial
MAQVINTNSLSLLTQNNLNKSQSSLSSAIERLSSGLRINGAKDDAAGQAI



delta ND0 mutant based

Sequence
ANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQAT



on CBLB506T


NGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGA






NDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAA






AAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNS






ARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGS






HHHHHHGMASMTGGQQMGRDLYDDDDKDP





0045
Mutant 37CT
DNA
Artificial
CTCTGGTCATATGATCAACAGCGCGAAAGACGATGC



Forward F37CT

Sequence






0046
Mutant 37CT
DNA
Artificial
TCTAGAGTCGACTATTAAGCCATACCATGATGATGATGATGATGAG



Reverse R37CT

Sequence






0047
Mutant 37CT
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



37CT construct

Sequence
GAAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGATCAACAGC






GCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAA






TATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTA






TTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAG






CGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTC






CGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCG






ATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAG






GACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTAC






CATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCA






ATGTTAATTCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTCTAGACTCC






ATGGGTACATTAATCAATGAAGACGCTGCCGCAGCCAAGAAAAGTACCGC






TAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTC






GTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAAC






CTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGA






TGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGC






AGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAAC






GTCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGG






TATGGCTTAATAGTCGAC





0048
Mutant 37CT
PRT
Artificial
MINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNFIN



Mutant 37CT

Sequence
NNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVK






VLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGG






ILDSMGTLINEDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDS






AITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQ






VPQNVLSLLVPRGSHHHHHHGMA





0049
Mutant 445
PRT
Artificial
MRGSHHHHHHGMASMTGGQQMGRDLYDLVPRGSAKDPMAQVINTNSLSLL



502-SY1

Sequence
TQNNLNKSQSSLSSAIERLSSGLRINSAKDDAAGQAIANRFTSNIKGLTQ






ASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQ






DEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKI






DVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASI






DSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDADYATE






VSNMSKAQILQQAGTSVLAQANQVPQNVLSLLR





0050
Mutant 445
DNA
Artificial
ATGCGGGGTTCTCATCATCATCATCATCATGGTATGGCTAGCATGACTGG



502-SY1

Sequence
TGGACAGCAAATGGGTCGGGATCTGTACGACCTGGTTCCGCGCGGTAGCG






CGAAGGATCCGATGGCACAAGTCATTAATACAAACAGCCTGTCGCTGTTG






ACCCAGAATAACCTGAACAAATCTCAGTCCTCACTGAGTTCCGCTATTGA






GCGTCTGTCCTCTGGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAG






GCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAG






GCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGG






TGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTG






TTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAG






GATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGAC






TCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCC






AGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATT






GATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAT






TTCCGGTGGTGGTGGTGGAATTCTAGACTCCATGGGTACATTAATCAATG






AAGACGCTGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATT






GATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAAT






TCAAAACCGTTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCA






ATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAA






GTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGT






TCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGCGTT






AA





0051
Mutant 445
DNA
Artificial
GGCAATTCAAAACCGTTTTGATTAAGCCATTACCAACCTTGG



Forward Primer

Sequence




CBLB445








0052
Mutant 445
DNA
Artificial
CCAAGGTTGGTAATGGCTTAATCAAAACGGTTTTGAATTGCC



Reverse Primer

Sequence




CBLB445








0053
Mutant 445
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



mutant 445

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGCGGGGTTCTC






ATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAATG






GGTCGGGATCTGTACGACCTGGTTCCGCGCGGTAGCGCGAAGGATCCGAT






GGCACAAGTCATTAATACAAACAGCCTGTCGCTGTTGACCCAGAATAACC






TGAACAAATCTCAGTCCTCACTGAGTTCCGCTATTGAGCGTCTGTCCTCT






GGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGC






TAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACG






CTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAA






ATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAA






CGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGC






AACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGT






GTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAA






CGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCC






TTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGT






GGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCGC






AGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGT






CAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGTTTT






GATTAA





0054
Mutant 445
PRT
Artificial
MRGSHHHHHHGMASMTGGQQMGRDLYDLVPRGSAKDPMAQVINTNSLSLL



mutant 445

Sequence
TQNNLNKSQSSLSSAIERLSSGLRINSAKDDAAGQAIANRFTSNIKGLTQ






ASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQ






DEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKI






DVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASI






DSALSKVDAVRSSLGAIQNRFD





0055
Mutant 461
DNA
Artificial
CAATCTGAACTCCGCGCGTTGACGTATCTAAGATGCTGACTATGC



Forward Primer

Sequence




CBLB461








0056
Mutant 461
DNA
Artificial
GCATAGTCAGCATCTTAGATACGTCAACGCGCGGAGTTCAGATTG



Reverse Primer

Sequence




CBLB461








0057
Mutant 461
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



Mutant 461

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGCGGGGTTCTC






ATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAATG






GGTCGGGATCTGTACGACCTGGTTCCGCGCGGTAGCGCGAAGGATCCGAT






GGCACAAGTCATTAATACAAACAGCCTGTCGCTGTTGACCCAGAATAACC






TGAACAAATCTCAGTCCTCACTGAGTTCCGCTATTGAGCGTCTGTCCTCT






GGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGC






TAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACG






CTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAA






ATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAA






CGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGC






AACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGT






GTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAA






CGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCC






TTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGT






GGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCGC






AGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGT






CAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGTTTT






GATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGC






GCGTTGACGTATCTAA





0058
Mutant 461
PRT
Artificial
MRGSHHHHHHGMASMTGGQQMGRDLYDLVPRGSAKDPMAQVINTNSLSLL



Mutant 461

Sequence
TQNNLNKSQSSLSSAIERLSSGLRINSAKDDAAGQAIANRFTSNIKGLTQ






ASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQ






DEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKI






DVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASI






DSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSAR





0059
Mutant 467
DNA
Artificial
CGTAGCCGTATCGAAGATGCTTAATAGGCAACGGAAGTTTCTAATATG



Forward Primer

Sequence




CBLB467








0060
Mutant 467
DNA
Artificial
CATATTAGAAACTTCCGTTGCCTATTAAGCATCTTCGATACGGCTACG



Reverse Primer

Sequence




CBLB467








0061
Mutant 467
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



Mutant 467

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGCGGGGTTCTC






ATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAATG






GGTCGGGATCTGTACGACCTGGTTCCGCGCGGTAGCGCGAAGGATCCGAT






GGCACAAGTCATTAATACAAACAGCCTGTCGCTGTTGACCCAGAATAACC






TGAACAAATCTCAGTCCTCACTGAGTTCCGCTATTGAGCGTCTGTCCTCT






GGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGC






TAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACG






CTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAA






ATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAA






CGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGC






AACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGT






GTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAA






CGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCC






TTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGT






GGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCGC






AGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGT






CAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGTTTT






GATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGC






GCGTAGCCGTATCGAAGATGCTTAATAG





0062
Mutant 467
PRT
Artificial
MRGSHHHHHHGMASMTGGQQMGRDLYDLVPRGSAKDPMAQVINTNSLSLL



Mutant 467

Sequence
TQNNLNKSQSSLSSAIERLSSGLRINSAKDDAAGQAIANRFTSNIKGLTQ






ASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQ






DEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKI






DVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASI






DSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDA





0063
Mutant 470CT
DNA
Artificial
ATGCGGGGTTCTCATCATCATCATCATCATGGTATGGCTAGCATGACTGG



CBLB502

Sequence
TGGACAGCAAATGGGTCGGGATCTGTACGACGATGACGATAAGGATCCGA






TGGCACAAGTCATTAATACAAACAGCCTGTCGCTGTTGACCCAGAATAAC






CTGAACAAATCTCAGTCCTCACTGAGTTCCGCTATTGAGCGTCTGTCCTC






TGGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTG






CTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAAC






GCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGA






AATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTA






ACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAG






CAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGG






TGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTA






ACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGC






CTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGG






TGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCG






CAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTG






TCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGTTT






TGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCG






CGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATG






TCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGC






TAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGCGTTAA





0064
Mutant 470CT
DNA
Artificial
CGATAAGGATCATATGGCACAAGTCATTAATAC



Forward Primer F470CT

Sequence






0065
Mutant 470CT
DNA
Artificial
AGATCTGTCGACTTAACCATGATGATGATGATGATGAGAACCCCGCGGAA



Reverse Primer R470CT

Sequence
CCAGTGCATAGTCAGCATCTTCGATACG





0066
Mutant 470CT
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



Mutant 470CT

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGGCACAAGTCA






TTAATACAAACAGCCTGTCGCTGTTGACCCAGAATAACCTGAACAAATCT






CAGTCCTCACTGAGTTCCGCTATTGAGCGTCTGTCCTCTGGTCTGCGTAT






CAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCA






CTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGC






ATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAA






CCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACT






CTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAA






GAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCT






GTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAA






CCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGAT






GGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTCT






AGACTCCATGGGTACATTAATCAATGAAGACGCTGCCGCAGCCAAGAAAA






GTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGAC






GCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGTTTTGATTCAGCCAT






TACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTA






TCGAAGATGCTGACTATGCACTGGTTCCGCGGGGTTCTCATCATCATCAT






CATCATGGTTAAGTCGAC





0067
Mutant 470CT
PRT
Artificial
MAQVINTNSLSLLTQNNLNKSQSSLSSAIERLSSGLRINSAKDDAAGQAI



Mutant 470CT

Sequence
ANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQAT






NGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGA






NDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAA






AAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNS






ARSRIEDADYALVPRGSHHHHHHG





0068
Mutant 485CT
DNA
Artificial
AGATCTCCGCGGAACCAGACCAGCCTGCTGCAGAATCTGC



Reverse primer R485MC

Sequence






0069
Mutant 485CT
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



DNA Sequence of

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC



485CT


GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACT






AACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCT






GGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAG






TCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGT






GAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCT






TGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTT






CAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGG






GCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGT






AACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAA






CGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTCTG






GTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC





0070
Mutant 485CT
DNA
Artificial
ATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGC



Mutant 485CT

Sequence
GATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCC






GTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTG






AATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGC






CACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAA






TTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTT






AACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGG






TGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGA






AAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCT






AACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCG






TTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACC






TTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGAT






GCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCA






GCAGGCTGGTCTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTT






AA





0071
Mutant 485CT
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



Mutant 485CT

Sequence
NEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQF






NGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIED






ADYATEVSNMSKAQILQQAGLVPRGSHHHHHHG





0072
Mutant 485D
DNA
Artificial
AACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCG



DNA template for

Sequence
TTCTTCTCTGGGGGCAATTCAAAACCGTTTTGATTCAGCCATTACCGCCC



deletion mutations from


TTGGCAATACGGTAACCAAT



Mutant 485CT variant








0073
Mutant 485D
PRT
Artificial
NPLASIDSALSKVDAVRSSLGAIQNRFDSAITALGNTVTN



PRT sequence for

Sequence




deletion mutations from






Mutant 485CT variant








0074
Mutant 485D
DNA
Artificial
GTTCGTTCTTCTCTGGGGGCAATTGATTCAGCCATTACCGCCCTTG



Forward Primer F485D

Sequence






0075
Mutant 485D
DNA
Artificial
CAAGGGCGGTAATGGCTGAATCAATTGCCCCCAGAGAAGAACGAAC



Reverse Primer R485D

Sequence






0076
Mutant 485D
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



DNA Sequence of

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC



485CT_Delta construct


GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACT






AACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCT






GGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAG






TCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGT






GAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCT






TGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTT






CAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGG






GCAATTGATTCAGCCATTACCGCCCTTGGCAATACGGTAACCAATCTGAA






CTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTA






ATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTCTGGTTCCGCGGGGT






TCTCATCATCATCATCATCATGGTTAAGTCGAC





0077
Mutant 485D
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



Mutant 485D (CT_Delta

Sequence
NEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQF



439-442


NGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIDSAITALGNTVTNLNSARSRIEDADYA






TEVSNMSKAQILQQAGLVPRGSHHHHHHG








0078
Mutant CGD1
DNA
Artificial
ATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGC



Mutant SY3CT

Sequence
GATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCC






GTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTG






AATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGC






CACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAA






TTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTT






AACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGG






TGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGA






AAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCT






AACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCG






TTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACC






TTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGAT






GCTGACTATGCACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGG






TTAA





0079
Mutant CGD1
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



Mutant SY3CT

Sequence
NEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQF






NGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIED






ADYALVPRGSHHHHHHG





0080
Mutant CGD1
DNA
Artificial
ATGAGTAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGA



GFPuv4

Sequence
ATTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTG






AAGGTGATGCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACT






GGAAAACTACCTGTTCCATGGCCAACACTTGTCACTACTCTGACGTATGG






TGTTCAATGCTTTTCCCGTTATCCGGATCATATGAAACGGCATGACTTTT






TCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAACGCACTATATCTTTC






AAAGATGACGGGAACTACAAGACGCGTGCTGAAGTCAAGTTTGAAGGTGA






TACCCTTGTTAATCGTATCGAGTTAAAAGGTATTGATTTTAAAGAAGATG






GAAACATTCTCGGACACAAACTCGAGTACAACTATAACTCACACAATGTA






TACATCACGGCAGACAAACAAAAGAATGGAATCAAAGCTAACTTCAAAAT






TCGCCACAACATTGAAGATGGATCCGTTCAACTAGCAGACCATTATCAAC






AAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTAC






CTGTCGACACAATCTGCCCTTTTGAAAGATCCCAACGAAAAGCGTGACCA






CATGGTCCTTCTTGAGTTTGTAACTGCTGCTGGGATTACACATGGCATGG






ATGAACTATACAAA





0081
Mutant CGD1
PRT
Artificial
MSKGEELFTGWPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTG



GFPuv4

Sequence
KLPVPWPTLVTTLTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFK






DDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVY






ITADKQKNGIKANFKIRHNINHYLSTQSALLKDPNEKRDHMVLLEFVTAA






GITHGMDELYK





0082
Mutant CGD1
DNA
Artificial
ATGAGTAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGA



GFPuv4 mutation of wt

Sequence
ATTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTG



NdeI site


AAGGTGATGCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACT






GGAAAACTACCTGTTCCATGGCCAACACTTGTCACTACTCTGACGTATGG






TGTTCAATGCTTTTCCCGTTATCCGGATCACATGAAACGGCATGACTTTT






TCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAACGCACTATATCTTTC






AAAGATGACGGGAACTACAAGACGCGTGCTGAAGTCAAGTTTGAAGGTGA






TACCCTTGTTAATCGTATCGAGTTAAAAGGTATTGATTTTAAAGAAGATG






GAAACATTCTCGGACACAAACTCGAGTACAACTATAACTCACACAATGTA






TACATCACGGCAGACAAACAAAAGAATGGAATCAAAGCTAACTTCAAAAT






TCGCCACAACATTGAAGATGGATCCGTTCAACTAGCAGACCATTATCAAC






AAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTAC






CTGTCGACACAATCTGCCCTTTTGAAAGATCCCAACGAAAAGCGTGACCA






CATGGTCCTTCTTGAGTTTGTAACTGCTGCTGGGATTACACATGGCATGG






ATGAACTATACAAATAA





0083
Mutant CGD1
DNA
Artificial
TCTAGACGGCCGATCTCAGGTAAGAATGGAATCAAAGCTAACTTCAAAAT



Forward primer FCGFP

Sequence
TCGC





0084
Mutant CGD1
PRT
Artificial
NVYIPISGKNGIKANFKIRH



PRT altered GFPuv4

Sequence




sequence








0085
Mutant CGD1
DNA
Artificial
AGATCTCCGCGGTTTGTATAGTTCATCCATGCCATGTGTAATCCC



Reverse RCGFP

Sequence






0086
Mutant CGD1
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



DNA Sequence of CGD1

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC



construct


GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACT






AACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCT






GGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAG






TCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGT






GAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCT






TGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTT






CAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGG






GCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGT






AACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAC






TGGTTCCGCCGATCTCAGGTAAGAATGGAATCAAAGCTAACTTCAAAATT






CGCCACAACATTGAAGATGGATCCGTTCAACTAGCAGACCATTATCAACA






AAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTACC






TGTCGACACAATCTGCCCTTTTGAAAGATCCCAACGAAAAGCGTGACCAC






ATGGTCCTTCTTGAGTTTGTAACTGCTGCTGGGATTACACATGGCATGGA






TGAACTATACAAACCGCGGGGTTCTCATCATCATCATCATCATGGTTAAG






TCGAC





0087
Mutant CGD1
DNA
Artificial
ATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGC



Expressed Mutant CGD1

Sequence
GATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCC






GTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTG






AATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGC






CACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAA






TTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTT






AACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGG






TGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGA






AAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCT






AACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCG






TTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACC






TTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGAT






GCTGACTATGCACTGGTTCCGCCGATCTCAGGTAAGAATGGAATCAAAGC






TAACTTCAAAATTCGCCACAACATTGAAGATGGATCCGTTCAACTAGCAG






ACCATTATCAACAAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCA






GACAACCATTACCTGTCGACACAATCTGCCCTTTTGAAAGATCCCAACGA






AAAGCGTGACCACATGGTCCTTCTTGAGTTTGTAACTGCTGCTGGGATTA






CACATGGCATGGATGAACTATACAAACCGCGGGGTTCTCATCATCATCAT






CATCATGGTTAA





0088
Mutant CGD1
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



Expressed Mutant CGD1

Sequence
NEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQF






NGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIED






ADYALVPPISGKNGIKANFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLP






DNHYLSTQSALLKDPNEKRDHMVLLEFVTAAGITHGMDELYKPRGSHHHH






HHG





0089
Mutant CPM194
DNA
Artificial
ATGAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGT



Mutant CPM194

Sequence
GGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAG






CCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGC






CGTATCGAAGATGCTGACTATGCATCCCCGGGAAGCGGGTTACGGATCAA






CAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTT






CTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATT






TCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCT






GCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTG






ATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAA






ATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTC






TCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTCTGGTTC






CGCGGGGTTCTCATCATCATCATCATCATGGTTAA





0090
Mutant CPM194
PRT
Artificial
MSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARS



Mutant CPM194

Sequence
RIEDADYASPGSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGI






SIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEE






IDRVSNQTQFNGVKVLSQDNQMKIQVGANDGLVPRGSHHHHHHG





0091
Mutant CPM194
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



Mutant CPM194

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGTACCGCTA






ACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGT






TCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCT






TGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATG






CTGACTATGCATCCCCGGGAAGCGGGTTACGGATCAACAGCGCGAAAGAC






GATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGG






TCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGA






CCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGT






GAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAA






ATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTT






CTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAG






ATGAAAATCCAGGTTGGTGCTAACGATGGTCTGGTTCCGCGGGGTTCTCA






TCATCATCATCATCATGGTTAAGTCGAC





0092
Mutant CPM194
DNA
Artificial
TCTAGACATATGAGTACCGCTAACCCACTGGCTTCAATTG



Forward primer FCD1

Sequence






0093
Mutant CPM194
DNA
Artificial
GCTTCCCGGGGATGCATAGTCAGCATCTTCGATACGGC



Reverse primer RCD1J

Sequence






0094
Mutant CPM194
DNA
Artificial
GCATCCCCGGGAAGCGGGTTACGGATCAACAGCG



Forward primer FND1J

Sequence






0095
Mutant CPM194
DNA
Artificial
AGATCTCCGCGGAACCAGACCATCGTTAGCACCAACCTGGATTTTCATCT



Reverse primer RND1

Sequence






0096
Mutant CPM217
DNA
Artificial
ATGAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGT



Mutant CPM217

Sequence
GGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAG






CCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGC






CGTATCGAAGATGCTGACTATGCATCCCCGGGAAGCGGGTTACGGATCAA






CAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTT






CTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATT






TCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCT






GCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTG






ATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAA






ATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTC






TCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCA






TTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGG






TTCAATGTTAATCTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGG






TTAA





0097
Mutant CPM217
PRT
Artificial
MSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARS



Mutant CPM217

Sequence
RIEDADYASPGSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGI






SIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEE






IDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDG






FNVNLVPRGSHHHHHHG





0098
Mutant CPM217
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



Mutant CPM217

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGTACCGCTA






ACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGT






TCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCT






TGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATG






CTGACTATGCATCCCCGGGAAGCGGGTTACGGATCAACAGCGCGAAAGAC






GATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGG






TCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGA






CCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGT






GAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAA






ATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTT






CTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAG






ATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCT






GCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATC






TGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC





0099
Mutant CPM217
DNA
Artificial
AGATCTCCGCGGAACCAGATTAACATTGAACCCATCAAGGCCAAG



Reverse primer

Sequence




RCPM217








0100
Mutant GD1G
DNA
Artificial
CCCGTTATCCGGATCACATGAAACGGCATGACTTTTTC



Forward Primer FGFP77

Sequence






0101
Mutant GD1G
DNA
Artificial
GAAAAAGTCATGCCGTTTCATGTGATCCGGATAACGGG



Reverse Primer RGFP77

Sequence






0102
Mutant GD1G
DNA
Artificial
CTGTTCCATGGCCAACACTTG



FGFP54

Sequence






0103
Mutant GD1G
DNA
Artificial
TCTAGACATATGAGTAAAGGAGAAGAACTTTTCACTGGAGTTGTCC



Forward primer FNGFP

Sequence






0104
Mutant GD1G
DNA
Artificial
GGCCTATGCGGCCGCAGTAAAGGAGAAGAACTTTTCACTGGAGTTGTCCC



altered GFP DNA

Sequence
AATTCTTGTTGAA



sequence








0105
Mutant GD1G
DNA
Artificial
AGATCTATTAATGCGGCCTGATAGGCCTTGTTTGTCTGCCGTGATGTATA



Reverse RNGFP

Sequence
CATTGTG





0106
Mutant GD1G
PRT
Artificial
SHNVYITADKQGLSGRNM



altered GFP PRT

Sequence




sequence








0107
Mutant GD1G
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



DNA Sequence of GD1G

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGTAAAGGAG



construct


AAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGATGGTGAT






GTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGATGCAAC






ATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTG






TTCCATGGCCAACACTTGTCACTACTCTGACGTATGGTGTTCAATGCTTT






TCCCGTTATCCGGATCACATGAAACGGCATGACTTTTTCAAGAGTGCCAT






GCCCGAAGGTTATGTACAGGAACGCACTATATCTTTCAAAGATGACGGGA






ACTACAAGACGCGTGCTGAAGTCAAGTTTGAAGGTGATACCCTTGTTAAT






CGTATCGAGTTAAAAGGTATTGATTTTAAAGAAGATGGAAACATTCTCGG






ACACAAACTCGAGTACAACTATAACTCACACAATGTATACATCACGGCAG






ACAAACAAGGCCTATCAGGCCGCATTATGAGCGGGTTACGGATCAACAGC






GCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAA






TATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTA






TTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAG






CGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTC






CGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCG






ATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAG






GACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTAC






CATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCA






ATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCT






GCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAA






CCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGA






ACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCACTGGTTCCGCCG






ATCTCAGGTAAGAATGGAATCAAAGCTAACTTCAAAATTCGCCACAACAT






TGAAGATGGATCCGTTCAACTAGCAGACCATTATCAACAAAATACTCCAA






TTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTACCTGTCGACACAA






A=TCTGCCCTTTTGAAAGATCCCAACGAAAAGCGTGACCACATGGTCCTT






CTTGAGTTTGTAACTGCTGCTGGGATTACACATGGCATGGATGAACTATA






CAAACCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC





0108
Mutant GD1G
DNA
Artificial
ATGAGTAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGA



Expressed Mutant

Sequence
ATTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTG



GD1G


AAGGTGATGCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACT






GGAAAACTACCTGTTCCATGGCCAACACTTGTCACTACTCTGACGTATGG






TGTTCAATGCTTTTCCCGTTATCCGGATCACATGAAACGGCATGACTTTT






TCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAACGCACTATATCTTTC






AAAGATGACGGGAACTACAAGACGCGTGCTGAAGTCAAGTTTGAAGGTGA






TACCCTTGTTAATCGTATCGAGTTAAAAGGTATTGATTTTAAAGAAGATG






GAAACATTCTCGGACACAAACTCGAGTACAACTATAACTCACACAATGTA






TACATCACGGCAGACAAACAAGGCCTATCAGGCCGCATTATGAGCGGGTT






ACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACC






GCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAAC






GACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAA






CAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGA






CTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGT






CTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAA






AGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATG






GTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGC






CTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGC






TTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGG






GGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACG






GTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGC






ACTGGTTCCGCCGATCTCAGGTAAGAATGGAATCAAAGCTAACTTCAAAA






TTCGCCACAACATTGAAGATGGATCCGTTCAACTAGCAGACCATTATCAA






CAAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTA






CCTGTCGACACAATCTGCCCTTTTGAAAGATCCCAACGAAAAGCGTGACC






ACATGGTCCTTCTTGAGTTTGTAACTGCTGCTGGGATTACACATGGCATG






GATGAACTATACAAACCGCGGGGTTCTCATCATCATCATCATCATGGTTA






A





0109
Mutant GD1G
PRT
Artificial
MSKGEELFTGWPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTG



Expressed Mutant

Sequence
KLPVPWPTLVTTLTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFK



GD1G


DDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVY






ITADKQGLSGRIMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNAND






GISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRL






EEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGL






DGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTV






TNLNSARSRIEDADYALVPPISGKNGIKANFKIRHNIEDGSVQLADHYQQ






NTPIGDGPVLLPDNHYLSTQSALLKDPNEKRDHMVLLEFVTAAGITHGMD






ELYKPRGSHHHHHHG





0110
Mutant MF227C
DNA
Artificial
CTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGG



mutant 470CT template

Sequence
TGGTGGAATTACATTAATCAATGAAGACGCTGCCGCAGCCAAGAAAAGTA






CCGCTAACCCACTGGCTTCAATTG





0111
Mutant MF227C
PRT
Artificial
LGLDGFNVNSPGISGGGGGITLINEDAAAAKKSTANPLASI



mutant 470CT template

Sequence






0112
Mutant MF227C
DNA
Artificial
AGATCTCCGCGGAACCAGTAAAGAGAGGACGTTTTGCGGAACCTGGTTTG



Reverse Primer R2YY

Sequence
CATAGTCAGCATCTTCGATACG





0113
Mutant MF227C
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



DNA sequence of

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC



Mutant MF227C


GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACT






AACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCT






GGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAG






TCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGT






GAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCT






TGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTT






CAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGG






GCAATTCAAAACCGTTTTGATTCAGCCATTACCAACCTTGGCAATACGGT






AACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAA






ACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCAT






CATCATCATCATCATGGTTAAGTCGAC





0114
Mutant MF227C
DNA
Artificial
ATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGC



Mutant MF227C

Sequence
GATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCC






GTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTG






AATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGC






CACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAA






TTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTT






AACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGG






TGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGA






AAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCT






AACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCG






TTCTTCTCTGGGGGCAATTCAAAACCGTTTTGATTCAGCCATTACCAACC






TTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGAT






GCTGACTATGCAAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCC






GCGGGGTTCTCATCATCATCATCATCATGGTTAA





0115
Mutant MF2270
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



Mutant MF2270

Sequence
NEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQF






NGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIED






ADYANQVPQNVLSLLVPRGSHHHHHHG





0116
Mutant MF227N
DNA
Artificial
AGATCTCCCGGGGAACCATCGTTAGCACCAACCTGGATTTTC



Reverse Primer

Sequence




RMF227N








0117
Mutant MF227N
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



DNA sequence of

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC



mutant MF227N


GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACT






AACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCT






GGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAG






TCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGT






TCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTC






AAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGCTTTG






ATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCG






CGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTC






TAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTA






ACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCCGCGGGGTTCTCAT






CATCATCATCATCATGGTTAAGTCGAC





0118
Mutant MF227N
DNA
Artificial
ATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGC



mutant MF227N

Sequence
GATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCC






GTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTG






AATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGC






CACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAA






TTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTT






AACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGG






TGCTAACGATGGTTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTG






ATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATT






CAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAA






TCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAG






TTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTT






CTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGGTTCC






GCGGGGTTCTCATCATCATCATCATCATGGTTAA





0119
Mutant MF227N
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



mutant MF227N

Sequence
NEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQF






NGVKVLSQDNQMKIQVGANDGSPGSTANPLASIDSALSKVDAVRSSLGAI






QNRFDSAITNLGNTVTNLNSARSRIEDADYATEVSNMSKAQILQQAGTSV






LAQANQVPQNVLSLLVPRGSHHHHHHG





0120
Mutant MF233
DNA
Artificial
AGATCTCCGCGGAACCAGCAGGTTATTCTGGGTCAACAGCGACAGGCTGT



Reverse primer RMF233

Sequence
TTGTATTAATGACTTGTGCATAGTCAGCATCTTCGATACG





0121
Mutant MF233
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



DNA Sequence of

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC



construct MF233


GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACT






AACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCT






GGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAG






TCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGT






GAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCT






TGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTT






CAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGG






GCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGT






AACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAC






AAGTCATTAATACAAACAGCCTGTCGCTGTTGACCCAGAATAACCTGCTG






GTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC





0122
Mutant MF233
DNA
Artificial
ATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGC



MF233

Sequence
GATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCC






GTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTG






AATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGC






CACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAA






TTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTT






AACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGG






TGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGA






AAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCT






AACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCG






TTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACC






TTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGAT






GCTGACTATGCACAAGTCATTAATACAAACAGCCTGTCGCTGTTGACCCA






GAATAACCTGCTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTT






AA





0123
Mutant MF233
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



MF233

Sequence
NEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQF






NGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIED






ADYAQVINTNSLSLLTQNNLLVPRGSHHHHHHG





0124
Mutant MF471
DNA
Artificial
GCTGACTATGCAACGGCAGTTTCTGCTATGTCTGCAGCGCAGATTCTGC



Forward primer F471-77

Sequence






0125
Mutant MF471
DNA
Artificial
GCAGAATCTGCGCTGCAGACATAGCAGAAACTGCCGTTGCATAGTCAGC



Reverse Primer R471-77

Sequence






0126
Mutant MF471
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



DNA Sequence of

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC



construct MF471


GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACT






AACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCT






GGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAG






TCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGT






GAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCT






TGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTT






CAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGG






GCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGT






AACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAA






CGGCAGTTTCTGCTATGTCTGCAGCGCAGATTCTGCAGCAGGCTGGTCTG






GTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC





0127
Mutant MF471
DNA
Artificial
ATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGC



MF471

Sequence
GATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCC






GTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTG






AATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGC






CACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAA






TTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTT






AACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGG






TGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGA






AAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCT






AACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCG






TTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACC






TTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGAT






GCTGACTATGCAACGGCAGTTTCTGCTATGTCTGCAGCGCAGATTCTGCA






GCAGGCTGGTCTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTT






AA





0128
Mutant MF471
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



MF471

Sequence
NEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQF






NGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIED






ADYATAVSAMSAAQILQQAGLVPRGSHHHHHHG





0129
Mutant MF479
DNA
Artificial
GTTTCTAATATGTCTAAAGCGGCGATTCTGGGAGCGGCTGGTCTGGTTCC



Forward primer F479-83

Sequence
GCGG





0130
Mutant MF479
DNA
Artificial
CCGCGGAACCAGACCAGCCGCTCCCAGAATCGCCGCTTTAGACATATTAG



Reverse Primer R479-83

Sequence
AAAC





0131
Mutant MF479
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



DNA Sequence of

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC



construct MF479


GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACT






AACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCT






GGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAG






TCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGT






GAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCT






TGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTT






CAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGG






GCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGT






AACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAA






CGGAAGTTTCTAATATGTCTAAAGCGGCGATTCTGGGAGCGGCTGGTCTG






GTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC





0132
Mutant MF479
DNA
Artificial
ATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGC



Mutant MF479

Sequence
GATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCC






GTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTG






AATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGC






CACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAA






TTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTT






AACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGG






TGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGA






AAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCT






AACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCG






TTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACC






TTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGAT






GCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGGCGATTCTGGG






AGCGGCTGGTCTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTT






AA





0133
Mutant MF479
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



Mutant MF479

Sequence
NEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQF






NGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIED






ADYATEVSNMSKAAILGAAGLVPRGSHHHHHHG





0134
Mutant N45
DNA
Artificial
TCTAGAGGATCCGGCAGGCCAGGCG



Forward primer N45_F

Sequence






0135
Mutant N45
DNA
Artificial
CGCAAGCTTGTCGACTTAACGC



Reverse R502D0

Sequence






0136
Mutant N45
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



DNA sequence of

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGCGGGGTTCTC



Mutant N45


ATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAATG






GGTCGGGATCTGTACGACCTGGTTCCGCGCGGTAGCGCGAAGGATCCGGC






AGGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTC






AGGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAA






GGTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTC






TGTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCC






AGGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAG






ACTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAAT






CCAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAA






TTGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGA






ATTTCCGGTGGTGGTGGTGGAATTCTAGACTCCATGGGTACATTAATCAA






TGAAGACGCTGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAA






TTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCA






ATTCAAAACCGTTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAAC






CAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGG






AAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCC






GTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGCG






TTAAGTCGACAAGCTTGCGG





0137
Mutant N45
PRT
Artificial
MRGSHHHHHHGMASMTGGQQMGRDLYDLVPRGSAKDPAGQAIANRFTSNI



Mutant N45

Sequence
KGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSD






LKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITI






DLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTAN






PLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIEDA






DYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLR





0138
Mutant NGD1
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



DNA Sequence of NGD1

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGTAAAGGAG



construct


AAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGATGGTGAT






GTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGATGCAAC






ATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTG






TTCCATGGCCAACACTTGTCACTACTCTGACGTATGGTGTTCAATGCTTT






TCCCGTTATCCGGATCACATGAAACGGCATGACTTTTTCAAGAGTGCCAT






GCCCGAAGGTTATGTACAGGAACGCACTATATCTTTCAAAGATGACGGGA






ACTACAAGACGCGTGCTGAAGTCAAGTTTGAAGGTGATACCCTTGTTAAT






CGTATCGAGTTAAAAGGTATTGATTTTAAAGAAGATGGAAACATTCTCGG






ACACAAACTCGAGTACAACTATAACTCACACAATGTATACATCACGGCAG






ACAAACAAGGCCTATCAGGCCGCATTATGAGCGGGTTACGGATCAACAGC






GCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCACTTCTAA






TATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGCATTTCTA






TTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAACCTGCAG






CGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACTCTGATTC






CGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAAGAAATCG






ATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCTGTCTCAG






GACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAACCATTAC






CATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGATGGGTTCA






ATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTTCAATTGATTCT






GCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAA






CCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGA






ACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCACTGGTTCCGCGG






GGTTCTCATCATCATCATCATCATGGTTAAGTCGAC





0139
Mutant NGD1
DNA
Artificial
ATGAGTAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGA



Expressed Mutant

Sequence
ATTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTG



SY3-GFP


AAGGTGATGCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACT






GGAAAACTACCTGTTCCATGGCCAACACTTGTCACTACTCTGACGTATGG






TGTTCAATGCTTTTCCCGTTATCCGGATCACATGAAACGGCATGACTTTT






TCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAACGCACTATATCTTTC






AAAGATGACGGGAACTACAAGACGCGTGCTGAAGTCAAGTTTGAAGGTGA






TACCCTTGTTAATCGTATCGAGTTAAAAGGTATTGATTTTAAAGAAGATG






GAAACATTCTCGGACACAAACTCGAGTACAACTATAACTCACACAATGTA






TACATCACGGCAGACAAACAAGGCCTATCAGGCCGCATTATGAGCGGGTT






ACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACC






GCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAAC






GACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAA






CAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGA






CTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGT






CTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAA






AGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATG






GTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGC






CTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGC






TTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGG






GGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACG






GTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGC






ACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAA





0140
Mutant NGD1
PRT
Artificial
MSKGEELFTGWPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTG



Expressed Mutant SY3-

Sequence
KLPVPWPTLVTTLTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFK



GFP/Mutant NGD1


DDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVY






ITADKQGLSGRIMSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNAND






GISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRL






EEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGL






DGFNVNSPGSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTV






TNLNSARSRIEDADYALVPRGSHHHHHHG





0141
Mutant S33
DNA
Artificial
TCTAGAGGATCCGTCTGGTCTGCGTATCAACAGCGC



Forward F502_S33

Sequence






0142
Mutant S33
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



DNA sequence of

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGCGGGGTTCTC



Mutant S33


ATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAATG






GGTCGGGATCTGTACGACCTGGTTCCGCGCGGTAGCGCGAAGGATCCGTC






TGGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTG






CTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAAC






GCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGA






AATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTA






ACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAG






CAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGG






TGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTA






ACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGC






CTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGG






TGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCG






CAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTG






TCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGTTT






TGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCG






CGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATG






TCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGC






TAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGCGTTAAGTCGAC





0143
Mutant S33
DNA
Artificial
ATGCGGGGTTCTCATCATCATCATCATCATGGTATGGCTAGCATGACTGG



Mutant S33

Sequence
TGGACAGCAAATGGGTCGGGATCTGTACGACCTGGTTCCGCGCGGTAGCG






CGAAGGATCCGTCTGGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCA






GGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCA






GGCTTCCCGTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAG






GTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCT






GTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCA






GGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGA






CTCAATTTAACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATC






CAGGTTGGTGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAAT






TGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAA






TTTCCGGTGGTGGTGGTGGAATTCTAGACTCCATGGGTACATTAATCAAT






GAAGACGCTGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAAT






TGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAA






TTCAAAACCGTTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACC






AATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGA






AGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCG






TTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGCGT






TAA





0144
Mutant S33
PRT
Artificial
MRGSHHHHHHGMASMTGGQQMGRDLYDLVPRGSAKDPSGLRINSAKDDAA



Mutant S33

Sequence
GQAIANRFTSNIKGLTQASRNANDGISIAQTTEGALNEINNNLQRVRELS






VQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQFNGVKVLSQDNQMKI






QVGANDGETITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLIN






EDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVT






NLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLR





0145
Mutant SY3CT
DNA
Artificial
AGATCTCCGCGGAACCAGTGCATAGTCAGCATCTTCGATACGGC



Reverse primer RSY3CT

Sequence






0146
Mutant SY3CT
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



DNA Sequence of

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC



SY3CT construct


GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACT






AACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCT






GGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAG






TCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGT






GAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCT






TGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTT






CAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGG






GCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGT






AACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAC






TGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC





0147
Mutant SY3CT
DNA
Artificial
ATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGC



Expressed Mutant

Sequence
GATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCC



SY3CT


GTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTG






AATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGC






CACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAA






TTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTT






AACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGG






TGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGA






AAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCT






AACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCG






TTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACC






TTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGAT






GCTGACTATGCACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGG






TTAA





0148
Mutant SY3CT
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



Expressed Mutant

Sequence
NEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQF



SY3CT


NGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIED






ADYALVPRGSHHHHHHG





0149
Mutant 33MX
DNA
Artificial
ATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGC



Mutant 33MX

Sequence
GATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCC






GTAACGCTGCAGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTG






AATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGC






CACTGCCGGGGCTAACGCTGATGCCGCTCTGAAAGCTATCCAGGCTGAAA






TTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTCAGCAGACTCAAGCT






GCCGCTGTTAAAGTCCTGTCTCAGGACAACGCAATGGCAATCCAGGTTGG






TGCTAACGATGGTGCCGCTATTACCATCGATCTGCAAAAAATTGATGTGA






AAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCT






AACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCG






TTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACC






TTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGAT






GCTGACTATGCAACGGAAGTTTCTCAAATGTCTAAAGCGCAGATTCTGCA






GCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACG






TCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGT






TAA





0150
Mutant 33MX
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNAADGISIAQTTEGAL



Mutant 33MX

Sequence
NEINNNLQRVRELSVQATAGANADAALKAIQAEIQQRLEEIDRVSQQTQA






AAVKVLSQDNAMAIQVGANDGAAITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIED






ADYATEVSQMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHG





0151
Mutant 33MX
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



DNA sequence of 33MX

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC






GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTGCAGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTGCCGGGGCT






AACGCTGATGCCGCTCTGAAAGCTATCCAGGCTGAAATTCAGCAACGTCT






GGAAGAAATCGATCGCGTTTCTCAGCAGACTCAAGCTGCCGCTGTTAAAG






TCCTGTCTCAGGACAACGCAATGGCAATCCAGGTTGGTGCTAACGATGGT






GCCGCTATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCT






TGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTT






CAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGG






GCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGT






AACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAA






CGGAAGTTTCTCAAATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACT






TCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACT






GGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC





0152
Mutant 485MX
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



DNA Sequence of

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC



485MX construct


GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTGCAGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTGCCGGGGCT






AACGCTGATGCCGCTCTGAAAGCTATCCAGGCTGAAATTCAGCAACGTCT






GGAAGAAATCGATCGCGTTTCTCAGCAGACTCAAGCTGCCGCTGTTAAAG






TCCTGTCTCAGGACAACGCAATGGCAATCCAGGTTGGTGCTAACGATGGT






GCCGCTATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCT






TGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTT






CAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGG






GCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGT






AACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAA






CGGAAGTTTCTCAAATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTCTG






GTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC





0153
Mutant 485MX
DNA
Artificial
ATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGC



485MX construct

Sequence
GATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCC






GTAACGCTGCAGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTG






AATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGC






CACTGCCGGGGCTAACGCTGATGCCGCTCTGAAAGCTATCCAGGCTGAAA






TTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTCAGCAGACTCAAGCT






GCCGCTGTTAAAGTCCTGTCTCAGGACAACGCAATGGCAATCCAGGTTGG






TGCTAACGATGGTGCCGCTATTACCATCGATCTGCAAAAAATTGATGTGA






AAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCT






AACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCG






TTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACC






TTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGAT






GCTGACTATGCAACGGAAGTTTCTCAAATGTCTAAAGCGCAGATTCTGCA






GCAGGCTGGTCTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTT






AA





0154
Mutant 485MX
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNAADGISIAQTTEGAL



485MX construct

Sequence
NEINNNLQRVRELSVQATAGANADAALKAIQAEIQQRLEEIDRVSQQTQA






AAVKVLSQDNAMAIQVGANDGAAITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIED






ADYATEVSQMSKAQILQQAGLVPRGSHHHHHHG





0155
Mutant MIM4
DNA
Artificial
ATGCGGGGTTCTCATCATCATCATCATCATGGTATGGCTAGCATGACTGG



CBLB502 variant

Sequence
TGGACAGCAAATGGGTCGGGATCTGTACGACGATGACGATAAGGATCCGA






TGGCACAAGTCATTAATACAAACAGCCTGTCGCTGTTGACCCAGAATAAC






CTGCAGAAATCTCAGTCCTCACTGAGTTCCGCTATTGAGCGTCTGTCCTC






TGGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTG






CTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAAC






GCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGA






AATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTC






AAGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAG






CAACGTCTGGAAGAAATCGATCGCGTTTCTCAGCAGACTCAATTTAACGG






TGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTA






ACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGC






CTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGG






TGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCG






CAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTG






TCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAAACCGTTT






TGATTCAGCCATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCG






CGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTCAAATG






TCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGC






TAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGCGTTAA





0156
Mutant MIM4
DNA
Artificial
AACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCG



Primers design (for

Sequence
TTCTTCTCTGGGGGCAATTCAAAACCGTTTTGATTCAGCCATTACCGCCC



deletion aa Gln439;


TTGGCGCTACGGTAACCGCTCTGGCCTCCGCGCGTAGCGCTATCGAAGAT



Asn440; Arg441;


GCTGACTATGCAACGGAAGTTTCTCAAATG



Phe442):








0157
Mutant MIM4
PRT
Artificial
NPLASIDSALSKVDAVRSSLGAIQNRFDSAITALGATVTALASARSAIED



Primers design (for

Sequence
ADYATEVSNM



deletion aa Gln439;






Asn440; Arg441;






Phe442):








0158
Mutant MIM4
DNA
Artificial
GCAGTTCGTTCTTCTCTGGGGGCAATTGATTCAGCCATTACCGCCCTTGG



Forward Primer MIM4

Sequence






0159
Mutant MIM4
DNA
Artificial
CCAAGGGCGGTAATGGCTGAATCAATTGCCCCCAGAGAAGAACGAACTGC



Reverse Primer MIM4

Sequence






0160
Mutant MIM4
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



MIM4

Sequence
GAAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGCGGGGTTCT






CATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAAT






GGGTCGGGATCTGTACGACGATGACGATAAGGATCCGATGGCACAAGTCA






TTAATACAAACAGCCTGTCGCTGTTGACCCAGAATAACCTGAACAAATCT






CAGTCCTCACTGAGTTCCGCTATTGAGCGTCTGTCCTCTGGTCTGCGTAT






CAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCA






CTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGC






ATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAA






CCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACT






CTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAA






GAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCT






GTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAA






CCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGAT






GGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTCT






AGACTCCATGGGTACATTAATCAATGAAGACGCTGCCGCAGCCAAGAAAA






GTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGAC






GCAGTTCGTTCTTCTCTGGGGGCAATTGATTCAGCCATTACCGCCCTTGG






CGCTACGGTAACCGCTCTGGCCTCCGCGGCTAGCCGTATCGAAGATGCTG






ACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAG






GCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCT






CTCTTTACTGCGTTAA





0161
Mutant MIM4
PRT
Artificial
MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPMAQVINTNSLSLLTQNN



MIM4

Sequence
LNKSQSSLSSAIERLSSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRN






ANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQ






QRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKS






LGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSAL






SKVDAVRSSLGAIDSAITALGATVTALASAASRIEDADYATEVSNMSKAQ






ILQQAGTSVLAQANQVPQNVLSLLR





0162
Mutant MIM5
DNA
Artificial
AACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCG



Primers design

Sequence
TTCTTCTCTGGGGGCAATTGCAAAGGCTTTTGATTCAGCCATTACCGCCC



(mutations Gln439Ala;


TTGGCGCTACGGTAACCGCTCTGGCCTCCGCGCGTAGCGCTATCGAAGAT



Asn440Lys; Arg441Ala):


GCTGACTATGCAACGGAAGTTTCTCAAATG





0163
Mutant MIM5
PRT
Artificial
NPLASIDSALSKVDAVRSSLGAIAKAFDSAITALGATVTALASARSAIED



Primers design

Sequence
ADYATEVSNM



(mutations Gln439Ala;






Asn440Lys; Arg441Ala):








0164
Mutant MIM5
DNA
Artificial
CGTTCTTCTCTGGGGGCAATTGCAAAGGCTTTTGATTCAGCCATTACCGC



Forward Primer MIM5

Sequence






0165
Mutant MIM5
DNA
Artificial
GCGGTAATGGCTGAATCAAAAGCCTTTGCAATTGCCCCCAGAGAAGAACG



Reverse Primer MIM5

Sequence






0166
Mutant MIM5
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



MIM5

Sequence
GAAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGCGGGGTTCT






CATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAAT






GGGTCGGGATCTGTACGACGATGACGATAAGGATCCGATGGCACAAGTCA






TTAATACAAACAGCCTGTCGCTGTTGACCCAGAATAACCTGAACAAATCT






CAGTCCTCACTGAGTTCCGCTATTGAGCGTCTGTCCTCTGGTCTGCGTAT






CAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGCTTCA






CTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGACGGC






ATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACAACAA






CCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACTAACT






CTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCTGGAA






GAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAGTCCT






GTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGTGAAA






CCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCTTGAT






GGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTCT






AGACTCCATGGGTACATTAATCAATGAAGACGCTGCCGCAGCCAAGAAAA






GTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGAC






GCAGTTCGTTCTTCTCTGGGGGCAATTGCAAAGGCTTTTGATTCAGCCAT






TACCGCCCTTGGCGCTACGGTAACCGCTCTGGCCTCCGCGGCTAGCCGTA






TCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAG






ATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCC






GCAAAACGTCCTCTCTTTACTGCGTTAA





0167
Mutant MIM5
PRT
Artificial
MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPMAQVINTNSLSLLTQNN



MIM5

Sequence
LNKSQSSLSSAIERLSSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRN






ANDGISIAQTTEGALNEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQ






QRLEEIDRVSNQTQFNGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKS






LGLDGFNVNSPGISGGGGGILDSMGTLINEDAAAAKKSTANPLASIDSAL






SKVDAVRSSLGAIAKAFDSAITALGATVTALASAASRIEDADYATEVSNM






SKAQILQQAGTSVLAQANQVPQNVLSLLR





0168
Mutant MIMX
DNA
Artificial
ATGCGGGGTTCTCATCATCATCATCATCATGGTATGGCTAGCATGACTGG



Mutant 33MIMX

Sequence
TGGACAGCAAATGGGTCGGGATCTGTACGACCTGGTTCCGCGCGGTAGCG






CGAAGGATCCGTCTGGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCA






GGCCAGGCGATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCA






GGCTTCCCGTAACGCTGCAGACGGCATTTCTATTGCGCAGACCACTGAAG






GTGCGCTGAATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCT






GTTCAGGCCACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCA






GGATGAAATTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGA






CTCAAGCTAACGGTGTTAAAGTCCTGTCTCAGGACAACGCAATGAAAATC






CAGGTTGGTGCTAACGATGGTGCCGCTATTACCATCGATCTGCAAAAAAT






TGATGTGAAAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAA






TTTCCGGTGGTGGTGGTGGAATTCTAGACTCCATGGGTACATTAATCAAT






GAAGACGCTGCCGCAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAAT






TGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAA






TTCAAGCTCGTTTTGCCGCGGCCATTGCTAACCTTGGCAATACGGTAACC






AATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGA






AGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCG






TTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGCGT






TAA





0169
Mutant MIMX
PRT
Artificial
MRGSHHHHHHGMASMTGGQQMGRDLYDLVPRGSAKDPSGLRINSAKDDAA



MIMx

Sequence
GQAIANRFTSNIKGLTQASRNAADGISIAQTTEGALNEINNNLQRVRELS






VQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQANGVKVLSQDNAMKI






QVGANDGAAITIDLQKIDVKSLGLDGFNVNSPGISGGGGGILDSMGTLIN






EDAAAAKKSTANPLASIDSALSKVDAVRSSLGAIQARFAAAIANLGNTVT






NLNSARSRIEDADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLR





0170
Mutant MIMX
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



DNA sequence of

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGCGGGGTTCTC



33MIMx


ATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAATG






GGTCGGGATCTGTACGACCTGGTTCCGCGCGGTAGCGCGAAGGATCCGTC






TGGTCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTG






CTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAAC






GCTGCAGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGA






AATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTA






ACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAG






CAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAAGCTAACGG






TGTTAAAGTCCTGTCTCAGGACAACGCAATGAAAATCCAGGTTGGTGCTA






ACGATGGTGCCGCTATTACCATCGATCTGCAAAAAATTGATGTGAAAAGC






CTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAATTTCCGGTGGTGG






TGGTGGAATTCTAGACTCCATGGGTACATTAATCAATGAAGACGCTGCCG






CAGCCAAGAAAAGTACCGCTAACCCACTGGCTTCAATTGATTCTGCATTG






TCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGGGCAATTCAAGCTCGTTT






TGCCGCGGCCATTGCTAACCTTGGCAATACGGTAACCAATCTGAACTCCG






CGCGTAGCCGTATCGAAGATGCTGACTATGCAACGGAAGTTTCTAATATG






TCTAAAGCGCAGATTCTGCAGCAGGCTGGTACTTCCGTTCTGGCGCAGGC






TAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGCGTTAAGTCGAC





0171
Mutant MIXC
DNA
Artificial
AGATCTGTCGACTTAACCATGATGATGATGATGATGAGAACCCCGCGGAA



Reverse primer RMIXC

Sequence
CCAGTAAAGAGAGGACGTTTTGCGGAACC





0172
Mutant MIXC
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



DNA sequence of MIXC

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC






GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACT






AACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCT






GGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAG






TCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGT






GAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCT






TGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTT






CAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGG






GCAATTCAAGCTCGTTTTGCCGCGGCCATTGCTAACCTTGGCAATACGGT






AACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAA






CGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACT






TCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACT






GGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC





0173
Mutant MIXC
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



MIXC

Sequence
NEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQF






NGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIQARFAAAIANLGNTVTNLNSARSRIED






ADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHG





0174
Mutant MIXN
DNA
Artificial
AGATCTCATATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGC



Forward primer FMIMxN

Sequence






0175
Mutant MIXN
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



DNA sequence of MIX.N

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC






GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTGCAGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACT






AACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCT






GGAAGAAATCGATCGCGTTTCTAATCAGACTCAAGCTAACGGTGTTAAAG






TCCTGTCTCAGGACAACGCAATGAAAATCCAGGTTGGTGCTAACGATGGT






GCCGCTATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCT






TGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTT






CAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGG






GCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGT






AACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAA






CGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACT






TCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACT






GGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC





0176
Mutant MIXN
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNAADGISIAQTTEGAL



Expressed Mutant MIX.N

Sequence
NEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQA






NGVKVLSQDNAMKIQVGANDGAAITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIED






ADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHG





0177
Mutants MIM1; MIM2
DNA
Artificial
AACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCG



and MIM3

Sequence
TTCTTCTCTGGGGGCAATTCAAAACCGTTTTGATTCAGCCATTACCAACC



502 Mutants MIM1;


TTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGAT



MIM2 and MIM3


GCTGACTATGCAACGGAAGTTTCTCAAATGTCTAAAGCGCAGATTCTGCA



C-terminal part of


GCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACG



CBLB502


TCCTCTCTTTACTGCGTTAA





0178
Mutants MIM1; MIM2
DNA
Artificial
ATTACCAACCTTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCG



and MIM3

Sequence
TATCGAAGAT



Primers design (mutant






MIM1)








0179
Mutants MIM1; MIM2
PRT
Artificial
ITNLGNTVTNLNSARSRIED



and MIM3

Sequence




Primers design (mutant






MIM1)








0180
Mutants MIM1; MIM2
DNA
Artificial
CCTTGGCAATACGGTAACCGCTCTGGCCTCCGCGCGTAGCCGTATC



and MIM3

Sequence




Forward Primer 455-57








0181
Mutants MIM1; MIM2
DNA
Artificial
GATACGGCTACGCGCGGAGGCCAGAGCGGTTACCGTATTGCCAAGG



and MIM3

Sequence




Reverse Primer 455-57








0182
Mutants MIM1; MIM2
DNA
Artificial
ACGGTAACCGCTCTGGCCTCCGCGCGTAGCCGTATCGAAGATGCTGACTA



and MIM3

Sequence
TGCAACGGAA



Primers design (mutant






MIM2_MIM1 plus






R460A)








0183
Mutants MIM1; MIM2
PRT
Artificial
TVTALASARSRIEDADYATE



and MIM3

Sequence




Primers design (mutant






MIM2_MIM1 plus






R460A)








0184
Mutants MIM1; MIM2
DNA
Artificial
GCTCTGGCCTCCGCGGCTAGCCGTATCGAAGATG



and MIM3

Sequence




Forward Primer 460








0185
Mutants MIM1; MIM2
DNA
Artificial
CATCTTCGATACGGCTAGCCGCGGAGGCCAGAGC



and MIM3

Sequence




Reverse Primer 460








0186
Mutants MIM1; MIM2
DNA
Artificial
CAAAACCGTTTTGATTCAGCCATTACCAACCTTGGCAATACGGTAACCGC



and MIM3

Sequence
TCTGGCCTCC



Primers design (mutant






MIM3_MIM2 plus






N448A; N451A)








0187
Mutants MIM1; MIM2
PRT
Artificial
QNRFDSAITNLGNTVTALAS



and MIM3

Sequence




Primers design (mutant






MIM3_MIM2 plus






N448A; N451A)








0188
Mutants MIM1; MIM2
DNA
Artificial
GTTTTGATTCAGCCATTACCGCCCTTGGCGCTACGGTAACCGCTCTGG



and MIM3

Sequence




Forward Primer 448-51








0189
Mutants MIM1; MIM2
DNA
Artificial
CCAGAGCGGTTACCGTAGCGCCAAGGGCGGTAATGGCTGAATCAAAAC



and MIM3

Sequence




Reverse Primer 448-51








0190
Mutant ME42
DNA
Artificial
CAACAGCGCGAAAGCCGATGCGGGAGGCCAGGCGATTGC



Forward Primer ME42

Sequence






0191
Mutant ME42
DNA
Artificial
GCAATCGCCTGGCCTCCCGCATCGGCTTTCGCGCTGTTG



Reverse Primer ME42

Sequence






0192
Mutant ME42
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



Sequence of ME42

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC



construct


GGATCAACAGCGCGAAAGCCGATGCGGGAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACT






AACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCT






GGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAG






TCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGT






GAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCT






TGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTT






CAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGG






GCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGT






AACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAA






CGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACT






TCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACT






GGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC





0193
Mutant ME42
PRT
Artificial
MSGLRINSAKADAGGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



Mutant ME42

Sequence
NEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQF






NGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIED






ADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHG





0194
Mutant ME110
DNA
Artificial
GTCTGTTCAGGCCACTGCCGGGGCTAACTCTGATTCCGATCTG



Forward Primer ME100

Sequence






0195
Mutant ME110
DNA
Artificial
CAGATCGGAATCAGAGTTAGCCCCGGCAGTGGCCTGAACAGAC



Reverse Primer ME100

Sequence






0196
Mutant ME110
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



Sequence of ME100

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC



construct


GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTGCCGGGGCT






AACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCT






GGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAG






TCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGT






GAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCT






TGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTT






CAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGG






GCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGT






AACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAA






CGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACT






TCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACT






GGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC





0197
Mutant ME110
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



Mutant ME110

Sequence
NEINNNLQRVRELSVQATAGANSDSDLKSIQDEIQQRLEEIDRVSNQTQF






NGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIED






ADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHG





0198
Mutant ME100/110
DNA
Artificial
CTGATTCCGATCTGAAAGCTATCCAGGCTGAAATTCAGCAACGTC



Forward Primer ME110

Sequence






0199
Mutant ME100/110
DNA
Artificial
GACGTTGCTGAATTTCAGCCTGGATAGCTTTCAGATCGGAATCAG



Reverse Primer ME110

Sequence






0200
Mutant ME100/110
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



Sequence of ME100/110

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC



construct


GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTGCCGGGGCT






AACTCTGATTCCGATCTGAAAGCTATCCAGGCTGAAATTCAGCAACGTCT






GGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAG






TCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGT






GAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCT






TGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTT






CAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGG






GCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGT






AACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAA






CGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACT






TCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACT






GGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC





0201
Mutant ME104N
DNA
Artificial
ATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGC



Intermediate Mutant

Sequence
GATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCC



ME100/110


GTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTG






AATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGC






CACTGCCGGGGCTAACTCTGATTCCGATCTGAAAGCTATCCAGGCTGAAA






TTCAGCAACGTCTGGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTT






AACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGG






TGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGA






AAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCT






AACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCG






TTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACC






TTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGAT






GCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCA






GCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACG






TCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGT






TAA





0202
Mutant ME100/110
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



Mutant ME110/110

Sequence
NEINNNLQRVRELSVQATAGANSDSDLKAIQAEIQQRLEEIDRVSNQTQF






NGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIED






ADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHG





0203
Mutant ME104
DNA
Artificial
GCCACTAACGGGACTAACGCTGATGCCGCTCTGAAATCTATCCAG



Forward Primer ME104

Sequence






0204
Mutant ME104
DNA
Artificial
CTGGATAGATTTCAGAGCGGCATCAGCGTTAGTCCCGTTAGTGGC



Reverse Primer ME104

Sequence






0205
Mutant ME104
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



Sequence of ME104

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC



construct


GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACT






AACGCTGATGCCGCTCTGAAATCTATCCAGGATGAAATTCAGCAACGTCT






GGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAG






TCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGT






GAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCT






TGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTT






CAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGG






GCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGT






AACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAA






CGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACT






TCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACT






GGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC





0206
Mutant ME104
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



Mutant ME104

Sequence
NEINNNLQRVRELSVQATNGTNADAALKSIQDEIQQRLEEIDRVSNQTQF






NGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIED






ADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHG





0207
Mutant ME104N
DNA
Artificial
GCCACTGCCGGGGCTAACGCTGATGCCGCTCTGAAAGCTATCCAG



Primer FME104New

Sequence






0208
Mutant ME104N
DNA
Artificial
CTGGATAGCTTTCAGAGCGGCATCAGCGTTAGCCCCGGCAGTGGC



Primer RME104New

Sequence






0209
Mutant ME104N
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



Sequence of construct

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC



ME104New


GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTGCCGGGGCT






AACGCTGATGCCGCTCTGAAAGCTATCCAGGCTGAAATTCAGCAACGTCT






GGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAG






TCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGT






GAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCT






TGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTT






CAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGG






GCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGT






AACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAA






CGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACT






TCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACT






GGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC





0210
Mutant ME104N
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



Mutant ME104N

Sequence
NEINNNLQRVRELSVQATAGANADAALKAIQAEIQQRLEEIDRVSNQTQF






NGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIED






ADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHG





0211
Mutant ME110
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



Sequence of ME110

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC



construct


GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACT






AACTCTGATTCCGATCTGAAAGCTATCCAGGCTGAAATTCAGCAACGTCT






GGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAG






TCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGT






GAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCT






TGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTT






CAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGG






GCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGT






AACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAA






CGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACT






TCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACT






GGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC





0212
Mutant ME110
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



Mutant ME110

Sequence
NEINNNLQRVRELSVQATNGTNSDSDLKAIQAEIQQRLEEIDRVSNQTQF






NGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIED






ADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHG





0213
Mutant ME117
DNA
Artificial
CTATCCAGGATGAAATTCAGGCACGTCTGGCAGAAATCGATCGCG



Forward Primer ME117

Sequence






0214
Mutant ME117
DNA
Artificial
CGCGATCGATTTCTGCCAGACGTGCCTGAATTTCATCCTGGATAG



Reverse Primer ME117

Sequence






0215
Mutant ME117
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



Sequence of 33ML

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC



construct


GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC



(should this say


TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGA



ME117?)


CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACT






AACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGGCACGTCT






GGCAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAG






TCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGT






GAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCT






TGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTT






CAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGG






GCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGT






AACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAA






CGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACT






TCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACT






GGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC





0216
Mutant ME117
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



Mutant ME117

Sequence
NEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQARLAEIDRVSNQTQF






NGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIED






ADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHG





0217
Mutant ME124
DNA
Artificial
GGAAGAAATCGATGCCGTTTCTGCTGCGACTCAATTTAACGGTGTTAAAG



Forward Primer ME104

Sequence
TCCTGTCTC





0218
Mutant ME124
DNA
Artificial
GAGACAGGACTTTAACACCGTTAAATTGAGTCGCAGCAGAAACGGCATCG



Reverse Primer ME104

Sequence
ATTTCTTCC





0219
Mutant ME124
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



Sequence of ME124

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC



construct


GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACT






AACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCT






GGAAGAAATCGATGCCGTTTCTGCTGCGACTCAATTTAACGGTGTTAAAG






TCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGT






GAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCT






TGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTT






CAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGG






GCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGT






AACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAA






CGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACT






TCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACT






GGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC





0220
Mutant ME124
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



Mutant ME124

Sequence
NEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDAVSAATQF






NGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIED






ADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHG





0221
Mutant ME124P
DNA
Artificial
CAGCAACGTCTGGAAGAAATCGATGCCGTTTCTAATCAGACTCAATTTAA



Forward Primer ME124P

Sequence
CGG





0222
Mutant ME124P
DNA
Artificial
CCGTTAAATTGAGTCTGATTAGAAACGGCATCGATTTCTTCCAGACGTTG



Reverse Primer ME124P

Sequence
CTG





0223
Mutant ME124
DNA
Artificial
ATGAGCGGGTTACGGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGC



Expressed Mutant

Sequence
GATTGCTAACCGCTTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCC



ME124P


GTAACGCTAACGACGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTG






AATGAAATCAACAACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGC






CACTAACGGGACTAACTCTGATTCCGATCTGAAATCTATCCAGGATGAAA






TTCAGCAACGTCTGGAAGAAATCGATGCCGTTTCTAATCAGACTCAATTT






AACGGTGTTAAAGTCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGG






TGCTAACGATGGTGAAACCATTACCATCGATCTGCAAAAAATTGATGTGA






AAAGCCTTGGCCTTGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCT






AACCCACTGGCTTCAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCG






TTCTTCTCTGGGGGCAATTCAAAACCGCTTTGATTCAGCCATTACCAACC






TTGGCAATACGGTAACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGAT






GCTGACTATGCAACGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCA






GCAGGCTGGTACTTCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACG






TCCTCTCTTTACTGGTTCCGCGGGGTTCTCATCATCATCATCATCATGGT






TAA





0224
Mutant ME124P
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



ME124P

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC






GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACT






AACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCT






GGAAGAAATCGATGCCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAG






TCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGT






GAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCT






TGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTT






CAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGG






GCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGT






AACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAA






CGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACT






TCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACT






GGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC





0225
Mutant ME124P
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



ME124P

Sequence
NEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDAVSNQTQF






NGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIED






ADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHG





0226
Mutant ME132
DNA
Artificial
CGTTTCTAATCAGACTCAATTTGCCGCTGTTAAAGTCCTGTCTCAGGACA



Forward Primer ME132

Sequence
ACC





0227
Mutant ME132
DNA
Artificial
GGTTGTCCTGAGACAGGACTTTAACAGCGGCAAATTGAGTCTGATTAGAA



Reverse Primer ME132

Sequence
ACG





0228
Mutant ME132
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



Sequence of ME132

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC



construct


GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACT






AACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCT






GGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTGCCGCTGTTAAAG






TCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGT






GAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCT






TGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTT






CAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGG






GCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGT






AACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAA






CGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACT






TCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACT






GGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC





0229
Mutant ME132
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



Mutant ME117

Sequence
NEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQF



(ME132?)


AAVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIED






ADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHG





0230
Mutant ME142
DNA
Artificial
GTTAAAGTCCTGTCTCAGGACAACGCGATGGCAATCCAGGTTGGTGCTAA



Forward Primer ME142

Sequence
CG





0231
Mutant ME142
DNA
Artificial
CGTTAGCACCAACCTGGATTGCCATCGCGTTGTCCTGAGACAGGACTTTA



Reverse Primer ME142

Sequence
AC





0232
Mutant ME142
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



Sequence of ME142

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC



construct


GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACT






AACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCT






GGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAG






TCCTGTCTCAGGACAACGCGATGGCAATCCAGGTTGGTGCTAACGATGGT






GAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCT






TGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTT






CAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGG






GCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGT






AACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAA






CGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACT






TCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACT






GGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC





0233
Mutant ME142
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



Mutant ME142

Sequence
NEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQF






NGVKVLSQDNAMAIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIED






ADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHG





0234
Mutant ME150
DNA
Artificial
GATGAAAATCCAGGTTGGTGCTAGCGCTGCTGAAACCATTACCATCGATC



Forward Primer ME150

Sequence
TGC





0235
Mutant ME150
DNA
Artificial
GCAGATCGATGGTAATGGTTTCAGCAGCGCTAGCACCAACCTGGATTTTC



Reverse Primer ME150

Sequence
ATC





0236
Mutant ME150
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



Sequence of ME150

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC



construct


GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACT






AACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCT






GGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAG






TCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAGCGCTGCT






GAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCT






TGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTT






CAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGG






GCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGT






AACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACTATGCAA






CGGAAGTTTCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACT






TCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACT






GGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC





0237
Mutant ME150
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



Mutant ME150

Sequence
NEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQF






NGVKVLSQDNQMKIQVGASAAETITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIED






ADYATEVSNMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHG





0238
Mutant ME468
DNA
Artificial
GCCGTATCGAAGATGCTGACGCTGGAGCGGAAGTTGCTAATATGTCTAAA



Forward Primer ME468

Sequence
GCGCAG





0239
Mutant ME468
DNA
Artificial
CTGCGCTTTAGACATATTAGCAACTTCCGCTCCAGCGTCAGCATCTTCGA



Reverse Primer ME468

Sequence
TACGGC





0240
Mutant ME468
DNA
Artificial
TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTA



Sequence of ME468

Sequence
GAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAGCGGGTTAC



construct


GGATCAACAGCGCGAAAGACGATGCGGCAGGCCAGGCGATTGCTAACCGC






TTCACTTCTAATATCAAAGGTCTGACTCAGGCTTCCCGTAACGCTAACGA






CGGCATTTCTATTGCGCAGACCACTGAAGGTGCGCTGAATGAAATCAACA






ACAACCTGCAGCGTGTGCGTGAGTTGTCTGTTCAGGCCACTAACGGGACT






AACTCTGATTCCGATCTGAAATCTATCCAGGATGAAATTCAGCAACGTCT






GGAAGAAATCGATCGCGTTTCTAATCAGACTCAATTTAACGGTGTTAAAG






TCCTGTCTCAGGACAACCAGATGAAAATCCAGGTTGGTGCTAACGATGGT






GAAACCATTACCATCGATCTGCAAAAAATTGATGTGAAAAGCCTTGGCCT






TGATGGGTTCAATGTTAATTCCCCGGGAAGTACCGCTAACCCACTGGCTT






CAATTGATTCTGCATTGTCAAAAGTGGACGCAGTTCGTTCTTCTCTGGGG






GCAATTCAAAACCGCTTTGATTCAGCCATTACCAACCTTGGCAATACGGT






AACCAATCTGAACTCCGCGCGTAGCCGTATCGAAGATGCTGACGCTGGAG






CGGAAGTTGCTAATATGTCTAAAGCGCAGATTCTGCAGCAGGCTGGTACT






TCCGTTCTGGCGCAGGCTAACCAGGTTCCGCAAAACGTCCTCTCTTTACT






GGTTCCGCGGGGTTCTCATCATCATCATCATCATGGTTAAGTCGAC





0241
Mutant ME468
PRT
Artificial
MSGLRINSAKDDAAGQAIANRFTSNIKGLTQASRNANDGISIAQTTEGAL



Mutant ME468

Sequence
NEINNNLQRVRELSVQATNGTNSDSDLKSIQDEIQQRLEEIDRVSNQTQF






NGVKVLSQDNQMKIQVGANDGETITIDLQKIDVKSLGLDGFNVNSPGSTA






NPLASIDSALSKVDAVRSSLGAIQNRFDSAITNLGNTVTNLNSARSRIED






ADAGAEVANMSKAQILQQAGTSVLAQANQVPQNVLSLLVPRGSHHHHHHG





0242
Linker
PRT
Artificial
SPG





Sequence






0243
Lru283
PRT
Artificial
mghhhhhhsgMEEFNMRINTNVAAMNTYSRLTAANTAKSNSLAKLSSGLR





Sequence
INKAGDDAAGLAISEKMKSQIGGLTQAKRNAQDGISLVQTAEGALNETHS






ILERMRDLAVQGSNGTLTSSDRGSINKELKALHQELTRISNTTEFNTQKL






FSQTKQKSVTFTFQIGANAGQTLSVAITAMSGEALLVSTDAKFSLNAAGT






NAGAMIKSIDAAIAKVSDQRADLGAVQNRLEHTINNLTATNENLSDANSR






IRDVDMAEEMMTFTKSNILSQAATSMLAQANAMPNSVLNLLQG





0244
Tpe270
PRT
Artificial
mghhhhhhsgMRINHNISALNAWRNIDQTQYSMSKTLERLSSGLRINRAG





Sequence
DDAAGLAISEKMRGQIKGLNMAIKNAQDAISLIQTAEGALTEVHSILQRM






RELAVQAASDTNTNVDREQIQKEIDQLREEIDRIARTTEFNTKKLLDGKL






EGFRSQVDAKVVTGGNINVQLGTVSSKAVEGTYVIEVGaAERAIMVVDAA






IHRVSTARAALGAIQNRLEHTISNLGVAAENLTAAESRIRDADMAKEMME






FTKQQILLQSSMAMLAQSNTLPQNVLQLMR





0245
Tpe159w
PRT
Artificial
mghhhhhhsGLNMAIKNAQDAISLIQTAEGALTEVHSILQRMRELAVQAA





Sequence
SDTNTNVDREQIQKEIDQLREEIDRIARTTEFNTKKLLDGKLEGFRSQVD






AKWTGGNINVQLGTVSSKAVEGTYVIEVGaAERAIMVVDAAIHRVSTARA






ALGAIQNRLEHTISNLG





0246
Chy275
PRT
Artificial
mghhhhhhsgMSLRINNNIEALNAWRALNSTSNALQKSMEKLSSGLRINR





Sequence
AGDDAAGLAISEKLRAQIRGLNQAIRNAQDGISLIQTAEGGLSEIQNILQ






RMRELGVQAANGTLNNQDISAITTELNQLFNEIDRIAGATEFNTKNLLAV






STGLVVTLQVGANAGQVIAFTIDNAGTASLGLSSADLAINDNASASAFIS






KVDSALQKVSTYRANLGSIQNRLEHTIANLGIASENLSASESRIRDVDMA






AEMMNFTKNQILQQAGVAILAQANQAPQAVLQLLR





0247
Chy162w
PRT
Artificial
mghhhhhhsGLNQAIRNAQDGISLIQTAEGGLSEIQNILQRMRELGVQAA





Sequence
NGTLNNQDISAITTELNQLFNEIDRIAGATEFNTKNLLAVSTGLVVTLQV






GANAGQVIAFTIDNAGTASLGLSSADLAINDNASASAFISKVDSALQKVS






TYRANLGSIQNRLEHTIANLG





0248
ChyU137
PRT
Artificial
mghhhhhhsGLNQAIRNAQDGISLIQTAEGGLSEIQNILQRMRELGVQAA





Sequence
NGTLNNQDISAITTELNQLFNEIDRIAGATEFNTKNLLAAGTASLGLSSA






DLAINDNASASAFISKVDSALQKVSTYRANLGSIQNRLEHTIANLG





0249
ChyN108
PRT
Artificial
mghhhhhhSASAFISKVDSALQKVSTYRANLGSIQNRLEHTIANLGpdGL





Sequence
NQAIRNAQDGISLIQTAEGGLSEIQNILQRMRELGVQAANGTLNNQDISA






ITTELNQLFNEIDRIA





0250
ChyZ94
PRT
Artificial
mghhhhhhsNNQDISAITTELNQLFNEIDRIAGATgsGGLSEIQNILQRM





Sequence
RELGVQAANGTLNggSASAFISKVDSALQKVSTYRANLGSIQNRLEHTIA






NLG





0251
Fir161B
PRT
Artificial
mghhhhhhsGLAQASRNAQDAISIAQTAEGALDETQSILQRVRELGVQGA





Sequence
NGTLTADDINALQAEVDQLIAEIDRIAGATEFNTQNLLDGSFTTKAFQVG






ANSGQNMTLTIGKMDTTTLGLSSADLAINDNAFANGAISTVDSALQKVSA






ERAKLGAIQNRLEHTIANLG





0252
Fir161MNB
PRT
Artificial
mghhhhhhsGLAQASRQAQDAISIAQTAEGALDETQSILQRVRELGVQGA





Sequence
DGTLTADDIDALQAEVDQLIAEIDRIAGATEFATQKLLDGSFTTKAFQVG






AASGQDVTLTIGKVDTTTLGLSSADLAIDSAAFADGAISTVDSALQKVSA






ERAKLGAIQNRLEHTIAQLG









In some embodiments, the aluminum gel or salt is selected from aluminum hydroxide, aluminum phosphate, and potassium aluminum sulfate, AS04 (which is composed of aluminum salt and MPL), and ALHYDROGEL. In some embodiments, the aluminum gel or salt is a formulation or mixture with any of the additional adjuvants described herein.


In some embodiments, adjuvants in addition to the described flagellin-based agent and an aluminum gel or salt find use in the present invention. In some embodiments, the additional adjuvant is selected from, oil-in-water emulsion formulations, saponin adjuvants, ovalbumin, Freunds Adjuvant, cytokines, and chitosans. Illustrative additional adjuvants include, but are not limited to: (1) ovalbumin (e.g. ENDOFIT), which is often used for biochemical studies; (2) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides or bacterial cell wall components), such as for example (a) MF59 (PCT Publ. No. WO 90/14837), containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing various amounts of MTP-PE) formulated into submicron particles using a microfluidizer such as, for example, Model HOy microfluidizer (Microfluidics, Newton, Mass.), (b) SAF, containing 10% Squalane, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, (c) RIBI adjuvant system (RAS), (RIBI IMMUNOCHEM, Hamilton, Mo.) containing 2% Squalene, 0.2% Tween 80, and, optionally, one or more bacterial cell wall components from the group of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), including MPL+CWS (DETOX″); and (d) ADDAVAX (Invitrogen); (3) saponin adjuvants, such as STIMULON (Cambridge Bioscience, Worcester, Mass.) may be used or particles generated therefrom such as ISCOMs (immunostimulating complexes); (4) Complete Freunds Adjuvant (CFA) and Incomplete Freunds Adjuvant (IFA); (5) cytokines, such as interleukins (by way of non-limiting example, IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.), interferons (e.g., gamma interferon), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc; (6) chitosans and other derivatives of chitin or poly-N-acetyl-D-glucosamine in which the greater proportion of the N-acetyl groups have been removed through hydrolysis (see, e.g., European Patent Application 460 020, which is hereby incorporated by reference in its entirety, disclosing pharmaceutical formulations including chitosans as mucosal absorption enhancers; and (7) other substances that act as immunostimulating agents to enhance the effectiveness of the composition, e.g., monophosphoryl lipid A. In other embodiments, the additional adjuvant is one or more of a flagellin-based agent (e.g. CBLB502 or any of the agents of Table 1), an aluminium salt or gel, a pattern recognition receptors (PRR) agonist, CpG ODNs and imidazoquinolines. In some embodiments, the additional adjuvant is one or more of cyclic [G(3′,5′)pA(3′,5′)p] (e.g. 3′3′-cGAMP VACCIGRADE); cyclic [G(2′,5′)pA(3′,5′)p]2′3′ (e.g. 2′3′ cGAMP VACCIGRADE); cyclic [G(2′,5′)pA(2′,5′)p] (e.g. 2′2′- cGAMP VACCIGRADE), cyclic diadenylate monophosphate (e.g. c-di-AMP VACCIGRADE); cyclic diguanylate monophosphate (e.g. c-di-GMP VACCIGRADE); TLR7 agonist-imidazoquinolines compound (e.g. TLR7 agonists, such as, for example, Gardiquimod VACCIGRADE, Imiquimod VACCIGRADE, R848 VACCIGRADE); lipopolysaccharides (e.g. TLR4 agonists), such as that from E. coli 0111:B4 strain (e.g. LPS-EB VACCIGRADE); monophosphoryl lipid A (e.g. MPLA-SM VACCIGRADE and MPLA Synthetic VACCIGRADE); N-glycolylated muramyldipeptide (e.g. N-Glycolyl-MDP VACCIGRADE); CpG ODN, class A and/oror CpG ODN, class B and/or CpG ODN, class C (e.g. ODN 1585 VACCIGRADE, ODN 1826 VACCIGRADE, ODN 2006 VACCIGRADE, ODN 2395 VACCIGRADE), a triacylated lipoprotein (e.g. Pam3CSK4 VACCIGRADE); Polyinosine-polycytidylic acid (e.g. Poly(I:C) (HMW) VACCIGRADE); and cord factor (i.e. mycobacterial cell wall component trehalose 6,6′ dimycolate (TDM,) or an analog thereof (e.g. TDB VACCIGRADE, TDB-HS15 VACCIGRADE). In some embodiments, the additional adjuvant is a TLR agonist (e.g. TLR1, and/or TLR2, and/or TLR3, and/or TLR4, and/or TLR5, and/or TLR6, and/or TLR7, and/or TLR8, and/or TLR9, and/or TLR10, and/or TLR11, and/or TLR12, and/or TLR13), a nucleotide-binding oligomerization domain (NOD) agonist, a stimulator of interferon genes (STING) ligand, or related agent.


In some embodiments, the additional adjuvants is one or more of a mineral adjuvant, gel-based adjuvant, tensoactive agent, bacterial product, oil emulsion, particulated adjuvant, fusion protein, and lipopeptide. Other mineral salt adjuvants, besides the aluminum adjuvants described elsewhere, include salts of calcium (e.g. calcium phosphate), iron and zirconium. Other gel-based adjuvants, besides the aluminum gel-based adjuvants described elsewhere, include Acemannan. Tensoactive agents include Quil A, saponin derived from an aqueous extract from the bark of Quillaja saponaria; saponins, tensoactive glycosides containing a hydrophobic nucleus of triterpenoid structure with carbohydrate chains linked to the nucleus, and QS-21. Bacterial products include cell wall peptidoglycan or lipopolysaccharide of Gram-negative bacteria (e.g. from Mycobacterium spp., Corynebacterium parvum, C. granulosum, Bordetella pertussis and Neisseria meningitidis), N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP), different compounds derived from MDP (e.g. threonyl-MDP), lipopolysaccharides (LPS) (e.g. from the cell wall of Gram-negative bacteria), trehalose dimycolate (TDM), and DNA containing CpG motifs. Oil emulsions include FIA, Montanide, Adjuvant 65, Lipovant, the montanide family of oil-based adjuvants, and various liposomes. Among particulated and polymeric systems, poly (DL-lactide-coglycolide) microspheres have been extensively studied and find use herein.


Further, in some embodiments, cytokines are an adjuvant of the present invention (e.g. IFN-γ and granulocyte-macrophage colony stimulating factor (GM-CSF)). Also carbohydrate adjuvants (e.g. inulin-derived adjuvants, such as, gamma inulin, algammulin (a combination of γ-inulin and aluminum hydroxide), and polysaccharides based on glucose and mannose, such as glucans, dextrans, lentinans, glucomannans and galactomannans) find use in the present invention. In some embodiments, adjuvant formulations are useful in the present invention and include alum salts in combination with other adjuvants such as Lipid A, algammulin, immunostimulatory complexes (ISCOMS), which are virus like particles of 30-40 nm and dodecahedric structure, composed of Quil A, lipids, and cholesterol.


In some embodiments, the additional adjuvants are described in Jennings et al. Adjuvants and Delivery Systems for Viral Vaccines-Mechanisms and Potential. In: Brown F, Haaheim L R, (eds). Modulation of the Immune Response to Vaccine Antigens. Dev. Biol. Stand, Vol. 92. Basel: Karger 1998; 19-28 and/or Sayers et al. J Biomed Biotechnol. 2012; 2012: 831486, and/or Petrovsky and Aguilar, Immunology and Cell Biology (2004) 82, 488-496 the contents of which are hereby incorporated by reference in their entireties.


In various embodiments, the present adjuvants (e.g. flagellin-based agent and an aluminum gel or salt) may be part of live and attenuated, or killed or inactivated, or toxoid, or subunit or conjugate vaccines.


In various embodiments, the present adjuvants (e.g. flagellin-based agent and an aluminum gel or salt) may be part of one or more approved vaccines and/or the antigens of one or more approved vaccines may be the antigens of the present invention. In some embodiments, the approved vaccines include: Adenovirus; Anthrax (Biothrax); BCG (Tice); DT (Sanofi); DTaP (Daptacel); DTaP (Infanrix); DTaP-HepB-IPV (Pediarix); DTaP-IPV (Kinrix); DTaP-IPV/Hib (Pentacel); Hib (ActHIB); Hib (Hiberix); Hib (PedvaxHlB); Hib/Hep B (Comvax); Hib/Mening. CY (MenHibrix); Hep A (Havrix); Hep A (Havrix); Hep B (Engerix-B); Hep B (Recombivax); Hep A/Hep B (Twinrix); Human Papillomavirus (HPV) (Cerverix); Human Papillomavirus (HPV) (Gardasil); Influenza (Afluria); Influenza (Agriflu); Influenza (Fluarix); Influenza (Flublok); Influenza (Flucelvax); Influenza (Fluvirin); Influenza (Flulevel); Influenza (Fluzone: Standard, High-Dose, & Intradermal); Influenza (FluMist); Japanese Encephalitis (Ixiaro); Meningococcal (MCV4-Menactra); Meningococcal (MCV4-Menveo); Meningococcal (MPSV4-Menomune); MMR (MMR-II); MMRV (ProQuad); Pneumococcal (PCV13-Prevnar 13); Pneumococcal (PPSV-23-Pneumovax); Polio (IPV-Ipol); Rabies (Imovax); Rabies (RabAvert); Rotavirus (RotaTeq); Rotavirus (Rotarix); Smallpox (Vaccinia-ACAM2000); Td (Decavac); Td (Tenivac); Td (Mass Biologics); Tdap (Adacel); Tdap (Boostrix); Typhoid (inactivated-Typhim Vi); Typhoid (oral-Ty21a); Varicella (Varivax); Yellow Fever (YF-Vax); and Zoster (Shingles-Zostavax).


In various embodiments, the present adjuvants (e.g. flagellin-based agent and an aluminum gel or salt) may be part of one or more illustrative vaccines and/or the antigens of one or more illustrative vaccines may be the antigens of the present invention. Illustrative vaccines include, by way of example, subunit vaccine and inactivated or “killed” vaccine (e.g. Infanrix-IPV/Hib (Bordetella pertussis), Infanrix-IPV/Hib (Haemophilus influenzae), Infanrix-IPV/Hib (Poliovirus), Infanrix-IPV/Hib (Clostridium tetani), Infanrix-IPV/Hib (Corynebacterium diphtheriae), Infanrix-hexa (Bordetella pertussis), Infanrix-hexa (Haemophilus influenzae), Infanrix-hexa (Poliovirus), Infanrix-hexa (Hepatitis B virus), Infanrix-hexa (Clostridium tetani), Infanrix-hexa (Corynebacterium diphtheriae), Infanrix-IPV (Bordetella pertussis), Infanrix-IPV (Poliovirus), Infanrix-IPV (Clostridium tetani), Infanrix-IPV (Corynebacterium diphtheriae), Infanrix/Hib (Corynebacterium diphtheriae), Pediarix (Clostridium tetani), Pediarix (Poliovirus), Pediarix (Hepatitis B virus), ViVaxim (Salmonella spp.), ViVaxim (Hepatitis A virus); subunit vaccines (e.g. 5CVMB (Neisseria meningitidis), B. pertussis CyaA protein vaccine (Bordetella pertussis), B. pertussis PTx protein vaccine (Bordetella pertussis), Cancer VEGFA protein vaccine (Cancer), E. coli vaccine using intimin polypeptide (Escherichia coli), Engerix-B (Hepatitis B virus), H. pylori VacA protein vaccine (Helicobacter pylori), HC of type C and D (Clostridium botulinum), Infanrix/Hib (Bordetella pertussis), Infanrix/Hib (Haemophilus influenzae), Infanrix/Hib (Clostridium tetani), M. gallisepticum TM-1 Protein Subunit Vaccine (Mycoplasma gallisepticum), MDA-modified human apo B-100 peptide Vaccine (Atherosclerosis), MSP3-LSP with aluminium hydroxide (Plasmodium spp.), Mumps HN Protein Subunit Vaccine (Mumps virus), N. miningitidis TBP2 Protein Vaccine (Neisseria meningitidis), P. aeruginosa Oprl Protein Vaccine (Pseudomonas aeruginosa), P. falciparum Subunit SE36 Protein Vaccine (Plasmodium spp.), Phleum pratense Allergy Phl p 12 Subunit Vaccine (Allergy), Recombivax HB (Hepatitis B virus), S. pneumoniae ClpP protein Vaccine (Streptococcus pneumoniae); toxoid vaccine (e.g. BoNT/F(Hc) (Clostridium botulinum), DAPTACEL (Corynebacterium diphtheriae), Infanrix (Bordetella pertussis), Infanrix (Clostridium tetani), KINRIX (Clostridium tetani), PBT (Clostridium botulinum), Pediarix (Bordetella pertussis), inactivated or “killed” vaccines (e.g. Avaxim (Hepatitis A virus), Avaxim-Pediatric (Hepatitis A virus), FSME-IMMUN (Tick-borne Encephalitis Virus (TBEV)), Infanrix (Corynebacterium diphtheriae), Ixiaro (Japanese encephalitis virus), KINRIX (Corynebacterium diphtheriae), and Pediarix (Corynebacterium diphtheriae)); and conjugate vaccines (e.g., Arabinomannan-tetanus toxoid conjugate (Mycobacterium tuberculosis)), CCPS-P64kR (Neisseria meningitidis), COMVAX (Haemophilus influenzae), Menjugate (Neisseria meningitidis), Neisvac-C(Neisseria meningitidis), and PedvaxHIB (Haemophilus influenzae)).


In some embodiments, the present adjuvants (e.g. flagellin-based agent and an aluminum gel or salt) are combined in a vaccine targeting a substance abuse. For example, in one embodiment, the present adjuvants are used in vaccines against addition to fentanyl, heroin, morphine, opium, oxycodone, hydrocodone, ketamine, PCP, barbiturates, benzodiazepines, flunitrazepam, GHB, methaqualone, hashish, marijuana, LSD, mescaline, psilocybin, amphetamine, cocaine, MDMA, methamphetamine, methylphenidate, and nicotine (e.g. TA-CD (Celtic Pharma), those described in US Patent Publication No. 2013/0011432, the contents of which are hereby incorporated by reference (e.g. using 6-(2R,3S)-3-(benzoyloxy)-8-methyl-8-azabicyclo [3.2.1]octane-2-carbonyloxy-hexanoic acid (GNC) or 6-((2R,3S)-3-(benzoyloxy)-8-methyl-8-azabicyclo [3.2.1] octane-2-carboxamido)hexanoic acid) (GNE) as the antigen, and TA-NIC (Celtic Pharma)).


In some embodiments, the present adjuvants (e.g. flagellin-based agent and an aluminum gel or salt) and/or the present vaccines may comprise any one of the adjuvants or antigens annotated in the VIOLIN or Vaxjo databases (as described in He et al. Nucleic Acids Research. 2014. 42 (D1): D1124-D1132 and Xiang et al. Nucleic Acids Res. 2008 January; 36: D923-8, the contents of which are hereby incorporated by reference in their entirety).


In various embodiments, the present adjuvants (e.g. flagellin-based agent and an aluminum gel or salt) may be part of one or more cancer vaccines and/or the antigens of one or more cancer vaccines may be the antigens of the present invention. Illustrative cancer vaccines include therapeutic and preventative vaccines. For instance, cancer vaccines include ONCOPHAGE (ANTIGENICS INC., approved in Russia in 2008 for kidney cancer), APC8015/Sipuleucel-T/PROVENGE (DENDREON, for, e.g. metastatic hormone-refractory prostate cancer), CANCERVAX (CANVAXIN), GENITOPE CORP (MYVAX personalized immunotherapy), and FAVRILLE INC (FAVID), preventive vaccines which attack the cancer-causing viruses human papillomavirus (e.g. CERVARIX (GSK) and GARDASIL (MERCK)), hepatitis A virus (e.g. CERVARIX (GSK) and GARDASIL (MERCK)), and hepatitis B virus (e.g. RECOMBIVAX HB (MERCK), ENGERIX-B (GSK), ELOVAC B (HUMAN BIOLOGICALS INSTITUTE), GENEVAC B (SERUM INSTITUTE), SHANVAC B, etc.


In various embodiments, the present adjuvants (e.g. flagellin-based agent and an aluminum gel or salt) may be part of one or more allergen vaccines and/or the antigens of one or more allergen vaccines may be the antigens of the present invention. For instance, subcutaneous immunotherapy (SCIT) allergen compositions and methods are applicable to the present invention (e.g. “allergy shots”). For example, vaccinations for allergic rhinitis and conjunctivitis (e.g. pollen (including ragweed), dust mites, animal dander and airborne mold spores); allergic or extrinsic bronchial asthma (e.g. house dust mites, pollen, animal dander, mold (Cladosporium), latex); and insect venom hypersensitivity. Allergens include pollen (e.g. tree, grass, weed), pet dander (e.g. cat pelt), dust mites, airborne molds, occupational aeroallergens, honey bee venom, yellow jacket venom, hornet venom, wasp venom, and fire ant venom.


In various embodiments, the antigens of the present vaccines may be the antigens of live and attenuated or killed or inactivated or toxoid or a subunit or conjugate vaccines. In various embodiments, the antigen of the present vaccines is an antigen of any of the vaccines described herein. For example, in some embodiments, the present antigen is that of one or more of the following vaccines: DTP (diphtheria-tetanus-pertussis vaccine), DTaP (diphtheria-tetanus-acellular pertussis vaccine), Hib (Haemophilus influenzae type b) conjugate vaccines, Pneumococcal conjugate vaccine, Hepatitis A vaccines, Poliomyelitis vaccines, Yellow fever vaccines, Hepatitis B vaccines, combination DTaP, Tdap, Hib, Human Papillomavirus (HPV) vaccine, Anthrax vaccine, Bacillus Calmette-Guérin (Tb), and Rabies vaccine.


In various embodiments, the flagellin-based agent and antigen are adsorbed to the aluminum gel or salt. In some embodiments, the flagellin-based agent and aluminum gel or salt are mixed to form a stable complex. In some embodiments, the flagellin-based agent and aluminum gel or salt are mixed in a ratio that is substantially below a loading capacity of the aluminum salt. In some embodiments, the flagellin-based agent and aluminum gel or salt are present in a ratio that is substantially below a loading capacity of the aluminum salt. In various embodiments, the flagellin-based agent and aluminum gel or salt are mixed or present in a ratio (w/w) of about 1:500, or about 1:600, or about 1:700, or about 1:800, or about 1:900, or about 1:1000, or about 1:2000, or about 1:5000, or about 1:6000, or about 1:7000, or about 1:8000, or about 1:9000, or about 1:10000. In some embodiments, the flagellin-based agent and aluminum gel or salt are mixed in a ratio (w/w) of about 1:500 or less. In some embodiments, the flagellin-based agent and aluminum gel or salt are present in a ratio that is substantially below a loading capacity of the aluminum salt even in the presence of antigen.


The loading (or adsorption) capacity of the adjuvant (e.g. the aluminum gel or salt) can be measured using a variety of analytical methods. In general, it is done by comparing the protein content in the aqueous phase of the agent being loaded or adsorbed (e.g. flagellin-based agent and/or antigen solution) before and after adsorption onto the adjuvant. For instance, the Ramon flocculation test may be used (as is used to determine the adsorption of diphtheria and tetanus toxoid). Further, loading can be measured using immunoprecipitation techniques (e.g. quantitative immunoelectrophoresis or single radial immunodiffusion) or spectrophotometric techniques (e.g. the BCA method) ELISA methods may also be used as can immunoelectrophoresis or HPLC. The aluminum content in the final vaccine can be monitored using a number of known techniques, including spectrometric methods, such as for example atomic adsorption spectrometry.


In some embodiments, the amount of aluminum gel or salt in the vaccines and/or adjuvants described herein is about 0.05 to about 1.0 mg/dose, or about 0.125 to about 0.625 mg/dose. In some embodiments, the amount of aluminum gel or salt in the vaccines and/or adjuvants described herein is about 0.05, or about 0.10, or about 0.15, or about 0.20, or about 0.25, or about 0.30, or about 0.35, or about 0.40, or about 0.45, or about 0.50, or about 0.55, or about 0.60, or about 0.65, or about 0.70, or about 0.75, or about 0.80, or about 0.85, or about 0.90, or about 0.95, or about 1.0 mg/dose.


In some embodiments, the amount of flagellin-based agent is about 0.03 to about 5 μg/dose (e.g. about 0.03 μg/dose, about 0.1 μg/dose, about 0.3 μg/dose, about 0.5 μg/dose about 1.0 μg/dose, about 1.5 μg/dose, about 2.0 μg/dose, about 2.5 μg/dose, about 3.0 μg/dose, about 4.0 μg/dose, about 4.5 μg/dose, about 5.0 μg/dose). In various embodiments, the present compositions and methods comprise doses of flagellin-based agent that are less than about 5 μg/dose, or less than 4 μg/dose, or less than 3 μg/dose, or less than 2 μg/dose, or less than 1 μg/dose, or less than 0.5 μg/dose. In some embodiments, the present compositions and methods comprise low doses of flagellin-based agent.


In various embodiments, the present compositions and methods do not involve covalently attaching an antigen to the flagellin-based agent either as a fusion protein or via chemical conjugation. In various embodiments, the present compositions do not have either equimolar ratio of antigen to flagellin-based agent (as in a fusion) or several molecules of hapten per one molecule of flagellin-based agent (as in chemical conjugates). In various embodiments, the amount of flagellin-based agent in any of the present vaccines is less than the amount of antigen. In various embodiments, the amount of flagellin-based agent in any of the present vaccines is less than the amount of antigen. In various embodiments, the amount of flagellin-based agent in any of the present vaccines is substantially less than the amount of antigen. In various embodiments, the amount of flagellin-based agent in any of the present vaccines is about 500-fold, or about 450-fold, or about 400-fold, or about 350-fold, or about 325-fold, or about 300-fold, or about 250-fold, or about 200-fold, or about 150-fold, or about 100-fold, or about 50-fold less than the amount of antigen.


In various embodiments, the combination of flagellin-based agent and alum do not substantially effect TLR5 interaction by the flagellin-based agent.


In various embodiments, the present compositions and methods do not induce production of TNFα.


In various embodiments the present combination of flagellin-based agent and alum is substantially stable at low temperatures for about one week (e.g. at about 4° C. for about 3 days, or about 5 days, or about 6 days, or about 7 days, or about 10 days).


In another aspect, the present invention relates to a method of vaccinating a subject against a disorder, comprising administering an effective amount of a vaccine comprising an adjuvant comprising a flagellin-based agent and an aluminum gel or salt and an antigen associated with the disorder. In another aspect, the invention relates to a use of vaccine comprising an adjuvant comprising a flagellin-based agent and an aluminum gel or salt and an antigen associated with a disorder for vaccinating a subject against the disorder. In another aspect, the invention relates to a use of an effective amount of vaccine comprising an adjuvant comprising a flagellin-based agent and an aluminum gel or salt and an antigen associated with a disorder in the manufacture of a medicament for vaccinating a subject against the disorder.


In another aspect, the present invention relates to a method of immunostimulating a subject in advance of or concurrent with vaccination, comprising administering an effective amount of an adjuvant comprising a flagellin-based agent and an aluminum gel or salt, wherein both TH1 and TH2-mediated immune responses are immunostimulated. In another aspect, the invention relates to a use of an effective amount of an adjuvant comprising a flagellin-based agent and an aluminum gel or salt for immunostimulating a subject in advance of or concurrent with vaccination. In another aspect, the invention relates to a use of an effective amount of an adjuvant comprising a flagellin-based agent and an aluminum gel or salt in the manufacture of a medicament for immunostimulating a subject in advance of or concurrent with vaccination.


In various embodiments, the vaccine described herein causes an improvement in adjuvant properties relative to a vaccine comprising the antigen and the aluminum gel or salt alone (or flagellin-based agent and antigen alone). In various embodiments, the vaccine and/or adjuvant described herein causes a broader, more diverse, more robust and longer lasting immunostimulatory effect than the vaccine comprising the antigen and the aluminum gel or salt alone (or flagellin-based agent and antigen alone) and/or the adjuvant comprising the aluminum gel or salt alone (or the adjuvant comprising the flagellin-based agent alone).


In some embodiments, the described vaccine and/or described adjuvant causes an increase in titer of 1 or more of, or 2 or more of, or 3 or more of, or all of IgG1, IgG2a, IgG2b, and IgG3 antibodies (e.g. relative to the adjuvant comprising the aluminum gel or salt or flagellin-based agent alone, or relative to the vaccine comprising the antigen and the aluminum gel or salt alone or flagellin-based agent alone)). In some embodiments, the described vaccine and/or described adjuvant causes a relative increase in the titer of all of IgG1, IgG2a, IgG2b, and IgG3 antibodies. In some embodiments, the described vaccine and/or described adjuvant causes a relative increase in the titer of more IgG3 antibodies than the described vaccine and/or described adjuvant in the absence of a flagellin-based agent (or the described vaccine and/or described adjuvant in the absence of an aluminum gel or salt alone).


In some embodiments, the antigen is administered simultaneously with or sequentially to the adjuvant.


In some embodiments, the disorder is selected from infectious diseases, cancer, allergy, and autoimmune diseases.


In some embodiments, the disorder is selected from diphtheria, tetanus, pertussis, influenza, pneumonia, hepatitis A, hepatitis B, polio, yellow fever, Human Papillomavirus (HPV) infection, anthrax, rabies, Japanese Encephalitis, meningitis, measles, mumps, rubella, gastroenteritis, smallpox, typhoid fever, varicella (chickenpox), rotavirus, and shingles.


In some embodiments, the disorder is a cancer is selected from, but not limited to, a basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancer; breast cancer; cancer of the peritoneum; cervical cancer; choriocarcinoma; colon and rectum cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; cancer of the head and neck; gastric cancer (including gastrointestinal cancer); glioblastoma; hepatic carcinoma; hepatoma; intra-epithelial neoplasm; kidney or renal cancer; larynx cancer; leukemia; liver cancer; lung cancer (e.g., small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung); melanoma; myeloma; neuroblastoma; oral cavity cancer (lip, tongue, mouth, and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; cancer of the respiratory system; salivary gland carcinoma; sarcoma; skin cancer; squamous cell cancer; stomach cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; vulval cancer; lymphoma including Hodgkin's and non-Hodgkin's lymphoma, as well as B-cell lymphoma (including low grade/follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade/follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia; as well as other carcinomas and sarcomas; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses, edema (such as that associated with brain tumors), and Meigs' syndrome.


In some embodiments, the disorder is an allergy, selected from, by way of non-limiting example, allergic rhinitis and conjunctivitis, allergic or extrinsic bronchial asthma, and insect venom hypersensitivity.


In some embodiments, the disorder is a substance abuse disorder (e.g. of fentanyl, heroin, morphine, opium, oxycodone, hydrocodone, ketamine, PCP, barbiturates, benzodiazepines, flunitrazepam, GHB, methaqualone, hashish, marijuana, LSD, mescaline, psilocybin, amphetamine, cocaine, MDMA, methamphetamine, methylphenidate, and nicotine).


In some embodiments, the compositions of the present invention (e.g. the described adjuvants and vaccines) can possess a sufficiently basic functional group, which can react with an inorganic or organic acid, or a carboxyl group, which can react with an inorganic or organic base, to form a pharmaceutically acceptable salt. A pharmaceutically acceptable acid addition salt is formed from a pharmaceutically acceptable acid, as is well known in the art. Such salts include the pharmaceutically acceptable salts listed in, for example, Journal of Pharmaceutical Science, 66, 2-19 (1977) and The Handbook of Pharmaceutical Salts; Properties, Selection, and Use. P. H. Stahl and C. G. Wermuth (eds.), Verlag, Zurich (Switzerland) 2002, which are hereby incorporated by reference in their entirety.


Pharmaceutically acceptable salts include, by way of non-limiting example, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, camphorsulfonate, pamoate, phenylacetate, trifluoroacetate, acrylate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate, o-acetoxybenzoate, naphthalene-2-benzoate, isobutyrate, phenylbutyrate, α-hydroxybutyrate, butyne-1,4-dicarboxylate, hexyne-1,4-dicarboxylate, caprate, caprylate, cinnamate, glycollate, heptanoate, hippurate, malate, hydroxymaleate, malonate, mandelate, mesylate, nicotinate, phthalate, teraphthalate, propiolate, propionate, phenylpropionate, sebacate, suberate, p-bromobenzenesulfonate, chlorobenzenesulfonate, ethylsulfonate, 2-hydroxyethylsulfonate, methylsulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, naphthalene-1,5-sulfonate, xylenesulfonate, and tartarate salts.


The term “pharmaceutically acceptable salt” also refers to a salt of the compositions of the present invention having an acidic functional group, such as a carboxylic acid functional group, and a base. Suitable bases include, but are not limited to, hydroxides of alkali metals such as sodium, potassium, and lithium; hydroxides of alkaline earth metal such as calcium and magnesium; hydroxides of other metals, such as aluminum and zinc; ammonia, and organic amines, such as unsubstituted or hydroxy-substituted mono-, di-, or tri-alkylamines, dicyclohexylamine; tributyl amine; pyridine; N-methyl, N-ethylamine; diethylamine; triethylamine; mono-, bis-, or tris-(2-OH-lower alkylamines), such as mono-; bis-, or tris-(2-hydroxyethyl)amine, 2-hydroxy-tert-butylamine, or tris-(hydroxymethyl)methylamine, N,N-di-lower alkyl-N-(hydroxyl-lower alkyl)-amines, such as N,N-dimethyl-N-(2-hydroxyethyl)amine or tri-(2-hydroxyethyl)amine; N-methyl-D-glucamine; and amino acids such as arginine, lysine, and the like.


In some embodiments, the compositions of the present invention (e.g. the described adjuvants and vaccines) described herein are in the form of a pharmaceutically acceptable salt.


In some embodiments, the compositions of the present invention (e.g. the described adjuvants and vaccines) may comprise a pharmaceutically acceptable carrier or vehicle. Such compositions can optionally comprise a suitable amount of a pharmaceutically acceptable excipient so as to provide the form for proper administration.


Pharmaceutical excipients can be liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The pharmaceutical excipients can be, for example, saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea and the like. In addition, auxiliary, stabilizing, thickening, lubricating, and coloring agents can be used. In one embodiment, the pharmaceutically acceptable excipients are sterile when administered to a subject. Water is a useful excipient when any agent described herein is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid excipients, specifically for injectable solutions. Suitable pharmaceutical excipients also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. Any composition described herein, if desired, can also comprise minor amounts of wetting or emulsifying agents, or pH buffering agents.


The present invention includes the compositions of the present invention (e.g. the described adjuvants and vaccines) in various formulations. Any composition of the present invention can take the form of solutions, suspensions, emulsion, drops, tablets, pills, pellets, capsules, capsules containing liquids, powders, sustained-release formulations, suppositories, emulsions, aerosols, sprays, suspensions, or any other form suitable for use. In one embodiment, the composition is in the form of a capsule (see, e.g., U.S. Pat. No. 5,698,155). Other examples of suitable pharmaceutical excipients are described in Remington's Pharmaceutical Sciences 1447-1676 (Alfonso R. Gennaro eds., 19th ed. 1995), incorporated herein by reference.


Where necessary, the compositions of the present invention can also include a solubilizing agent. Also, the agents can be delivered with a suitable vehicle or delivery device as known in the art. Combination therapies outlined herein can be co-delivered in a single delivery vehicle or delivery device. Compositions for administration can optionally include a local anesthetic such as, for example, lignocaine to lessen pain at the site of the injection.


The formulations comprising the compositions of the present invention may conveniently be presented in unit dosage forms and may be prepared by any of the methods well known in the art of pharmacy. Such methods generally include the step of bringing the therapeutic agents into association with a carrier, which constitutes one or more accessory ingredients. Typically, the formulations are prepared by uniformly and intimately bringing the therapeutic agent into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into dosage forms of the desired formulation (e.g., wet or dry granulation, powder blends, etc., followed by tableting using conventional methods known in the art).


In one embodiment, any composition of the present invention is formulated in accordance with routine procedures as a composition adapted for a mode of administration described herein.


Routes of administration include intramuscular, e.g. by injection or infusion. In some embodiments, the described adjuvant of a flagellin-based agent (e.g. CBLB502) and aluminum gel or salt may prevent systemic delivery of the flagellin-based agent and induce localized delivery. In other embodiments, routes of administration include nasal, oral, and sublingual delivery.


Routes of administration may also be intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, oral, sublingual, intranasal, transdermal, or by inhalation. In some embodiments, the administering is effected orally or by parenteral injection. The mode of administration can be left to the discretion of the practitioner, and depends in-part upon the site of the medical condition. In most instances, administration results in the release of any agent described herein into the bloodstream.


Any composition of the present invention (e.g. the described adjuvants and vaccines) can be administered orally. Such compositions can also be administered by any other convenient route, for example, by intravenous infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and can be administered together with another biologically active agent. Administration can be systemic or local. Various delivery systems are known, e.g., encapsulation in liposomes, microparticles, microcapsules, capsules, etc., and can be used to administer.


Dosage forms suitable for parenteral administration (e.g. intravenous, intramuscular, intraperitoneal, subcutaneous and intra-articular injection and infusion) include, for example, solutions, suspensions, dispersions, emulsions, and the like. They may also be manufactured in the form of sterile solid compositions (e.g. lyophilized composition), which can be dissolved or suspended in sterile injectable medium immediately before use. They may contain, for example, suspending or dispersing agents known in the art.


The dosage of any composition of the present invention (e.g. the described adjuvants and vaccines) as well as the dosing schedule can depend on various parameters, including, but not limited to, the disorder being treated, the subject's general health, and the administering physician's discretion.


In vitro or in vivo assays can be employed to help identify optimal dosage ranges. For example, doses may be determined with reference Physicians' Desk Reference, 66th Edition, PDR Network; 2012 Edition (Dec. 27, 2011), the contents of which are incorporated by reference in its entirety.


For administration of a composition of the present invention (e.g. the described adjuvants and vaccines) by parenteral injection, the dosage is normally about 0.1 mg to about 250 mg per day, about 1 mg to about 20 mg per day, or about 3 mg to about 5 mg per day. Injections may be given up to four times daily. Generally, when orally or parenterally administered, the dosage of any agent described herein is normally about 0.1 mg to about 1500 mg per day, or about 0.5 mg to about 10 mg per day, or about 0.5 mg to about 5 mg per day. A dosage of up to about 3000 mg per day can be administered.


In another embodiment, delivery can be in a vesicle, in particular a liposome (see Langer, 1990, Science 249:1527-1533; Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989).


Any composition of the present invention (e.g. the described adjuvants and vaccines) can be administered by controlled-release or sustained-release means or by delivery devices that are well known to those of ordinary skill in the art. Examples include, but are not limited to, those described in U.S. Pat. Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5,639,476; 5,354,556; and 5,733,556, each of which is incorporated herein by reference in its entirety. Such dosage forms can be useful for providing controlled- or sustained-release of one or more active ingredients using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination thereof to provide the desired release profile in varying proportions. Suitable controlled- or sustained-release formulations known to those skilled in the art, including those described herein, can be readily selected for use with the active ingredients of the agents described herein. The invention thus provides single unit dosage forms suitable for oral administration such as, but not limited to, tablets, capsules, gelcaps, and caplets that are adapted for controlled- or sustained-release.


Controlled- or sustained-release of an active ingredient can be stimulated by various conditions, including but not limited to, changes in pH, changes in temperature, stimulation by an appropriate wavelength of light, concentration or availability of enzymes, concentration or availability of water, or other physiological conditions or compounds.


In another embodiment, polymeric materials can be used (see Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Fla. (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, 1983, J. Macromol. Sci. Rev. Macromol. Chem. 23:61; see also Levy et al., 1985, Science 228:190; During et al., 1989, Ann. Neurol. 25:351; Howard et al., 1989, J. Neurosurg. 71:105).


In another embodiment, a controlled-release system can be placed in proximity of the target area to be treated, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)). Other controlled-release systems discussed in the review by Langer, 1990, Science 249:1527-1533) may be used.


Administration of a composition of the present invention (e.g. the described adjuvants and vaccines) can, independently, be once per patient or may be used in a booster strategy. Administration may be about one to about four times daily or about one to about four times per month or about one to about six times per year or once every two, three, four or five years. Administration can be for the duration of about one day or about one month, about two months, about three months, about six months, about one year, about two years, about three years, and may even be for the life of the subject. The dosage may be administered as a single dose or divided into multiple doses.


The dosage regimen utilizing any flagellin related composition (and/or additional agents) described herein can be selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the subject; the severity of the condition to be treated; the route of administration; the renal or hepatic function of the subject; the pharmacogenomic makeup of the individual; and the specific compound of the invention employed. Any flagellin related composition (and/or additional agents) described herein can be administered in a single daily dose, or the total daily dosage can be administered in divided doses of two, three or four times daily. Furthermore, any flagellin related composition (and/or additional agents) described herein can be administered continuously rather than intermittently throughout the dosage regimen.


In some embodiments, the composition of the present invention (e.g. the described adjuvants and vaccines) may be used in conjunction with one or more additional agents. In some embodiments, the invention pertains to co-administration and/or co-formulation. Any of the compositions described herein may be co-formulated and/or co-administered.


In some embodiments, any composition described herein acts synergistically when co-administered with another agent and is administered at doses that are lower than the doses commonly employed when such agents are used as monotherapy. In various embodiments, any agent referenced herein may be used in combination with any of the composition described herein.


In some embodiments, the present invention pertains to additional agents described elsewhere herein. In one embodiment, any flagellin-related agent or composition comprising the same may be used with agents that stimulate NOD receptors (e.g. NOD1 and NOD2 agonists, such as peptidoglycan, C12-iE-DAP and L18-MDP) and as described in Infect Immun. October 2013; 81(10): 3855-3864, the contents of which are hereby incorporated by reference in their entirety.


In some embodiments, the present invention pertains to chemotherapeutic agents as additional agents.


Examples of chemotherapeutic agents include, but are not limited to, alkylating agents such as thiotepa and CYTOXAN cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethiylenethiophosphoramide and trimethylolomelamine; acetogenins (e.g., bullatacin and bullatacinone); a camptothecin (including the synthetic analogue topotecan); bryostatin; cally statin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (e.g., cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CB 1-TM1); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics such as the enediyne antibiotics (e.g., calicheamicin, especially calicheamicin gammall and calicheamicin omegall (see, e.g., Agnew, Chem. Intl. Ed. Engl., 33: 183-186 (1994)); dynemicin, including dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, caminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, ADRIAMYCIN doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxy doxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as minoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; def of amine; demecolcine; diaziquone; elformithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK polysaccharide complex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin; sizofuran; spirogermanium; tenuazonic acid; triaziquone; 2,2′,2″-trichlorotriethylamine; trichothecenes (e.g., T-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside (“Ara-C”); cyclophosphamide; thiotepa; taxoids, e.g., TAXOL paclitaxel (Bristol-Myers Squibb Oncology, Princeton, N.J.), ABRAXANE Cremophor-free, albumin-engineered nanoparticle formulation of paclitaxel (American Pharmaceutical Partners, Schaumberg, 111.), and TAXOTERE doxetaxel (Rhone-Poulenc Rorer, Antony, France); chloranbucil; GEMZAR gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin, oxaliplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; NAVELBINE. vinorelbine; novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; irinotecan (Camptosar, CPT-11) (including the treatment regimen of irinotecan with 5-FU and leucovorin); topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids such as retinoic acid; capecitabine; combretastatin; leucovorin (LV); oxaliplatin, including the oxaliplatin treatment regimen (FOLFOX); lapatinib (Tykerb); inhibitors of PKC-α, Raf, H-Ras, EGFR (e.g., erlotinib (Tarceva)) and VEGF-A that reduce cell proliferation and pharmaceutically acceptable salts, acids or derivatives of any of the above. In addition, the methods of treatment can further include the use of radiation. In addition, the methods of treatment can further include the use of photodynamic therapy.


In some embodiments, the flagellin-based agents (and/or additional agents) described herein, include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the composition such that covalent attachment does not prevent the activity of the composition. For example, but not by way of limitation, derivatives include composition that have been modified by, inter alia, glycosylation, lipidation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications can be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of turicamycin, etc. Additionally, the derivative can contain one or more non-classical amino acids.


In still other embodiments, the flagellin-based agents (and/or additional agents) described herein further comprise a cytotoxic agent, comprising, in illustrative embodiments, a toxin, a chemotherapeutic agent, a radioisotope, and an agent that causes apoptosis or cell death. Such agents may be conjugated to a composition described herein.


The flagellin-based agents (and/or additional agents) described herein may thus be modified post-translationally to add effector moieties such as chemical linkers, detectable moieties such as for example fluorescent dyes, enzymes, substrates, bioluminescent materials, radioactive materials, and chemiluminescent moieties, or functional moieties such as for example streptavidin, avidin, biotin, a cytotoxin, a cytotoxic agent, and radioactive materials.


Illustrative cytotoxic agents include, but are not limited to, methotrexate, aminopterin, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine; alkylating agents such as mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU), mitomycin C, lomustine (CCNU), 1-methylnitrosourea, cyclothosphamide, mechlorethamine, busulfan, dibromomannitol, streptozotocin, mitomycin C, cis-dichlorodiamine platinum (II) (DDP) cisplatin and carboplatin (paraplatin); anthracyclines include daunorubicin (formerly daunomycin), doxorubicin (adriamycin), detorubicin, carminomycin, idarubicin, epirubicin, mitoxantrone and bisantrene; antibiotics include dactinomycin (actinomycin D), bleomycin, calicheamicin, mithramycin, and anthramycin (AMC); and antimytotic agents such as the vinca alkaloids, vincristine and vinblastine. Other cytotoxic agents include paclitaxel (taxol), ricin, pseudomonas exotoxin, gemcitabine, cytochalasin B, gramicidin D, ethidium bromide, emetine, etoposide, tenoposide, colchicin, dihydroxy anthracin dione, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, procarbazine, hydroxyurea, asparaginase, corticosteroids, mytotane (O,P′-(DDD)), interferons, and mixtures of these cytotoxic agents.


Further cytotoxic agents include, but are not limited to, chemotherapeutic agents such as carboplatin, cisplatin, paclitaxel, gemcitabine, calicheamicin, doxorubicin, 5-fluorouracil, mitomycin C, actinomycin D, cyclophosphamide, vincristine, bleomycin, VEGF antagonists, EGFR antagonists, platins, taxols, irinotecan, 5-fluorouracil, gemcytabine, leucovorine, steroids, cyclophosphamide, melphalan, vinca alkaloids (e.g., vinblastine, vincristine, vindesine and vinorelbine), mustines, tyrosine kinase inhibitors, radiotherapy, sex hormone antagonists, selective androgen receptor modulators, selective estrogen receptor modulators, PDGF antagonists, TNF antagonists, IL-1 antagonists, interleukins (e.g. IL-12 or IL-2), IL-12R antagonists, Toxin conjugated monoclonal antibodies, tumor antigen specific monoclonal antibodies, Erbitux, Avastin, Pertuzumab, anti-CD20 antibodies, Rituxan, ocrelizumab, ofatumumab, DXL625, HERCEPTIN®, or any combination thereof. Toxic enzymes from plants and bacteria such as ricin, diphtheria toxin and Pseudomonas toxin may be conjugated to the therapeutic agents (e.g. antibodies) to generate cell-type-specific-killing reagents (Youle, et al., Proc. Nat'l Acad. Sci. USA 77:5483 (1980); Gilliland, et al., Proc. Nat'l Acad. Sci. USA 77:4539 (1980); Krolick, et al., Proc. Nat'l Acad. Sci. USA 77:5419 (1980)).


Other cytotoxic agents include cytotoxic ribonucleases as described by Goldenberg in U.S. Pat. No. 6,653,104. Embodiments of the invention also relate to radioimmunoconjugates where a radionuclide that emits alpha or beta particles is stably coupled to the antibody, or binding fragments thereof, with or without the use of a complex-forming agent. Such radionuclides include beta-emitters such as Phosphorus-32, Scandium-47, Copper-67, Gallium-67, Yttrium-88, Yttrium-90, Iodine-125, Iodine-131, Samarium-153, Lutetium-177, Rhenium-186 or Rhenium-188, and alpha-emitters such as Astatine-211, Lead-212, Bismuth-212, Bismuth-213 or Actinium-225.


Illustrative detectable moieties further include, but are not limited to, horseradish peroxidase, acetylcholinesterase, alkaline phosphatase, beta-galactosidase and luciferase. Further illustrative fluorescent materials include, but are not limited to, rhodamine, fluorescein, fluorescein isothiocyanate, umbelliferone, dichlorotriazinylamine, phycoerythrin and dansyl chloride. Further illustrative chemiluminescent moieties include, but are not limited to, luminol. Further illustrative bioluminescent materials include, but are not limited to, luciferin and aequorin. Further illustrative radioactive materials include, but are not limited to, Iodine-125, Carbon-14, Sulfur-35, Tritium and Phosphorus-32.


In some embodiments, the subject and/or animal is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, rabbit, sheep, or non-human primate, such as a monkey, chimpanzee, or baboon. In other embodiments, the subject and/or animal is a non-mammal, such, for example, a zebrafish. In some embodiments, the subject and/or animal may comprise fluorescently-tagged cells (with e.g. GFP). In some embodiments, the subject and/or animal is a transgenic animal comprising a fluorescent cell.


In some embodiments, the subject and/or animal is a human. In some embodiments, the human is a pediatric human. In other embodiments, the human is an adult human. In other embodiments, the human is a geriatric human. In other embodiments, the human may be referred to as a patient.


In certain embodiments, the human has an age in a range of from about 0 months to about 6 months old, from about 6 to about 12 months old, from about 6 to about 18 months old, from about 18 to about 36 months old, from about 1 to about 5 years old, from about 5 to about 10 years old, from about 10 to about 15 years old, from about 15 to about 20 years old, from about 20 to about 25 years old, from about 25 to about 30 years old, from about 30 to about 35 years old, from about 35 to about 40 years old, from about 40 to about 45 years old, from about 45 to about 50 years old, from about 50 to about 55 years old, from about 55 to about 60 years old, from about 60 to about 65 years old, from about 65 to about 70 years old, from about 70 to about 75 years old, from about 75 to about 80 years old, from about 80 to about 85 years old, from about 85 to about 90 years old, from about 90 to about 95 years old or from about 95 to about 100 years old.


In other embodiments, the subject is a non-human animal, and therefore the invention pertains to veterinary use. In a specific embodiment, the non-human animal is a household pet. In another specific embodiment, the non-human animal is a livestock animal.


The invention provides kits that can simplify the administration of any agent described herein. An illustrative kit of the invention comprises any composition described herein in unit dosage form. In one embodiment, the unit dosage form is a container, such as a pre-filled syringe, which can be sterile, containing any agent described herein and a pharmaceutically acceptable carrier, diluent, excipient, or vehicle. The kit can further comprise a label or printed instructions instructing the use of any agent described herein. The kit may also include a lid speculum, topical anesthetic, and a cleaning agent for the administration location. The kit can also further comprise one or more additional agent described herein. In one embodiment, the kit comprises a container containing an effective amount of a composition of the invention and an effective amount of another composition, such those described herein.


The following definitions are used in connection with the invention disclosed herein. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of skill in the art to which this invention belongs.


As used herein, “a,” “an,” or “the” can mean one or more than one.


Further, the term “about” when used in connection with a referenced numeric indication means the referenced numeric indication plus or minus up to 10% of that referenced numeric indication. For example, the language “about 50” covers the range of 45 to 55.


An “effective amount,” when used in connection with medical uses is an amount that is effective for providing a measurable treatment, prevention, or reduction in the rate of pathogenesis of a disease of interest.


As used herein, something is “decreased” if a read-out of activity and/or effect is reduced by a significant amount, such as by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, at least about 98%, or more, up to and including at least about 100%, in the presence of an agent or stimulus relative to the absence of such modulation. As will be understood by one of ordinary skill in the art, in some embodiments, activity is decreased and some downstream read-outs will decrease but others can increase.


Conversely, activity is “increased” if a read-out of activity and/or effect is increased by a significant amount, for example by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, at least about 98%, or more, up to and including at least about 100% or more, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 50-fold, at least about 100-fold, in the presence of an agent or stimulus, relative to the absence of such agent or stimulus.


As referred to herein, all compositional percentages are by weight of the total composition, unless otherwise specified. As used herein, the word “include,” and its variants, is intended to be non-limiting, such that recitation of items in a list is not to the exclusion of other like items that may also be useful in the compositions and methods of this technology. Similarly, the terms “can” and “may” and their variants are intended to be non-limiting, such that recitation that an embodiment can or may comprise certain elements or features does not exclude other embodiments of the present technology that do not contain those elements or features.


Although the open-ended term “comprising,” as a synonym of terms such as including, containing, or having, is used herein to describe and claim the invention, the present invention, or embodiments thereof, may alternatively be described using alternative terms such as “consisting of” or “consisting essentially of.”


As used herein, the words “preferred” and “preferably” refer to embodiments of the technology that afford certain benefits, under certain circumstances. However, other embodiments may also be preferred, under the same or other circumstances. Furthermore, the recitation of one or more preferred embodiments does not imply that other embodiments are not useful, and is not intended to exclude other embodiments from the scope of the technology.


The amount of compositions described herein needed for achieving a therapeutic effect may be determined empirically in accordance with conventional procedures for the particular purpose. Generally, for administering therapeutic agents (e.g. flagellin-based agents, flagellin-based agents (and/or additional agents) described herein) for therapeutic purposes, the therapeutic agents are given at a pharmacologically effective dose. A “pharmacologically effective amount,” “pharmacologically effective dose,” “therapeutically effective amount,” or “effective amount” refers to an amount sufficient to produce the desired physiological effect or amount capable of achieving the desired result, particularly for treating the disorder or disease. An effective amount as used herein would include an amount sufficient to, for example, delay the development of a symptom of the disorder or disease, alter the course of a symptom of the disorder or disease (e.g., slow the progression of a symptom of the disease), reduce or eliminate one or more symptoms or manifestations of the disorder or disease, and reverse a symptom of a disorder or disease. For example, administration of therapeutic agents to a patient suffering from cancer provides a therapeutic benefit not only when the underlying condition is eradicated or ameliorated, but also when the patient reports a decrease in the severity or duration of the symptoms associated with the disease, e.g., a decrease in tumor burden, a decrease in circulating tumor cells, an increase in progression free survival. Therapeutic benefit also includes halting or slowing the progression of the underlying disease or disorder, regardless of whether improvement is realized.


Effective amounts, toxicity, and therapeutic efficacy can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to about 50% of the population) and the ED50 (the dose therapeutically effective in about 50% of the population). The dosage can vary depending upon the dosage form employed and the route of administration utilized. The dose ratio between toxic and therapeutic effects is the therapeutic index and can be expressed as the ratio LD50/ED50. In some embodiments, compositions and methods that exhibit large therapeutic indices are preferred. A therapeutically effective dose can be estimated initially from in vitro assays, including, for example, cell culture assays. Also, a dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the 1050 as determined in cell culture, or in an appropriate animal model. Levels of the described compositions in plasma can be measured, for example, by high performance liquid chromatography. The effects of any particular dosage can be monitored by a suitable bioassay. The dosage can be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment.


In certain embodiments, the effect will result in a quantifiable change of at least about 10%, at least about 20%, at least about 30%, at least about 50%, at least about 70%, or at least about 90%. In some embodiments, the effect will result in a quantifiable change of about 10%, about 20%, about 30%, about 50%, about 70%, or even about 90% or more. Therapeutic benefit also includes halting or slowing the progression of the underlying disease or disorder, regardless of whether improvement is realized.


In certain embodiments, a pharmacologically effective amount that will treat cancer will modulate the symptoms typically by at least about 10%, at least about 20%, at least about 30%, at least about 40%, or at least about 50%. In illustrative embodiments, such modulations will result in, for example, statistically significant and quantifiable changes in the numbers of cancerous cells.


This invention is further illustrated by the following non-limiting examples.


EXAMPLES
Example 1: Preparation of the Model Vaccine

Alum adjuvant (IMJECT ALUM, THERMO) was used in combination with CBLB502 to challenge the mice with a model antigen, ovalbumin (OVA). Vaccine was comprised of the following components as shown in TABLE A:
















Component
Amount (per mouse)




















Ovalbumin
10
mg










CBLB502
1 ug/10 ug











Alum Adjuvant
500
ug










To achieve excellent absorption CBLB502 (either 1 ug or 10 ug) was mixed with 10 mg of OVA and 500 μg of Alum adjuvant for 30 minutes at 300 rpm at room temperature.


Example 2: Mouse Immunization Study

C57Bl/6 male mice (10 weeks of age, n=6 for each experiment) were used for injection. Mice were divided into five groups with six animals in each group (n=6). Mice were injected with 100 μl of above described vaccine in each of the hind legs (200 μl total per mouse) as shown in TABLE B.

















Ovalbumin
CBLB502
Alum Adjuvant





















Group 1






Group 2
10 mg



Group 3
10 mg

500 ug



Group 4
10 mg
 1 ug
500 ug



Group 5
10 mg
10 ug
500 ug










Two weeks after the initial immunization mice were challenged with an additional booster following the same setup as the original injection. Plasma was collected one, two and four weeks after booster via mandibular vein. Using an ELISA based assay total IgG, IgG1, IgG2a, IgG2b and IgG3 were measured. Results are shown in FIGS. 2-3. In the figures, Group 1 is also called “Untreated;” Group 2 is also called “OVA,” Groups 3 is also called “OVA+Alum,” Group 4 is also called “SA 1 μg,” and Group 5 is also called “SA 10 μg.”



FIG. 2 shows ELISA data for the average response of the five aforementioned mouse treatment groups at the time point of 1 week post-boost. FIG. 3 shows ELISA data for the average response of the five aforementioned mouse treatment groups at the time point of 2 weeks post-boost. FIG. 4 shows ELISA data for the average response of the five aforementioned mouse treatment groups at the time point of 4 weeks post-boost.


Example 3: Evaluation of CBLB502 Binding to ALHYDROGEL

The binding capacity of ALHYDROGEL for CBLB502 was evaluated. ALHYDROGEL adjuvant 2%, aluminium hydroxide wet gel (colloidal) suspension (INVIVIGEN Catalog #vac-alu-250), was mixed with CBLB502 at different volume ratios, resulting in 10 to 52% ALHYDROGEL suspension in the reaction. CBLB502 concentration was maintained at 10 μg/ml, corresponding to a 1 μg/100 μl inoculation dose (100 μl inoculation volume is the recommended maximum volume for subcutaneous injection of antigen/adjuvant mixtures per injection site for mice). After overnight incubation at 4° C., the tubes were centrifuged to sediment ALHYDROGEL and unbound CBLB502, remaining in solution was measured by ELISA. The amounts of adsorbed CBLB502 were calculated as difference between total protein added to the mixture and unbound CBLB502 (TABLE C). The maximum adsorption of CBLB502, more than 99.9% bound, was observed when the reactions were formulated with 40 to 52 μl ALHYDROGEL/100 μl; at lower ratios, the binding efficiency decreased gradually to about 83% at 10 μl/100 μl ALHYDROGEL suspension.









TABLE C







CBLB502 adsorption at different ALHYDROGEL 2% volume ratios.


The binding reactions were composed of CBLB502, PBS and


the indicated volumes of ALHYDROGEl adjuvant 2%.














ALHYDROGEL 2%
CBLB502 dose
Total CBLB502
Unbound
Bound
Bound



μl/100 μl
μg/100 μl
ng/ml
ng/ml
ng/ml
(%)
















1
52
1
10000
2.1
9997.9
99.98


2
50
1
10000
1.6
9998.4
99.98


3
40
1
10000
2.9
9997.1
99.97


4
30
1
10000
22.7
9977.3
99.77


5
20
1
10000
173.4
9826.6
98.27


6
10
1
10000
1692.5
8307.5
83.07









CBLB502 binding to ALHYDROGEL was also evaluated at different CBLB502 doses. Adsorption of CBLB502 to ALHYDROGEL (52 μl/100 μl ALHYDROGEL adjuvant 2%) was determined at CBLB502 doses, ranging from approximately 0.02 to 20 μg per 100 μl. The reactions were incubated as described above and unbound CBLB502 was measured by ELISA. The results (TABLE D) demonstrated that almost complete binding of the drug to ALHYDROGEL, 99.82 to 99.99% bound, was accomplished at all tested CBLB502 concentrations.









TABLE D







Efficiency of CBLB502 binding to ALHYDROGEl in PBS. The


incubations were performed with CBLB502 at the indicated


doses in PBS and 52 μl/100 μl ALHYDROGEL adjuvant 2%.













CBLB502 dose
Total CBLB502
Unbound
Bound
Bound



μg/100 μl
ng/ml
ng/ml
ng/ml
(%)
















1
20
200000
199.3
199800.7
99.90


2
5
50000
90.6
49909.4
99.82


3
1.25
12500
0.79
12499.2
99.99


4
0.31
3125.0
0.029
3124.97
99.99


5
0.078
781.25
0.023
781.23
99.99


6
0.02
195.31
0.011
195.30
99.99









CBLB502 binding to ALHYDROGEL in the presence of TT-SMA vaccine was evaluated. Binding efficiency of CBLB502 to ALHYDROGEL was tested in the presence of a vaccine candidate TT-SMA, succinyl methamphetamine (SMA) hapten conjugated to tetanus toxoid. In a separate study, shown below, this vaccine was administered to mice at a 32 μg/100 μl dose to compare efficacy with and without CBLB502. This TT-SMA dose was co-incubated with CBLB502 (0.02 to 20 μg/100 μl) and ALHYDROGEL (52 μl/100 μl) under standard conditions and unbound CBLB502 was measured by ELISA. The binding efficiency was 99.7 to 99.9% at all tested CBLB502 concentrations, indicating that CBLB502 adsorption to ALHYDROGEL was unaffected with addition of TT-SMA to the reaction mixture









TABLE E







CBLB502 binding to ALHYDROGEL in the presence of TT-


SMA. The incubations were performed with CBLB502 at


the indicated doses in PBS, 52 μl/100 μl ALHYDROGEL


adjuvant 2% and 32 μg/100 μl TT-SMA conjugate.













CBLB502 dose
Total CBLB502
Unbound
Bound
Bound



μg/100 μl
ng/ml
ng/ml
ng/ml
(%)
















1
20
200000
668.88
199331.1
99.67


2
5
50000
50.21
49949.8
99.90


3
1.25
12500
11.44
12488.6
99.91


4
0.31
3125.0
1.65
3123.4
99.95


5
0.078
781.25
0.13
781.1
99.98


6
0.02
195.31
0.06
195.2
99.96









Example 4: Analysis of In Vitro CBLB502 Activity after Adsorption to ALHYDROGEL

An activity assay of CBLB502/ALHYDROGEL using 293-hTLR5-LacZ reporter cells was undertaken. Biological activity of CBLB502 after adsorption to ALHYDROGEL was tested using an in vitro assay which measures activation of a NF-κB-controlled reporter enzyme, 3-galactosidase, in HEK293-hTLR5::NF-κB-lacZ (293-hTLR5-LacZ) cells. Since 293-hTLR5-LacZ cells express only one cell membrane-bound toll-like receptor, human TLR5, CBLB502 activity could be determined without interference from other toll-like receptor ligands such as LPS (endotoxin).


Specific induction of the δ-galactosidase reporter by CBLB502/ALHYDROGEL was demonstrated after incubating the cells with a serially diluted CBLB502/ALHYDROGEL formulation (5 μg/100 μl), starting with a 2000-fold dilution in cell growth media and resulting in the concentration range of ALHYDROGEL-adsorbed CBLB502 from 25 to 0.004 ng/ml (FIG. 5). The maximum δ-galactosidase activity was observed at 0.93 ng/ml ALHYDROGEL-adsorbed CBLB502; this value was consistent with typical results of the assay using soluble CBLB502 where the reporter enzyme activity would normally peak around 1 ng/ml. ALHYDROGEL alone tested at same dilutions did not induce the reporter. Therefore, it could be concluded, inter alia, that CBLB502 retains its biological activity after adsorption to ALHYDROGEL and becomes readily available for interaction with its target receptor (TLR5) under regular cell culture conditions.


Next, CBLB502/ALHYDROGEL suspensions were prepared at CBLB502 inoculation doses ranging from 2.5 to 0.00015 μg/100 μl and were added to 293-hTLR5-LacZ cells at 200-fold dilution (FIG. 6). NF-κB-inducing activity followed a typical dose-response pattern and was measured at sub-nanogram doses of CBLB502/ALHYDROGEL (less than 0.001 μg/100 μl), indicating that at such low doses, CBLB502 was not irreversibly bound to the alum adjuvant and remained active.


An activity titration of CBLB502/ALHYDROGEL at different CBLB502 doses was undertaken. CBLB502/ALHYDROGEL suspensions were titrated in cell culture media and incubated with 293-hTLR5-LacZ cells. CBLB502 standards were included in the assay to compare the recovered activity. The resulting reporter enzyme activity was plotted against theoretical concentrations of ALHYDROGEL-bound CBLB502, assuming that the protein was completely available (FIG. 7).


The results of titration assay demonstrated that at a formulation dose of 20 μg/100 μl, the activity of CBLB502 followed the expected concentrations, essentially matching the activity of soluble standards. However, reduction of the dose 64- and 256-fold to respectively, about 0.31 and 0.078 μg/100 μl, resulted in lower relative recovery of NF-κB-inducing activity to approximately 15-30%. This apparent loss of CBLB502 activity could be due to stronger binding of the particular amounts of the protein relative to the amounts of alum in the formulation. These fixed amounts could represent a small fraction of total CBLB502 at the higher doses such as 20 μg/100 μl and would not affect significantly the measured activity. However, at lower doses, this tightly adsorbed fraction may become substantial compared to the total protein, leading to a lower measurable activity of CBLB502


Example 5: Assessment of CBLB502/ALHYDROGEL Short-Term Storage Stability at 4° C.

A formulation of 1 μg/100 μl CBLB502 (52 μl/100 μl ALHYDROGEL 2%) was prepared and tested for activity after 2 and 6 days storage at 4° C. The results of CBLB502 activity assay using 293-hTLR5-LacZ reporter cells are shown in FIG. 8. Based on comparison with the soluble CBLB502 standard, in can be concluded that NF-κB-inducing activity of ALHYDROGEL-adsorbed CBLB502 remained unchanged after 6 days under the storage conditions.


Example 6: Evaluation of CBLB502 Dissociation from ALHYDROGEL in PBS and Cell Media

Aliquots of CBLB502/ALHYDROGEL (1 μg/100 μl dose; 52 μl/100 μl ALHYDROGEL 2%) were re-suspended in PBS or cell media (DMEM supplemented with 10% FBS) and incubated for 3 hr at 22° C. and 37° C. After centrifugation to remove ALHYDROGEL, dissociated CBLB502 was measured in supernatants by ELISA. The calculation of CBLB502 amounts that were recovered during incubation demonstrated that the protein remained stably associated with ALHYDROGEL in PBS; however, in cell media, 28 and 53% CBLB502 was released from the complex at 22° C. and 37° C., respectively (TABLE F). Such rapid dissociation from ALHYDROGEL in media may be facilitated by serum proteins which could displace CBLB502 from the complex with alum, explaining how the protein becomes readily available in the cell-based activity assay.









TABLE F







CBLB502 recovery from ALHYDROGEL after incubation in PBS and cell media










22° C.
37° C.













Incubation
CBLB502 dose
Total CBLB502
Recovered
Desorption
Recovered
Desorption


conditions
μg/100 μl
ng/ml
ng/ml
(%)
ng/ml
(%)
















PBS
1
10000
2.3
0.02
33.2
0.33


Media
1
10000
2807.6
28.1
5300.9
53.0









Example 7: Quantitation of CBLB502 and Cytokine Levels in Mouse Serum after Subcutaneous Administration of CBLB502/ALHYDROGEL

An animal study was conducted to evaluate feasibility of methods to determine the levels of CBLB502 and cytokines in serum after administration of a CBLB502/ALHYDROGEL formulation. The study design is presented in TABLE G. In this study, mice were injected subcutaneously with a 1 μg dose CBLB502 adsorbed to 52 μl/100 μl ALHYDROGEL 2% and serum samples were collected between 0.5 and 24 hr post inoculation.









TABLE G







Study design.


















Time





Age

Injection
Point,


Group
Group
Strain

volume,
blood


No.
Size
Sex
Treatment
μl
collection
Evaluation

















1
3
8 wk old
ALHYDROGEL/PBS, sc
100
1
hr
Serum prepared from


2
3
C57BL/6
ALHYDROGEL/PBS/CBLB502,
100
30
min
collected blood and


3
3
Female
(1 μg/100 μl CBLB502; 52
100
1
h
analyzed for


4
3

μl/100 μl ALHYDROGEL 2%)
100
2
h
entolimod


5
3

sc
100
4
h
concentration and


6
3


100
8
h
cytokine levels by


7
3


100
24
h
ELISA









Serum concentrations of CBLB502 were determined by ELISA and were found at measurable levels in all groups of animals inoculated with CBLB502/ALHYDROGEL. The pharmacokinetic profile representing per-group mean serum CBLB502 concentrations is shown in FIG. 9. The maximum mean CBLB502 concentration, 0.516 ng/ml, was observed at the first blood collection time point, 0.5 hr post administration; the minimum concentration was 0.012 ng/ml at 24 hr. Half-time elimination of CBLB502 was calculated at 2.4 hr. As discussed above, CBLB502 dissociated rapidly from the complex with ALHYDROGEL after incubation in cell media, containing 10% fetal bovine serum. Therefore, it should be expected to see the protein released from alum into animal bloodstream shortly after inoculation.


The concentrations of three cytokines, KC, G-CSF and IL-6, were measured in the collected mouse serum samples by ELISA (FIG. 10). Rapid induction of KC and IL-6 was detected 1 hr after CBLB502/ALHYDROGEL administration; the maximum per-group mean concentrations, 29624 and 479 μg/ml, respectively, were determined at 2 hr time point. After reaching maximum, the blood levels of these cytokines decreased to baseline at 4 to 8 hr post injection. The serum G-CSF concentration increased about an hour later compared to KC and IL-6 and was maximal between 2 and 4 hr after CBLB502/ALHYDROGEL administration (7141 and 7169 μg/ml per-group mean concentrations at 2 and 4 hr, respectively). However, CBLB502-induced G-CSF level was decreasing at a slower rate, remaining above baseline at 24 hr time point. In general, the kinetics of cytokine induction after CBLB502/ALHYDROGEL administration was similar to the kinetics observed after injection of the soluble CBLB502 preparations, suggesting consistent effects of this drug formulation.


Example 8: CBLB502 Adjuvant with Methamphetamine Vaccine

This study evaluated CBLB502 adjuvant at a 32 μg dose of human methamphetamine vaccine (SMA-TT) to achieve high and long lasting levels of anti-MA antibody in mice. A low to high dose of CBLB502 ranging from 0.03 to 20 μg with TT-SMA and alum was studied. Ten groups (n=5) of Balb/c female mice were employed to test 0, 0.03, 0.1, 0.3, 1, 3, 10, 20 μg of 502 in combination with 32 μg of TT-SMA and 1.5 mg alum compared to unvaccinated controls and TT-SMA with 502 alone. All vaccinated groups were administered two boosters, at 3 and 6 weeks after the initial vaccination. Levels of anti-MA IgG were assessed by ELISA in pooled sera samples collected at 2, 4, and 6 weeks after initial vaccination. The antibody levels were higher at 0.03 to 0.3 μg 502 in comparison to the higher doses (1 to 20 μg) of 502. In this experiment, antibody levels were 2 fold higher in the groups with 0.1 μg of 502 in combination with TT-SMA and alum (group 4) than in the comparison group with TT-SMA and alum alone (group 1) and approx. 4 fold higher when compared to a group with TT-SMA and 502 alone (group 2), as demonstrated in FIG. 11 (panel A). Anti-502 antibodies in the same sera sample were also evaluated. As shown in FIG. 11 (panel B), the level of anti-502 antibodies was minimal at the low dose range of 502 and increases at higher doses of 502.


Example 9: Generation of Vaccines with Various Antigens

In this Example, the composition of an adjuvant component for adjuvant-enhanced vaccine is established by testing a range of doses of CBLB502 and CBLB502 optionally combined with an antigen, such as, by way of non-limitation, NOD1 agonist C12-iE-DAP. Additionally, characterization of the effects of these agents on humoral immune response to a model antigen (ovalbumin) is undertaken.


As shown above, aluminum hydroxide and CBLB502 form a complex which, without wishing to be bound by theory, is stabilized by electrostatic forces as substances with opposite charges in aqueous medium. To test relative efficacy of different compositions of the adjuvant component of the vaccine, a standard dose of aluminum is used (1.5 μg per injection) loaded with a range of doses of CBLB502 (up to 30 μg and including 10 μg, 3 μg, 1 μg, 0.3 μg and 0.1 μg). CBLB502 in aqueous solution is added to the alum suspension in PBS and stirred for 10 min at room temperature. Aluminum hydroxide is then spun down by centrifugation and traces of CBLB502 in supernatants are determined using two quantitative analytical assays: (i) ELISA-based and (ii) reporter cell based (TLR5-positive 293 cells carrying NF-kB responsive reporter and calibrated for detection of CBLB 502 in the medium). In light of, inter alia, the above Examples, it is expected that a substantial fraction of CBLB 502 will be stably bound to alum under these conditions and within the chosen range of doses of TLR5 agonists.


To determine whether this adjuvant remains localized at the vaccine injection site, adult BALB/c female mice (n=10) carrying in their germ line firefly luciferase cDNA under the control of NF-kB-responsive promoter will be used. These “NF-kB reporter mice” are a sensitive tool for the detection of release of CBLB502 from the injection site by monitoring the luciferase activity in TLR5-positive tissues such as liver or small intestine. Only one dose of CBLB502-containing adjuvant formulation will be used that corresponds to the highest dose that demonstrated stability as a composition with Alum in vitro (presumably 30 μg). Two doses of free CBLB502 (1 and 3 μg in aqueous solution, s.c. injection) will be used for comparison as positive controls of systemically distributed TLR5 agonist. Luciferase detection will be done using a luminescent imager in vivo following luciferin injection at 2, 4, 6 and 18 hours post injection of the adjuvant. For a more accurate and sensitive detection, 3 animals from each group are sacrificed 6 hours post injection of the adjuvant formulation and tissues will be collected from the injection site, lymph nodes nearest to injection site and the liver. The level of luciferase activity indicative of the presence of CBLB 502 is quantitated in these tissue samples following tissue lysis. In addition to functional detection of CBLB 502 based on its expected NF-kB-inducing activity, an alternative analytical method of an established sensitive ELISA assay for direct detection of CBLB502 in tissue extracts is used.


Adjuvant formulations containing the above-described range of doses of CBLB502 are mixed with 10 mg of ovalbumin and vaccination is performed, as described herein, followed by the ELISA determination of titers of different classes of anti-albumin IgG (IgG1, IgG2a, IgG2b and IgG3) antibodies. The results are compared with “Alum only” control. Determination of the effects on different IgG types provides definition of the degrees of engagement of different immunization paths (e.g. TH1-versus TH2-mediated routes) by the adjuvant.


After determination of the composition of the adjuvant (in terms of anti-ovalbumin antibody inducing efficacy), additional enhancement of immunization is tested by adding into the formulation a NOD1 agonist, C12-iE-DAP.


Also, determination of vaccine efficacy at different CBLB 502 doses to generate antibodies to antigen is undertaken in mice. Female mice are chosen because they have stronger immune responses than male mice and BALB/c mice are a commonly used strain in immunological studies due to their robust immune responses. At the beginning of the study, mice weigh about 25 g and are group-housed (5 per cage) in standard acrylic cages (7″×11″×5″) with corncob bedding polycarbonate and tops. Mice will have ad libitum access to food (Harlan) and water. The vivarium will be maintained at 22±1° C. and on a 12:12 light/dark cycle (lights on at 6 AM). All experimental procedures are approved by the Institutional Animal Care and Use Committee (IACUC) and are within the guidelines delineated in the Guide for the Care and Use of Laboratory Animals.


Mice are intramuscularly injected with the vaccine in the gluteal muscle. Each group is optionally immunized with a booster dose with the same vaccine formulation at 3 and 6 weeks post initial immunization. If persistent antibody levels are not maintained for at least 4 weeks, an additional immunization will be given at week 10.


Blood is drawn at 14, 28, 42, 56 and 84 days post initial immunization and allowed to clot at room temperature for 2 hours. Serum is collected after centrifugation at 4000 rpm for 15 min. Samples are stored at −80 degrees until ready to run the enzyme linked immunosorbent assays (ELISA). In the context of a vaccine with antigen X, anti-antigen X specific antibodies are assessed by ELISAs. To measure the antibodies, ELISA plates (Immulon 2HB, Daigger, Vernon Hills, Ill.) are coated overnight in carbonate buffer (0.05 M; pH 9.6) using fish gelatin, which is a heterologous carrier protein, as the conjugate partner for SMA. Pooled or individual serum samples are added to plates in 2 fold serial dilutions starting at 1K in phosphate buffered saline (PBS)-Tween (0.1%) and incubated for 2 hours. Plates are washed with PBS-Tween prior to adding goat anti-mouse IgG conjugated to horse-radish peroxidase (HRP) (Southern Biotech, Birmingham, Ala.). Plates are incubated for another 30 min and washed before adding substrate (Tetramethylbenzidine, Sigma, St. Louis, Mo.). Plates are incubated for 45 min in the dark prior to stopping the reaction with 1M HCl. The optical density (OD) of the resulting dark spots on the plates from the antibody with antigen X linking are used to measure titer levels on a microplate reader (iMark Microplate Absorbance Reader) using Microplate Manager v 6.1 software.


ELISA data is analyzed using SigmaPlot (Systat Software Inc.) and background antibody binding to the carrier alone will be subtracted from each sample. Comparisons are made in each plate with a standard curve of purified mouse IgG (Sigma) bound directly in the wells in serial dilution.


Example 10: Comparison of CBLB502-Based Adjuvants/Vaccines with Flagellin-Based Adjuvants/Vaccines

The CBLB502/alum adjuvant of the above Examples is tested head to head against a flagellin/alum adjuvant using the methods and study design of, for instance, Example 9 (optionally with an antigen). Further, the alum binding and dissociation studies, as well as the mouse evaluation studies, all described in the above Examples, are repeated with a flagellin/alum adjuvant for comparison to the CBLB502/alum adjuvant. The efficacy of the CBLB502 variant, i.e., CBLB502-S33MX is also tested. In one comparison experiment, a group of mice (n=6) is immunized with TT-SMA, which is a methamphetamine vaccine and is used illustratively, co-adsorbed onto Alhydrogel with either flagellin, CBLB502, or CBLB502-S33MX. Immunication is carried out on days 0, 14, and 28 of the study. Each immunization dose includes 32 μg of TT-SMA and adjuvants as follows: Group 1: 0.03 μg flagellin, Group 2: 0.1 μg flagellin, Group 3: 0.3 μg flagellin, Group 4: 1 μg flagellin, Group 5: 0.03 μg CBLB502, Group 6: 0.1 μg CBLB502, Group 7: 0.3 μg CBLB502, Group 8: 1 μg CBLB502, Group 9: 0.03 μg CBLB502-S33MX, Group 10: 0.1 μg CBLB502-S33MX, Group 11:0.3 μg CBLB502-S33MX, and Group 12: 1 μg CBLB502-S33MX.


Serum samples are collected and analyzed on days −1 (pre-immune serum), 14 (post-prime), 28 (post first boost), and 35 (post second boost). For example, the serum samples are analyzed for the levels of anti-methamphetamine and anti-entolimod antibodies. Analysis indicates that CBLB502/alum and CBLB502-S33MX/alum cause a broader, more diverse, more robust and longer immunostimulatory effect than flagellin/alum. In addition, CBLB502/alum and CBLB502-S33MX/alum activate both TH1 and TH2-mediated immune response and a greater TH1-mediated immune response than flagellin/alum.


EQUIVALENTS

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth and as follows in the scope of the appended claims.


Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific embodiments described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.


INCORPORATION BY REFERENCE

All patents and publications referenced herein are hereby incorporated by reference in their entireties.


The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.


As used herein, all headings are simply for organization and are not intended to limit the disclosure in any manner. The content of any individual section may be equally applicable to all sections.


REFERENCES



  • 1. Yoon S I, Kurnasov O, Natarajan V, Hong M, Gudkov A V, Osterman A L, Wilson I A., 2012. Structural Basis of TLR5-Flagellin Recognition and Signaling. Science 335:859-864 (PM ID: 22344444)

  • 2. Smith K D, Andersen-Nissen E, Hayashi F, Strobe K, Bergman M A, Barrett S L, Cookson B T, Aderem A. 2003. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol. 4:1247-53 (PMID: 14625549)

  • 3. Mizel, S. B., A. P. West, R. R. Hantgan. 2003. Identification of a sequence in human Toll-like receptor 5 required for the binding of Gram-negative flagellin. J. Biol. Chem. 278:23624-23629 (PMID: 12711596)

  • 4. Murthy, K. G., Deb, A., Goonesekera, S., Szabo, C. & Salzman, A. L. (2004) J. Biol. Chem. 279:5667-5675 (PMID: 14634022)

  • 5. Andersen-Nissen E., Smith K. D., Strobe K. L., Barrett S. L., Cookson B. T., Logan S. M., Aderem A. (2005) Evasion of Toll-like receptor 5 by flagellated bacteria. Proc. Natl. Acad. Sci. U.S.A. 102: 9247-9252 (PMID: 15956202)

  • 6. Andersen-Nissen E, Smith K D, Bonneau R, Strong R K, Aderem A. 2007. A conserved surface on Toll-like receptor 5 recognizes bacterial flagellin. J Exp Med. 204:393-403 (PMID: 17283206)

  • 7. Burdelya L G, Krivokrysenko V I, Tallant T C, Strom E, Gleiberman A S, Gupta D, Kurnasov O V, Fort F L, Osterman A L, Didonato J A, Feinstein E, Gudkov A V., 2008. An agonist of Toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 320:226-230 (PMID: 18403709).

  • 8. Huleatt J W, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, Tang J, McDonald W, Song L, Evans R K et al. 2008. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TRL5 ligand flagellin. Vaccine. 26:201-214.


Claims
  • 1. A method of vaccinating a subject against a disorder, comprising administering an effective amount of a vaccine comprising: (a) an adjuvant comprising:a flagellin-based agent comprising an amino acid sequence having at least 95% identity with SEQ ID NO: 17, andan aluminum gel or salt,wherein the ratio (w/w) of flagellin-based agent to aluminum gel or salt is about 1:500 or less and(b) an antigen which stimulates protective immunity against the disorder,wherein the antigen is selected from a constituent of an infectious agent selected from a live and attenuated, killed, inactivated, and toxoid infectious agent, an antigen associated with a cancer and an antigen associated with an allergy;and wherein the disorder is selected from infectious diseases, cancers, and allergies.
  • 2. The method of claim 1, wherein the disorder is selected from diphtheria, tetanus, pertussis, influenza, pneumonia, hepatitis A, hepatitis B, polio, yellow fever, Human Papillomavirus (HPV) infection, anthrax, rabies, Japanese Encephalitis, meningitis, measles, mumps, rubella, gastroenteritis, smallpox, typhoid fever, varicella (chickenpox), rotavirus, and shingles.
  • 3. The method of claim 1, wherein the flagellin-based agent comprises the amino sequence of SEQ ID NO: 17.
  • 4. The method of claim 1, wherein the flagellin-based agent inhibits and abrogates the ability of neutralizing anti-flagellin antibodies to neutralize the adjuvant.
  • 5. The method of claim 1, wherein the aluminum gel or salt is selected from aluminum hydroxide, aluminum phosphate, and aluminum sulfate.
  • 6. The method of claim 1, wherein one or more of the flagellin-based agent and/or the antigen is adsorbed to the aluminum gel or salt.
  • 7. The method of claim 1, wherein the flagellin-based agent and aluminum gel or salt are mixed to form a stable complex.
  • 8. The method of claim 1, wherein the flagellin-based agent and aluminum gel or salt are mixed in a ratio that is substantially below a loading capacity of the aluminum salt.
  • 9. The method of claim 8, wherein the flagellin-based agent and aluminum gel or salt are mixed in a ratio (w/w) of about 1:500, or about 1:600, or about 1:700, or about 1:800, or about 1:900, or about 1:1000, or about 1:2000, or about 1:5000, or about 1:10000.
  • 10. The method of claim 1, wherein the antigen is that of one or more of the following vaccines: DTP (diphtheria-tetanus-pertussis vaccine), DTaP (diphtheria-tetanus-acellular pertussis vaccine), Hib (Haemophilus influenzae type b) conjugate vaccines, Pneumococcal conjugate vaccine, Hepatitis A vaccines, Poliomyelitis vaccines, Yellow fever vaccines, Hepatitis B vaccines, combination DTaP, Tdap, Hib, Human Papillomavirus (HPV) vaccine, Anthrax vaccine, and Rabies vaccine.
  • 11. The method of claim 1, wherein the vaccine further comprises an additional adjuvant selected from oil-in-water emulsion formulations, saponin adjuvants, ovalbumin, Freund's Adjuvant, cytokines, and chitosans.
  • 12. The method of claim 1, wherein the vaccine and/or adjuvant causes immunostimulation of one or more of a TH1 and TH2-mediated immune response.
  • 13. The method of claim 1, wherein the administering is orally or by parenteral injection.
  • 14. The method of claim 1, wherein the administering takes place by controlled-release or sustained-release.
  • 15. The method of claim 1, wherein the vaccine is administered once per subject or is used in a booster strategy.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation application of U.S. application Ser. No. 16/910,347 (now U.S. Pat. No. 10,975,127), filed Jun. 24, 2020, which is a continuation application of U.S. application Ser. No. 16/414,403 (now U.S. Pat. No. 10,730,915), filed May 16, 2019, which is a continuation application of U.S. application Ser. No. 15/500,133 (now U.S. Pat. No. 10,336,793), filed on Jan. 30, 2017, which is a national stage entry of International Patent Application No. PCT/US2015/042887, filed Jul. 30, 2015, which claims the benefit of U.S. Provisional Patent Application No. 62/031,116, filed Jul. 30, 2014; 62/110,744, filed Feb. 2, 2015; and 62/117,366, filed Feb. 17, 2015, the entire contents of which are herein incorporated by reference.

US Referenced Citations (32)
Number Name Date Kind
4554101 Hopp Nov 1985 A
5399494 Kaper Mar 1995 A
5693476 Scheller Dec 1997 A
6130082 Majarian et al. Oct 2000 A
7404963 Sotomayor et al. Jul 2008 B2
7638485 Gudkov Dec 2009 B2
7794731 Mizel et al. Sep 2010 B2
3007812 Gudkov et al. Aug 2011 A1
8106005 Gudkov Jan 2012 B2
8287882 Gudkov et al. Oct 2012 B2
8324163 Gudkov et al. Dec 2012 B2
8580321 Gudkov et al. Nov 2013 B2
20020009747 Miller et al. Jan 2002 A1
20030044429 Aderem et al. Mar 2003 A1
20050147627 Aderem et al. Jul 2005 A1
20050266391 Bennett et al. Dec 2005 A1
20060275255 Gudkov Dec 2006 A1
20070202551 Gudkov Aug 2007 A1
20070269406 Ichim Nov 2007 A1
20080124361 Mizel et al. May 2008 A1
20080182797 Nudler et al. Jul 2008 A1
20090011982 Gudkov et al. Jan 2009 A1
20090081157 Kornbluth et al. Mar 2009 A1
20090123467 Bedi et al. May 2009 A1
20090175880 Keler et al. Jul 2009 A1
20090246303 Gudkov et al. Oct 2009 A1
20100056454 Gudkov Mar 2010 A1
20110206699 Hossain et al. Aug 2011 A1
20110319595 Gudkov et al. Dec 2011 A1
20120208871 Gudkov et al. Aug 2012 A1
20130004515 Gudkov et al. Jan 2013 A1
20130324462 Gudkov et al. Dec 2013 A1
Foreign Referenced Citations (23)
Number Date Country
1992005816 Apr 1992 WO
1993018150 Sep 1993 WO
1999029312 Jun 1999 WO
2001040280 Jun 2001 WO
2001055210 Aug 2001 WO
2002044363 Jun 2002 WO
2003027251 Apr 2003 WO
2003028659 Apr 2003 WO
2004086039 Oct 2004 WO
2005056041 Jun 2005 WO
2005056042 Jun 2005 WO
2005056054 Jun 2005 WO
2005056055 Jun 2005 WO
2005057218 Jun 2005 WO
2006066214 Jun 2006 WO
2006069198 Jun 2006 WO
2007030581 Mar 2007 WO
2008157473 Dec 2008 WO
2009102818 Aug 2009 WO
2010040096 Apr 2010 WO
2010133885 Nov 2010 WO
2011027222 Mar 2011 WO
2011044246 Apr 2011 WO
Non-Patent Literature Citations (83)
Entry
Coffman et al., “Vaccine Adjuvants: Putting Innate Immunity to Work,” Immunity, 2010, vol. 33, No. 4, pp. 492-503.
International Search Report and Written Opinion, Application No. PCT/US2015/042887, dated: Dec. 3, 2015, 9 pages.
Pashenkov et al. “Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastic melanoma” J Clin Oncol 24: 5716-5724 2006.
Patchen M. L. “Amifostine plus granulocyte colony-stimulating factor therapy enhances recovery from supralethal radiation exposures: preclinical experience in animals models” European Journal of Cancer 31A(1):S17-S21 (1995).
Rensing-Ehl et al., Local Fas/APO-1 )(CD95) Ligand-Mediated Tumor Cell Killing in vivo, Eur J Immunol, 1995, vol. 25, pp. 2253-2258.
Rhee et al. “Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer” Gastroenterology Aug. 2008; 135(2): 518-528.
Samatey F. A. et al. “Structure of the bacterial flagellar protofilament and implications for a switch for supercoiling” Nature 410:331-337 (2001).
Satyamitra M. et al. “In vivo postirradiation protection by a vitamin E analog a-TMG” Radiation Research 160 (6):655-661 (2003).
Schmidt et al. “Intratumoural injection of the toll-like receptor-2/6 agonist ‘macrophage-activating lipopeptide-2’ in patients with pancreatic carcinoma: a phase I/II trial” Brit J Cancer 97: 598-604 2007.
Sebastiani G. et al. “Cloning and characterization of the murine Toll-like Receptor 5 (Tlr5) gene: sequence and mRNA expression studies in Salmonella-susceptible MOLF/Ei mice” Genomics 64(3):230-240 (2000).
Seed T. et al. “New strategies for the prevention of radiation injury: possible implications for countering radiation hazards of long term space travel” Journal of Radiation Research 43:S239-S244 (2002).
Selander R. K. et al. “Molecular evolutionary genetics of the cattle-adapted serovar Salmonella dublin” Journal of Bacteriology 174(11):3587-3592 (1992).
Service R. F. “Tumor-Killer Made; How Does It Work?” Science 274:2009 (1996).
Sfondrini et al. “Antitumor Activity of the TLR-5 Ligand Flagellin in Mouse Models of Cancer” The Journal of Immunology 2006 176:6624-6630.
Smith K. D. et al. “Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility” Nature Immunology 4(12):1247-1253 (2003).
Song et al. “Flagellin promotes the proliferation of gastric cancers via the Toll-like receptor 5” Int J Mol Med 28:115-119 2011.
Spadaro J. A. et al. “Radioprotectant combinations spare radiation-induced damage to the physis more than fractionation alone” Int. J. Radiat. Biol. 81(10):759-765 (2005) Abstract.
Sredni B. et al. “The immunomodulator AS101 administered orally as a chemoprotective and radioprotective agent” Int. J. Immunopharmacol. 14(4):613-619 (1992).
Streeter P. R. et al. “Activation of the G-CSF and Flt-3 receptors protects hematopoietic stem cells from lethal irradiation” Experimental Hematology 31(11):1119-1125 (2003).
Symon Z. et al. “Selective radioprotection of hepatocytes by systemic and portal vein infusions of amifostine in a rat liver tumor model” Int. J. Radiation Oncology Biol. Phys. 50(2):473-478 (2001).
Tallant T. et al. “Flagellin acting via TLR5 is the major activator of key signaling pathways leading to NF-KB and proinflammatory gene program activation in intestinal epithelial cells” BMC Microbiology 4(1):33 (2004).
Timmer et al. “Fas receptor-mediated apoptosis: a clinical application?” J Pathol 196: 125-134 2002.
Trauth et al. “Monoclonal antibody-mediated tumor regression by induction of apoptosis” Science 245: 301-305 1989.
Tsujimoto H. et al. “Flagellin enhances NK cell proliferation and activation directly and through dendritic cell—NK cell interactions” Journal of Leukocyte Biology 78(4):888-897 (2005).
Vasquez R. J. et al. “Nanomolar concentrations of nocodazole alter microtubule dynamic instability in vivo and in vitro” Molecular Biology of the Cell 8(6):973-985 (1997).
Vijay-Kumar et al. “Flagellin Treatment Protects against Chemicals Bacteria Viruses and Radiation” The Journal of Immunology 2008 180:8280-8285.
Waddick K. G. et al. “In vitro and in vivo antileukemic activity of B43-pokeweed antiviral protein against radiation-resistant human B-cell precursor leukemia cells” Blood 86(11):4228-4233 (1995).
Watson A. J. et al. “Lessons from genetically engineered animal models. VII. Apoptosis in intestinal epithelium: lessons from transgenic and knockout mice” Am. J. Physiol. Gastrointest. Liver Physiol. 278(1):G1-G5 (2000).
Wheeler C. M. “Preventative vaccines for cervial cancer” Salud Publica de Mexico 39(4) (1997) 9 pages.
Whitnall M. H. et al. “In vivo radioprotection by 5-androstenediol: stimulation of the innate immune system” Radiation Research 156(3):283-293 (2001).
Wolska et al. “Toll-like receptors and their role in carcinogensis and anti-tumor treatment” Cell Mol Biol Letters 14:248-272 2009.
Wong G. H. W. “Protective roles of cytokines against radiation: induction of mitochondrial MnSOD” Biochimica et Biophysica Acta 1271:205-209 (1995).
Yang et al. “Antigen replacement of domains D2 and D3 in flagellin promotes mucosal IgA production and attenuates flagellin-induced inflammatory response after intranasal immunization” Human Vaccines and Immunotherap 9:5 1084-1092 2013.
Alavanja M. CR. “Biologic damage resulting from exposure to tobacco smoke from radon: implication for preventive interventions” Oncogene 21:7365-7375 (2002).
Andreassen C. N. et al. “Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy” Seminars in Radiation Oncology 13(1):62-72 (2003).
Androstenediol and Androstenedione Wikipedia (online) URL: < http://en.wikipedia.org/wiki/Androstenediol> [Retrieved from the Internet: Dec. 5, 2006] 4 pages.
Bachmann M. F. et al. “Recall proliferation potential of memory CD8+ T cells and antiviral protection” The Journal of Immunology 175:4677-4685 (2005).
Ben-Yedidia T. et al. “Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection” International Immunology 11(7):1043-1051 (1998).
Booth D. et. al. “Transforming growth faclor-B3 protects murine small intestinal crypt stem cells and animal survival after irradiation possibly by reducing stem-cell cycling” Int. J. Cancer 86(1):53-59 (2000).
Borges H. L. et al. “DNA damage-induced cell death: lessons from the central nervous system” Cell Research 18:17-26 (2008).
Bulinski J. C. et al. “Overexpression of MAP4 inhibits organelle motility and trafficking in vivo” Journal of Cell Sciences 110:3055-3064 (1997).
Burdelya L. G. et al. “An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models” Science 320:226-230 (2008).
Cai et al. “Activation of toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth” Cancer Res 71 (7): 2466-2475 2011.
Cai et al. “Activation of toll-like receptor 5 on breast cancer cells by flagellin suppresses tumor development and growth” Cancer Res 70: #3819 Apr. 2010.
Carnes B. A. et al. “Mortality of atomic bomb survivors predicted from laboratory animals” Radiation Research 160 (2):159-167 (2003) Abstract.
Caron G. et. al. “Direct stimulation of human T cells via TLR5 and TLR7/8: Flagellin and R-848 up-regulate proliferation and IFN-y production by memory CD4+ T cells” The Journal of Immunology 175(3):1551-1557 (2005).
Dummer et al. “An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastic melanoma” Clin Cancer Res 14(3): 856-864 2008.
Eaves-Pyles T. D. et al. “Salmonella flagellin-dependent proinflammatory responses are localized to the conserved amino and carboxyl regions of the protein” The Journal of Immunology 167(12):7009-7016 (2001).
Eaves-Pyles T. et al. “Flagellin a novel mediator of Salmonella-induced epithelial activation and systemic inflammation: IKBa degradation induction of nitric oxide synthase induction of proinflammatory mediators and cardiovascular dysfunction” The Journal of Immunology 166(2):1248-1260 (2001).
Efferson C. L. et al. “Stimulation of human T cells by an influenza A vector expressing a CTL epitope from the HER-2/neu protooncogene results in higher numbers of antigen-specific TCRhi cells than stimulation with peptide. Divergent roles of IL-2 and IL-15” Anticancer Research 25:715-724 (2005).
Egan L. J. et al. “IkB-kinase13-dependent NF-k13 activation provides radioprotection to the intestinal epithelium” PNAS 101(8):2452-2457 (2004).
Elewaut D. et al. “NF-KB is a central regulator of the intestinal epithelial cell innate immune response induced by infection with enteroinvasive bacteria” The Journal of Immunology 163:1457-1466 (1999).
Etter et al. “The combination of chemotherapy and intraperitoneal MegaFas ligand improves treatment of ovarian carcinoma” Gynecologic Oncol 107: 14-21 2007.
Foldes G. et al. “Toll-like receptor modulation in cardiovascular disease: a target for intervention?” Expert Opinion on Investigational Drugs 15(8):857-871 (2006).
Fukuzawa N. et al. “A TLR5 agonist inhibits acute renal ischemic failure” The Journal of Immunology 187:3831-3839 (2011).
GenBank databases NCBI Accession No. M84972 Apr. 26, 1993 [online] [retrieved on Sep. 29 2011] Retrieved from the Internet: <URL: http://www.ncbi.nlm.nih.gov/nuccore/M84972>.
Gewirtz A.T. et al. “Cutting edge: Bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression” The Journal of Immunology 167(4):1882-1885 (2001).
Grdina D. J. et al. “Relationships between cytoprotection and mutation prevention by WR-1065” Military Medicine 167(2):51-53 (2002).
Guan K. L. et al. “Eukaryotic proteins expressed in Escherichia coli: an improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-transferase” Analytical Biochemistry 192:262-267 (1991).
Gudkov A. V. et al. “The role of p53 in determining sensitivity to radiotherapy” Nat. Rev. Cancer 3:117-129 (2003).
Guicciardi et al., Life and Death by Death Receptors, FASEB J, 2009, vol. 23, No. 6, pp. 1625-1637.
Haimovitz-Friedman A. et al. “Ionizing radiation acts on cellular membranes to generate ceramide and apoptosis” J. Exp. Med. 180:525-535 (1994).
Hall “Physics and Chemisty of Radialion Absorption” Radiobiology for the Radiobiologist pp. 5-15 5th ed. Lippincott Williams and Wilkins Philadelphia PA (2000).
Herbert J. M. et al. “Involvement of u-PA in the anti-apoptotic activity of TGF-beta for vascular smooth muscle cells” FEBS Letters 413(3):401-404 (1997).
Honko A. N. et al. “Effects of flagellin on innate and adaptive immunity” Immunologic Research 33(1):83-101 (2005).
Jung C. W. et al. “Antiproliferative effect of a vitamin D3 analog EB1089 on HL-60 cells by the induction of TGF-beta receptor” Leukemia Research 23(12):1105-1112 (1999).
Kemp G. et al. “Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatininduced toxicities: results of a randomized control in patients with advanced ovarian cancer” Journal of Clinical Oncolouv 14 (7):2101-2112 (1996).
Krieg A.M. “Development of TLR9 agonists for cancer therapy” J Clinical Invest 117(5): 1184-1194 2007.
Kyte J. el al. “A simple method for displaying the hydropathic character of a protein” J. Mol. Biol. 157:105-132 (1982).
Lehnert B. E. et al. “A new mechanism for DNA alterations induced by alpha particles such as those emitted by radon and radon progeny” Environmental Health Perspectives 105(5):1095-1101 (1997).
Leigh et al. “A Flagellin-Derived Toll-Like Receptor 5 Agonist Stimulates Cytotoxic Lymphocyte-Mediated Tumor Immunity” PLOS ONE Jan. 2014 vol. 9 Issue 1 pp. 1-10.
Li G. et al. “A special issue on DNA damage responses and genome maintenance” Cell Research 18(1):1-2 (2008).
Li J. et al. “Evolutionary origin and radiation of the avian-adapted non-motile salmonellae” Journal of Medical Microbiology 38(2):129-139 (1993).
McQuiston J. R. et al. “Sequencing and comparative analysis of flagellin genes fliC fljB and flpA from Salmonella” Journal of Clinical Microbiology 42(5):1923-1932 (2004).
Melby T. E. et al. “The symmetrical structure of structural maintenance of chromosomes (SMC) and MukB proteins: Long antiparallel coiled coils folded at a flexible hinge” The Journal of Cell Biology 142(6):1595-1604 (1998).
Mercurio F. et al. “NF-kB as a primary regulator of the stress response” Oncogene 18:6163-6171 (1999).
Murley J. S. et al. “Delayed cytoprotection after enhancement of Sod2 (MnSOD) gene expression in SA-NH mouse sarcoma cells exposed to WR-1065 the active metabolite of amifostine” Radiation Research 158(1):101-109 (2002).
Murley J. S. et al. “Delayed radioprotection by NFKB-mediated induction of Sod2 {MnSOD) in SA-NH tumor cells after exposure to clinically used thiol-containing drugs” Radialion Research 162(5):536-546 (2004).
Mutlu-Turkoglu U. et al. “The effect of selenium and/or vitamin E treatments on radiation-induced intestinal injury in rats” Life Sciences 66(20):1905-1913 (2000).
Neish A. S. “TLRS in the Gut. II. Flagellin-induced inflammation and antiapoptosis” American Journal of Physiology: Gastrointestinal and Liver Physiology 292(2):G462-G466 (2006).
Newton S. M. C. el al. “Immune response to cholera toxin epitope inserted in Salmonella flagellin” Science 244:70-72 (1989).
Oitringa “Tumour immunology—Exploitation of the weapon of immune destruction for cancer therapy: taking aim before firing” Current Opinion in Immunology 2005 17:159-162.
Panda D. et al. “Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: A possible mechanistic basis for its antitumor action” Proc. Natl. Acad. Sci. USA 94(20):10560-10564 (1997).
Related Publications (1)
Number Date Country
20210269491 A1 Sep 2021 US
Provisional Applications (3)
Number Date Country
62117366 Feb 2015 US
62110744 Feb 2015 US
62031116 Jul 2014 US
Continuations (3)
Number Date Country
Parent 16910347 Jun 2020 US
Child 17195935 US
Parent 16414403 May 2019 US
Child 16910347 US
Parent 15500133 US
Child 16414403 US